Management of Heart Failure

230 question(s) with answers and explanations.

Question 1

A 62-year-old male with a history of essential hypertension and a remote anterior myocardial infarction presents for a routine evaluation. He leads an active lifestyle, jogging two miles daily, and explicitly denies any dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, or peripheral edema. A recent echocardiogram reveals a left ventricular ejection fraction of 38% with focal apical akinesis. Which of the following best describes his current heart failure (HF) classification and the primary goal of therapeutic intervention?

• ○ Stage A (At-risk for HF); the primary aim is to modify risk factors.
• ✓ Stage B (Pre-HF); the primary aim is to treat risk and structural heart disease to prevent HF.
• ○ Stage C (HF); the primary aim is to reduce symptoms, morbidity, and mortality.
• ○ Stage D (Advanced HF); the primary aim is to reduce symptoms, morbidity, and mortality.

Explanation. This patient has structural heart disease (a remote myocardial infarction with a reduced ejection fraction) but lacks current or prior symptoms or signs of heart failure. This clinical presentation classifies him as having Stage B, or pre-HF. The primary therapeutic aim in this asymptomatic stage is to treat the underlying risk and structural heart disease to prevent the onset of the clinical heart failure syndrome.

Question 2

A 65-year-old male presents to the clinic for a routine follow-up. Six months ago, he was diagnosed with heart failure when he presented with significant dyspnea on minimal exertion and orthopnea. At that time, his echocardiogram revealed a left ventricular ejection fraction of 35%, and he was initiated on comprehensive medical therapy. Today, he reports feeling excellent, routinely walks 3 miles daily without any shortness of breath, fatigue, or palpitations, and has no signs of fluid overload on examination. How should this patient's heart failure currently be classified?

• ○ Stage B Heart Failure, New York Heart Association (NYHA) Class I
• ✓ Stage C Heart Failure, New York Heart Association (NYHA) Class I
• ○ Stage A Heart Failure, New York Heart Association (NYHA) Class I
• ○ Stage C Heart Failure, New York Heart Association (NYHA) Class II

Explanation. A patient who previously exhibited symptoms of heart failure is initially designated as having stage C heart failure. Even though the patient has become completely asymptomatic following the initiation of medical treatment, effectively placing him in New York Heart Association functional class I, he must still be categorized permanently as stage C heart failure throughout the continuum of care.

Question 3

A 65-year-old woman presents to the cardiology clinic complaining of fatigue, shortness of breath when walking up a flight of stairs, and swelling in both ankles. She has a medical history of hypertension, obesity, and type 2 diabetes mellitus. Physical examination reveals an elevated jugular venous pressure, bilateral crackles at the lung bases, and 2+ pitting edema in the lower extremities. A transthoracic echocardiogram is performed, showing a left ventricular ejection fraction (LVEF) of 54% with evidence of impaired relaxation. Based on her LVEF, which of the following represents the correct classification for this patient's heart failure?

• ○ Heart failure with reduced ejection fraction (HFrEF)
• ✓ Heart failure with preserved ejection fraction (HFpEF)
• ○ Heart failure with mildly reduced ejection fraction
• ○ Heart failure with improved ejection fraction

Explanation. Heart failure with preserved ejection fraction (HFpEF) is defined by a left ventricular ejection fraction (LVEF) threshold of 50% or greater. Because the patient presents with clinical signs and symptoms of heart failure and has an LVEF of 54%, her condition is correctly classified as HFpEF.

Question 4

A 62-year-old man presents for a routine follow-up of heart failure. Two years ago, he experienced an anterior wall myocardial infarction, after which his left ventricular ejection fraction (LVEF) was measured at 35%. He was started on comprehensive medical therapy. A repeat echocardiogram today shows an LVEF of 44%. He currently experiences mild dyspnea only with strenuous activity. Which of the following is the most appropriate consideration regarding his current left ventricular ejection fraction status?

• ○ His LVEF represents a static condition of mildly reduced ejection fraction, requiring no further routine echocardiographic surveillance.
• ✓ His LVEF is on a dynamic trajectory, meaning a single measurement at one time point may not be adequate and the trajectory over time is important to evaluate.
• ○ His LVEF represents a permanent transition to heart failure with preserved ejection fraction (HFpEF), given the measurement is greater than 40%.
• ○ His LVEF indicates complete myocardial recovery, meaning his heart failure diagnosis has resolved and further LVEF tracking is unwarranted.

Explanation. Patients with heart failure and a mildly reduced ejection fraction (LVEF 41% to 49%) are usually in a dynamic trajectory to improvement from a reduced ejection fraction or to deterioration back to a reduced ejection fraction. Because of this dynamic nature, a single ejection fraction measurement at one time point may not be adequate, making it important to evaluate both the trajectory of the left ventricular ejection fraction over time and its underlying cause.

Question 5

A 68-year-old female presents with a 6-month history of exertional dyspnea and progressive fatigue. Her medical history includes hypertension, obesity, and type 2 diabetes mellitus. On physical examination, her blood pressure is 142/86 mmHg, and her heart rate is 78 beats per minute. A comprehensive metabolic panel and complete blood count are unremarkable. Her B-type natriuretic peptide (BNP) level is 35 pg/mL (normal). A resting transthoracic echocardiogram reveals a left ventricular ejection fraction (LVEF) of 55%, with no obvious structural heart disease or elevated filling pressures at rest. Which of the following is the most appropriate next step in the diagnostic evaluation for heart failure with preserved ejection fraction (HFpEF)?

• ✓ Perform testing to assess for provokable increased left ventricular filling pressures, such as during exercise or a fluid challenge.
• ○ Rule out heart failure entirely due to the normal B-type natriuretic peptide levels and investigate pulmonary causes.
• ○ Diagnose the patient with Stage A heart failure and focus exclusively on cardiovascular risk factor modification.
• ○ Initiate an angiotensin receptor-neprilysin inhibitor (ARNI) based on the presence of clinical symptoms and ejection fraction alone.

Explanation. In patients with suspected heart failure with preserved ejection fraction (HFpEF), normal natriuretic peptide levels do not exclude the diagnosis, as signs and symptoms frequently overlap with other clinical conditions. To improve diagnostic specificity when resting objective measures are unremarkable, the diagnosis of heart failure should be supported by evidence of provokable increased left ventricular filling pressures, which can be demonstrated during physiological stressors such as exercise or a fluid challenge.

Question 6

A 58-year-old male with a history of hypertension and coronary artery disease was diagnosed with heart failure two years ago. At the time of diagnosis, his left ventricular ejection fraction (LVEF) was 25%. He was started on guideline-directed medical therapy (GDMT) and has been strictly adherent. Today, he reports feeling well with no current symptoms of heart failure. A follow-up echocardiogram reveals an LVEF of 42%. Which of the following statements is most accurate regarding his current cardiac status?

• ✓ He meets the criteria for heart failure with recovered ejection fraction, although he likely still has underlying cardiac structural abnormalities.
• ○ He meets the criteria for full myocardial recovery, indicating normalization of left ventricular systolic and diastolic function.
• ○ He does not meet the criteria for heart failure with recovered ejection fraction because his absolute LVEF increase is less than 20%.
• ○ He should be strictly classified as having de novo heart failure with preserved ejection fraction (HFpEF).

Explanation. The patient meets the working definition for heart failure with recovered ejection fraction, which requires a baseline LVEF of 40% or less, an absolute increase of 10% or more from baseline, and a second measurement of LVEF greater than 40%. While this improvement is associated with better clinical outcomes, it does not equate to full myocardial recovery or complete normalization of left ventricular function, as structural abnormalities such as chamber dilatation typically persist.

Question 7

A 48-year-old woman with a history of non-ischemic cardiomyopathy presented two years ago with severe exertional dyspnea, orthopnea, and a left ventricular ejection fraction (LVEF) of 25%. She was started on guideline-directed medical therapy (GDMT) for heart failure (HF). During her current clinic visit, she reports feeling excellent and exercises daily without limitations. Her physical examination is unremarkable, with no signs of volume overload. A repeat echocardiogram shows an LVEF of 55%, normal left ventricular size, and complete resolution of her previous structural cardiac abnormalities. What is the most appropriate classification of this patient's current heart failure status?

• ✓ Heart failure in remission
• ○ Stage B heart failure
• ○ Persistent stage C heart failure
• ○ Stage A heart failure

Explanation. Patients who experience a complete resolution of all heart failure symptoms, clinical signs, and structural cardiac abnormalities are considered to have heart failure in remission.

Question 8

A 62-year-old male presents for a routine follow-up in the cardiology clinic. Two years ago, he was diagnosed with non-ischemic dilated cardiomyopathy and a left ventricular ejection fraction (LVEF) of 28%. He was initiated on comprehensive guideline-directed medical therapy (GDMT) and has been highly adherent. Today, he reports feeling well with no dyspnea or edema. A repeat echocardiogram demonstrates an LVEF of 53%. He asks if his heart failure has resolved and whether he can begin stopping his medications. Based on his trajectory, how should his current condition be classified and what is the appropriate approach to his pharmacological treatment?

• ○ Classify as heart failure with preserved ejection fraction (HFpEF); continue current GDMT.
• ✓ Classify as heart failure with improved ejection fraction (HFimpEF); continue current GDMT.
• ○ Classify as heart failure with recovered ejection fraction; initiate a gradual taper of his heart failure medications.
• ○ Classify as heart failure with improved ejection fraction (HFimpEF); discontinue medications as LVEF changes are permanently unidirectional once normalized.

Explanation. Patients who initially present with heart failure with reduced ejection fraction and subsequently demonstrate an improvement in left ventricular ejection fraction to greater than 50% are classified as having heart failure with improved ejection fraction (HFimpEF), which is considered a subgroup of heart failure with reduced ejection fraction. Because the ejection fraction can decrease again following the withdrawal of pharmacological treatment, comprehensive guideline-directed medical therapy must be continued to maintain this improvement and prevent clinical relapse.

Question 9

A 72-year-old woman presents with progressively worsening exertional dyspnea and fatigue. She has a history of hypertension and obesity. Her electrocardiogram (ECG) shows normal sinus rhythm. A resting transthoracic echocardiogram reveals a left ventricular ejection fraction (LVEF) of 58%, a left atrial volume index of 38 mL/m², an increased left ventricular (LV) mass index, and a resting E/e' ratio of 11. Her B-type natriuretic peptide (BNP) level is 85 pg/mL (normal < 100 pg/mL). Clinical suspicion for heart failure with preserved ejection fraction (HFpEF) remains high, but the diagnosis is uncertain given the equivocal resting filling pressures. Which of the following is the most appropriate next step to help definitively establish the diagnosis?

• ✓ Exercise stress testing with echocardiographic evaluation of diastolic parameters
• ○ Cardiac magnetic resonance imaging with gadolinium enhancement
• ○ Empiric initiation of loop diuretic therapy with symptomatic reassessment
• ○ Endomyocardial biopsy to evaluate for infiltrative cardiomyopathy

Explanation. In patients with suspected heart failure with preserved ejection fraction (HFpEF) whose diagnosis remains uncertain after initial resting evaluation, exercise stress testing with echocardiographic evaluation of diastolic parameters is indicated to help establish the diagnosis by demonstrating increased left ventricular filling pressures provoked by exertion.

Question 10

A 62-year-old male follows up in the cardiology clinic for a routine evaluation. Eighteen months ago, he presented with progressive dyspnea and was diagnosed with heart failure with reduced ejection fraction (HFrEF) based on a left ventricular ejection fraction (LVEF) of 32% on echocardiography. He was initiated on appropriate medical therapy, including sacubitril/valsartan, carvedilol, spironolactone, and dapagliflozin. He has been adherent to his medications and currently reports no dyspnea, orthopnea, or edema. A repeat echocardiogram performed today demonstrates an LVEF of 46%. Which of the following is the most appropriate recommendation regarding his medical therapy?

• ✓ Continue the current heart failure with reduced ejection fraction (HFrEF) treatment regimen.
• ○ Discontinue sacubitril/valsartan and spironolactone, maintaining only the beta-blocker.
• ○ Transition his therapy to match protocols specifically for heart failure with mildly reduced ejection fraction (HFmrEF).
• ○ Stop all heart failure medications as his left ventricular ejection fraction is now greater than 40%.

Explanation. Patients who initially present with heart failure with reduced ejection fraction (HFrEF) and subsequently experience an improvement in their left ventricular ejection fraction (LVEF) to greater than 40% are classified as having heart failure with improved ejection fraction (HFimpEF). These patients must continue their established HFrEF treatment regimen to maintain clinical stability and prevent the relapse of left ventricular dysfunction.

Question 11

A 68-year-old woman with a history of hypertension and obesity presents with unexplained exertional dyspnea. Echocardiography demonstrates a left ventricular ejection fraction (LVEF) of 60% and no significant heart valve disease. A composite diagnostic score ranging from 0 to 9 is utilized to help discriminate heart failure with preserved ejection fraction (HFpEF) from noncardiac causes. Her score is calculated to be 4. What is the most appropriate next step in evaluating this patient's diagnosis?

• ○ Reassure the patient, as the score reflects a low likelihood of HFpEF and no further cardiac testing is required.
• ○ Initiate targeted therapy immediately, as the score reflects a high likelihood of HFpEF.
• ✓ Perform an exercise echocardiogram or cardiac catheterization for further hemodynamic evaluation.
• ○ Perform an endomyocardial biopsy to evaluate for underlying infiltrative cardiomyopathy.

Explanation. For a patient presenting with unexplained exertional dyspnea, a composite diagnostic score between 2 and 5 indicates an intermediate likelihood of heart failure with preserved ejection fraction (HFpEF). This necessitates further evaluation of hemodynamics using an exercise echocardiogram or cardiac catheterization to definitively confirm or negate the diagnosis.

Question 12

A public health cardiologist is analyzing the recent epidemiological trends of heart failure (HF) in the United States to prepare a report on healthcare resource allocation. When reviewing the data from the past decade, which of the following statements accurately reflects the trends in HF hospitalizations and mortality?

• ○ Both age-adjusted death rates and hospitalizations have steadily decreased since 2012 due to advances in medical therapy.
• ○ Total deaths caused by HF have remained stable, while hospitalizations decreased continuously up to 2017.
• ✓ US hospitalizations for HF decreased until 2012, but subsequently increased between 2013 and 2017.
• ○ The number of unique patients hospitalized with HF decreased by 26% between 2013 and 2017.

Explanation. Epidemiological data indicates that while US hospitalizations for heart failure decreased up until 2012, an increase was observed from 2013 to 2017, highlighting the growing health and economic burden of the condition in part due to an aging population.

Question 13

A 72-year-old woman presents to the clinic with progressive dyspnea on exertion, orthopnea, and bilateral lower extremity edema. An echocardiogram reveals a left ventricular ejection fraction of 60%, severe left atrial enlargement, and elevated filling pressures consistent with diastolic dysfunction. She is formally diagnosed with heart failure with preserved ejection fraction (HFpEF). When analyzing the broader epidemiological landscape of heart failure (HF) phenotypes, which of the following best describes the recent trends in the incidence of HFpEF compared to heart failure with reduced ejection fraction (HFrEF)?

• ○ The incidence of both HFpEF and HFrEF has been steadily increasing over recent years.
• ✓ The incidence of HFpEF is increasing, whereas the incidence of HFrEF is decreasing.
• ○ The incidence of HFpEF is decreasing, whereas the incidence of HFrEF is increasing.
• ○ The incidence of both HFpEF and HFrEF has remained completely stable over the last decade.

Explanation. Epidemiological data reveal divergent trends in the incidence of different heart failure phenotypes, characterized specifically by an increasing incidence of heart failure with preserved ejection fraction (HFpEF) alongside a decreasing incidence of heart failure with reduced ejection fraction (HFrEF).

Question 14

A 55-year-old male presents for a clinical assessment, including a comprehensive history and physical examination. An electrocardiogram is obtained which demonstrates occasional ectopic beats originating from the lower chambers of the heart. The cardiologist documents the presence of PVCs. What does the abbreviation PVC indicate in this context?

• ✓ Premature ventricular contraction
• ○ Pulmonary venous congestion
• ○ Premature valvular closure
• ○ Pulmonary vascular capacitance

Explanation. The abbreviation PVC stands for premature ventricular contraction, which refers to an ectopic beat originating from the right or left ventricle.

Question 15

A 52-year-old woman is evaluated in the cardiology clinic for a routine follow-up. She recently completed a regimen of doxorubicin-based chemotherapy for early-stage breast cancer. She reports feeling well, has no shortness of breath, and continues to jog 3 miles daily without difficulty. Her physical examination is unremarkable. A recent echocardiogram demonstrates a left ventricular ejection fraction of 60%, but global longitudinal strain is abnormally reduced. Laboratory testing reveals an elevated high-sensitivity cardiac troponin level. Based on her clinical presentation and findings, how is her heart failure status best classified?

• ○ Stage A heart failure (At-risk)
• ✓ Stage B heart failure (Pre-HF)
• ○ Stage C heart failure (Symptomatic HF)
• ○ Stage D heart failure (Advanced HF)

Explanation. The detection of myocardial injury using biomarkers (e.g., elevated troponin) or early maladaptive structural changes via sensitive cardiac imaging (e.g., reduced global longitudinal strain), even in the absence of clinical symptoms or gross left ventricular dysfunction, indicates the presence of pre-heart failure, or stage B heart failure.

Question 16

A 72-year-old man with a known history of ischemic cardiomyopathy presents to the clinic complaining of worsening shortness of breath and new-onset orthopnea. Physical examination reveals elevated jugular venous pressure, bibasilar crackles, and bilateral pitting lower extremity edema. These clinical signs and symptoms are a critical target for medication adjustment and are strongly associated with the patient's prognosis. Which of the following best describes the underlying physiological derangement directly responsible for these specific findings of clinical congestion?

• ✓ Elevated cardiac filling pressures
• ○ Reduced left ventricular ejection fraction
• ○ Increased systemic vascular resistance
• ○ Decreased systemic perfusion

Explanation. Clinical congestion, manifesting as signs and symptoms such as elevated jugular venous pressure, orthopnea, and lower extremity edema, is the direct physiological result of elevated cardiac filling pressures.

Question 17

A 65-year-old man with a history of heart failure with reduced ejection fraction (HFrEF) presents to the clinic for a follow-up. He reports increasing shortness of breath when bending over to tie his shoes (bendopnea) and requires three pillows to sleep at night (orthopnea). Physical examination reveals jugular venous distention and 2+ bilateral lower extremity edema. Based on findings from the PARADIGM-HF trial, what is the prognostic significance of assessing the changes in this patient's clinical congestion?

• ○ It is associated with quality of life but provides prognostic information only when combined with elevated natriuretic peptides.
• ✓ It is associated with quality of life and provides prognostic information independently of natriuretic peptides or the MAGGIC risk score.
• ○ It primarily predicts short-term readmission rates but has no bearing on overall quality of life.
• ○ Its prognostic value is inferior to and entirely dependent on the MAGGIC risk score.

Explanation. In patients with chronic heart failure with reduced ejection fraction, changes in markers of clinical congestion are associated with quality of life (as assessed by the Kansas City Cardiomyopathy Questionnaire) and provide prognostic information independently of natriuretic peptides or the MAGGIC (Meta-analysis Global Group in Chronic Heart Failure) risk score.

Question 18

A 68-year-old female with chronic heart failure with reduced ejection fraction is evaluated in the cardiology clinic. Her history over the past year includes three hospitalizations for volume overload and a recent inability to tolerate her previously stable doses of beta-blockers and angiotensin receptor-neprilysin inhibitors due to recurrent symptomatic hypotension. Physical examination reveals an elevated jugular venous pressure of 12 cm H2O and cool, minimally perfused extremities. The cardiologist recognizes these clinical clues as signs of advanced heart failure and initiates a referral to an advanced heart failure center for consideration of mechanical circulatory support or cardiac transplantation. What is the primary rationale for making this referral at this current stage rather than waiting for further clinical deterioration?

• ✓ To identify and evaluate the patient before she progresses to a state of extremis, thereby minimizing the risk of death or severe complications from specialized interventions.
• ○ To ensure the patient has progressed to profound cardiogenic shock with end-organ failure, which is a prerequisite for advanced therapies.
• ○ To facilitate the immediate withdrawal of all neurohormonal antagonists in a monitored intensive care setting.
• ○ To exclusively transition the patient to comfort-focused hospice care before she requires admission to an intensive care unit.

Explanation. Recognizing simple clinical clues of advanced heart failure through a focused history and physical examination allows for prompt referral to an advanced heart failure center. Intervening before a patient progresses to a state of extremis is critical, as waiting until a patient is in a severely advanced state significantly increases the risk that they will succumb to their illness or suffer severe complications from interventions such as mechanical circulatory support or cardiac transplantation.

Question 19

A 45-year-old man recently diagnosed with dilated cardiomyopathy (DCM) of unclear etiology presents for a follow-up evaluation. His left ventricular ejection fraction is 35%, and his coronary angiogram is normal. He is referred to a genetic healthcare professional who obtains a detailed 3-generation family pedigree, revealing that a paternal uncle died unexpectedly at age 42 and a cousin recently received an implantable cardioverter-defibrillator. The patient is subsequently diagnosed with familial cardiomyopathy. Based on the identification of this positive family history through a 3-generation pedigree analysis, which of the following is most likely associated with his condition?

• ✓ Gadolinium enhancement on cardiac magnetic resonance imaging (MRI) and increased major adverse cardiac events
• ○ Diffuse myocardial edema on positron emission tomography and a higher rate of ventricular septal rupture
• ○ Extensive coronary artery calcification on computed tomography and increased risk of recurrent myocardial infarction
• ○ Severe left atrial enlargement on echocardiography and increased progression to persistent atrial fibrillation

Explanation. A family history of cardiomyopathy, as determined by a 3-generation pedigree analysis, is strongly associated with findings of gadolinium enhancement on cardiac magnetic resonance imaging (MRI) and an increased incidence of major adverse cardiac events.

Question 20

A 72-year-old male presents with a 6-month history of progressive dyspnea on exertion, bilateral lower extremity edema, and fatigue. His past medical history is notable for bilateral carpal tunnel syndrome treated surgically 3 years ago. Physical examination reveals elevated jugular venous pressure, an S4 gallop, and 2+ pitting edema to the mid-calves. Echocardiography shows severe left ventricular wall thickening with a "speckled" appearance, biatrial enlargement, and a left ventricular ejection fraction of 55%. An electrocardiogram (ECG) demonstrates low voltage QRS complexes. Based on the most likely diagnosis, which of the following statements highlights the primary importance of establishing a definitive and expeditious diagnosis in this patient?

• ✓ The underlying condition requires specific therapeutic approaches that are not part of the standard regimen for typical heart failure.
• ○ Standard heart failure therapies, including beta-blockers and angiotensin-converting enzyme inhibitors, must be up-titrated rapidly.
• ○ The patient will likely require emergent coronary revascularization to prevent further ischemic cardiomyopathy.
• ○ Establishing the diagnosis will primarily guide the timing for implantation of a left ventricular assist device.

Explanation. Certain conditions that cause heart failure, such as amyloid heart disease (which presents with signs like left ventricular thickening, low ECG voltage, and a history of carpal tunnel syndrome), require disease-specific therapies directed at transthyretin or light chain deposition that otherwise would not be used in general heart failure management, making an expeditious and accurate diagnosis crucial.

Question 21

A 74-year-old male with a history of ischemic cardiomyopathy, heart failure, and a permanent pacemaker presents with worsening orthopnea and a 10-lb weight gain over the last month. He reports strict adherence to his sodium-restricted diet and medical regimen. Six weeks ago, he was started on amiodarone for symptomatic atrial arrhythmias. Device interrogation reveals a substantial increase in the percentage of ventricular paced beats. Which of the following mechanisms is most likely responsible for his recent clinical deterioration?

• ✓ Amiodarone-induced bradycardia leading to resultant chronic right ventricular pacing
• ○ Amiodarone-induced hyperthyroidism precipitating high-output heart failure
• ○ Amiodarone-related pulmonary toxicity causing acute pulmonary embolism
• ○ Amiodarone-induced renal hypoperfusion resulting in acute diuretic resistance

Explanation. Amiodarone is an antiarrhythmic medication that can induce significant bradycardia. In a patient with a permanent pacemaker, this bradycardia triggers the device to pace more frequently, leading to a high burden of chronic right ventricular (RV) pacing. Chronic RV pacing causes abnormal electrical and mechanical activation of the ventricles (dyssynchrony), which is a recognized cause of clinical deterioration and worsening heart failure symptoms.

Question 22

A 62-year-old female presents to the cardiology clinic with a 3-week history of progressive exertional dyspnea, paroxysmal nocturnal dyspnea, and bilateral lower extremity edema. A physical examination reveals jugular venous distention and bilateral basilar crackles. Transthoracic echocardiography demonstrates a left ventricular ejection fraction of 35%, confirming a diagnosis of heart failure. You are formulating the initial diagnostic workup to optimize management, identify potential causes, and screen for comorbidities. Which of the following represents the appropriate standard initial evaluation for this patient?

• ✓ Complete blood count, urinalysis, serum electrolytes, blood urea nitrogen, serum creatinine, glucose, fasting lipid profile, liver function tests, iron studies, thyroid-stimulating hormone, and a 12-lead electrocardiogram (ECG).
• ○ Complete blood count, serum electrolytes, thyroid-stimulating hormone, iron studies, an exercise treadmill test, and a 12-lead electrocardiogram (ECG).
• ○ Comprehensive metabolic panel, B-type natriuretic peptide, a 12-lead electrocardiogram (ECG), and routine right heart catheterization.
• ○ Basic metabolic panel, liver function tests, hemoglobin A1c, screening cardiac magnetic resonance (CMR) imaging, and a 12-lead electrocardiogram (ECG).

Explanation. The standard diagnostic evaluation for a patient presenting with newly diagnosed heart failure includes a 12-lead electrocardiogram at the initial encounter, as well as a comprehensive laboratory evaluation. This laboratory workup involves a complete blood count, urinalysis, serum electrolytes (including sodium, potassium, calcium, and magnesium), blood urea nitrogen, serum creatinine, glucose, a fasting lipid profile, liver function tests, iron studies (serum iron, ferritin, transferrin saturation), and a thyroid-stimulating hormone level to appropriately optimize management and identify specific causes and comorbidities.

Question 23

A 45-year-old man presents with new-onset heart failure, characterized by exertional dyspnea and lower extremity edema. Echocardiography reveals a left ventricular ejection fraction of 30%. He reports a history of chronic fatigue, joint pains, and new-onset diabetes mellitus. Physical examination is notable for generalized hyperpigmentation of the skin. Laboratory testing reveals markedly elevated serum ferritin and transferrin saturation. While initiating standard guideline-directed medical therapy (GDMT) for his heart failure, what is the most appropriate rationale for further clinical evaluation based on his presentation?

• ✓ Pursuing additional diagnostic studies to confirm hemochromatosis, as it requires disease-specific management in addition to or beyond GDMT.
• ○ Empirically initiating high-dose corticosteroids to treat suspected sarcoidosis, deferring further diagnostic workup.
• ○ Delaying the initiation of GDMT until the underlying etiology is definitively established through an endomyocardial biopsy.
• ○ Foregoing further diagnostic testing, as GDMT alone is sufficient to manage all forms of non-ischemic cardiomyopathy.

Explanation. Identifying the specific cause of heart failure is important because conditions that cause heart failure, such as hemochromatosis, require disease-specific therapies in addition to or beyond standard guideline-directed medical therapy. Additional diagnostic studies are required to definitively diagnose these specific causes to ensure comprehensive and appropriate patient management.

Question 24

A 65-year-old male is evaluated in the cardiology clinic for new-onset exertional dyspnea, orthopnea, and bilateral lower extremity edema. A 12-lead electrocardiogram (ECG) reveals sinus rhythm with a left bundle branch block. Transthoracic echocardiography demonstrates a left ventricular ejection fraction of 30%. In addition to a complete blood count, urinalysis, basic metabolic panel, liver function tests, and a fasting lipid profile, which of the following laboratory studies should be included in the routine initial evaluation of this patient?

• ✓ Iron studies (serum iron, ferritin, transferrin saturation) and thyroid-stimulating hormone (TSH)
• ○ High-sensitivity C-reactive protein (hs-CRP) and erythrocyte sedimentation rate (ESR)
• ○ Serum and urine protein electrophoresis with immunofixation
• ○ Autoimmune panel including antinuclear antibodies (ANA) and rheumatoid factor

Explanation. Laboratory evaluation including iron studies (serum iron, ferritin, transferrin saturation) and thyroid-stimulating hormone levels provides important information regarding potential causes or confounders of heart failure, patient comorbidities, suitability for and adverse effects of treatments, as well as the severity and prognosis of the condition, making it an essential component of the initial evaluation.

Question 25

A 68-year-old female presents to the ambulatory clinic complaining of progressive exertional dyspnea. Her medical history is significant for hypertension, type 2 diabetes mellitus, and obesity with a body mass index of 38 kg/m2. Physical examination is equivocal, with clear lungs and trace bilateral pedal edema. To evaluate for a suspected cardiac cause of her symptoms, a B-type natriuretic peptide (BNP) level is ordered. Which of the following is the most accurate consideration when interpreting this patient's biomarker results?

• ✓ Obesity is associated with lower levels of BNP, thereby reducing the diagnostic sensitivity of the assay.
• ○ Obesity increases the half-life of circulating BNP, requiring the use of significantly higher diagnostic cut-points.
• ○ The absolute values and cut-points of BNP and N-terminal pro-B-type natriuretic peptide (NT-proBNP) can be used interchangeably in this patient.
• ○ Serial measurements of her BNP levels should be utilized as the primary evidence-based method to guide long-term medical therapy.

Explanation. Obesity is associated with lower circulating levels of B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). This physiological inverse relationship between body adiposity and natriuretic peptide concentrations leads to a reduction in the diagnostic sensitivity of these biomarker assays when evaluating obese patients for heart failure.

Question 26

A 65-year-old man with a history of hypertension, type 2 diabetes mellitus, and peripheral artery disease presents for a routine evaluation. He has no established left ventricular systolic dysfunction or symptomatic heart failure. His physician considers a biomarker-based screening strategy to prevent the development of heart failure. Which of the following approaches is most likely to reduce the incidence of asymptomatic left ventricular dysfunction and newly diagnosed heart failure in this patient?

• ✓ Measurement of B-type natriuretic peptide (BNP) levels, with echocardiography, specialist referral, and risk factor modification if levels are greater than or equal to 50 pg/mL.
• ○ Routine annual screening echocardiography for early detection of left ventricular hypertrophy and initiation of loop diuretics.
• ○ Routine screening with coronary artery calcium scoring followed by aggressive uptitration of beta blockers.
• ○ Measurement of high-sensitivity cardiac troponin levels followed by cardiac magnetic resonance imaging if elevated.

Explanation. In patients at risk for heart failure (such as those with hypertension, diabetes, or known vascular disease) but without established left ventricular systolic dysfunction or symptomatic heart failure, screening with B-type natriuretic peptide (BNP) followed by echocardiography, referral to a cardiovascular specialist, and targeted lifestyle and medical coaching for patients with BNP levels greater than or equal to 50 pg/mL has been shown to reduce the composite endpoint of incident asymptomatic left ventricular dysfunction with or without newly diagnosed heart failure. Furthermore, the accelerated uptitration of renin-angiotensin-aldosterone system (RAAS) antagonists and beta blockers in these patients reduces cardiac events.

Question 27

A 72-year-old female with a history of heart failure with reduced ejection fraction is admitted for an acute exacerbation. On admission, her N-terminal pro-B-type natriuretic peptide (NT-proBNP) level was 9,400 pg/mL. After 5 days of treatment with intravenous loop diuretics and optimization of her guideline-directed medical therapy (GDMT), she is clinically euvolemic, her symptoms have resolved, and she is deemed ready for discharge. Her predischarge NT-proBNP is checked and found to be 5,100 pg/mL. The resident physician asks whether they should delay discharge and intensify therapy to reach a specific NT-proBNP reduction goal before sending the patient home. Which of the following is the most appropriate response regarding the use of predischarge natriuretic peptide levels in this scenario?

• ○ Therapy should be intensified to achieve at least a 50% reduction in NT-proBNP prior to discharge to ensure improved long-term outcomes.
• ✓ Targeting a specific threshold, value, or relative change in NT-proBNP during hospitalization has not been consistently shown to improve outcomes.
• ○ Predischarge NT-proBNP levels are poor predictors of the risk of death or hospital readmission and should not be routinely checked.
• ○ The persistent elevation of NT-proBNP indicates the patient will no longer benefit from further outpatient GDMT optimization.

Explanation. Predischarge BNP and NT-proBNP levels are strong predictors of the risk of death or hospital readmission, and patients in whom these levels decrease with treatment represent a population with better long-term outcomes. However, targeting a certain threshold, absolute value, or relative change in these biomarker levels during hospitalization has not been shown to be consistently effective in improving outcomes, and their primary clinical utility remains in guiding discussions on prognosis, adherence, and the ongoing optimization of medical therapy.

Question 28

A 38-year-old male presents with progressively worsening dyspnea on exertion and lower extremity edema over the past three months. An echocardiogram reveals a dilated left ventricle with a severely reduced ejection fraction of 25%, consistent with dilated cardiomyopathy (DCM). A 12-lead electrocardiogram (ECG) demonstrates sinus rhythm with first-degree atrioventricular block and a right bundle branch block. A 24-hour Holter monitor captures frequent premature ventricular complexes and multiple runs of non-sustained ventricular tachycardia. Based on this presentation of DCM with significant conduction system disease and ventricular arrhythmias, which of the following etiologies should be highly suspected due to the elevated risk of sudden death?

• ✓ Cardiac sarcoidosis and arrhythmogenic cardiomyopathy
• ○ Hemochromatosis and transthyretin cardiac amyloidosis
• ○ Giant cell myocarditis and Chagas disease
• ○ Loeffler endocarditis and Fabry disease

Explanation. The presentation of dilated cardiomyopathy (DCM) accompanied by conduction disease or ventricular arrhythmias raises a specific clinical concern for cardiac sarcoidosis and arrhythmogenic cardiomyopathy. Identifying these conditions is critical because they carry an inherently high risk of sudden cardiac death for both the patient and potentially affected family members, which impacts risk stratification and the decision to utilize an implantable cardioverter-defibrillator for primary prevention.

Question 29

A 38-year-old woman is diagnosed with familial dilated cardiomyopathy. Subsequent genetic testing reveals a pathogenic variant known to cause the condition. She brings her 18-year-old son to the clinic for a consultation. The son is completely asymptomatic, exercises regularly without limitation, and has an unremarkable physical examination. After extensive counseling regarding the implications of genetic testing, including the possibility of genetic discrimination, the son decides he does not want to undergo genetic testing at this time. What is the most appropriate approach to clinical surveillance for the son?

• ✓ Periodic screening with echocardiography and electrocardiography
• ○ Clinical follow-up with testing only if he develops cardiovascular symptoms
• ○ A single, baseline evaluation with cardiac magnetic resonance imaging
• ○ Prophylactic initiation of low-dose beta-blocker therapy

Explanation. Unless shown to be free of the genetic variant implicated in the proband, first-degree relatives of affected patients should undergo periodic screening with echocardiography and electrocardiography.

Question 30

A 26-year-old man is diagnosed with arrhythmogenic cardiomyopathy after presenting with symptomatic premature ventricular complexes. Genetic testing reveals a pathogenic variant in a desmosomal protein. An echocardiogram shows a left ventricular ejection fraction of 50% with mild right ventricular dilation. He is an avid competitive cyclist and asks for advice regarding his training regimen. Which of the following is the most appropriate recommendation?

• ✓ Advise him to avoid strenuous exercise as it may accelerate ventricular remodeling.
• ○ Reassure him that competitive cycling is safe as long as his left ventricular ejection fraction remains greater than 35%.
• ○ Recommend placement of an implantable cardioverter-defibrillator so he can safely resume competitive cycling.
• ○ Instruct him to limit exercise only if he develops symptomatic heart failure or atrial arrhythmias.

Explanation. In patients with evidence of desmosomal cardiac disease, such as arrhythmogenic cardiomyopathy, it is crucial to advise the avoidance of strenuous exercise because it has been shown to accelerate ventricular remodeling and exacerbate the disease process.

Question 31

A 72-year-old woman with a history of poorly controlled hypertension presents to the emergency department with acute-onset severe dyspnea, orthopnea, and paroxysmal nocturnal dyspnea. On physical examination, her blood pressure is 180/100 mmHg, her heart rate is 110 beats per minute, and auscultation reveals an S3 gallop along with bilateral basal crackles. An initial chest x-ray is obtained to evaluate her symptoms. The radiograph reveals normal heart size (no cardiomegaly) and lacks clear evidence of alveolar edema or cephalization. Based on the diagnostic utility of chest radiography in this clinical setting, which of the following is the most accurate interpretation of these findings?

• ○ The absence of cardiomegaly and alveolar edema strongly excludes acute heart failure, pointing instead to a primary pulmonary pathology.
• ✓ The diagnosis of acute heart failure remains a strong clinical possibility because cardiomegaly can be absent and radiographic signs of edema are relatively insensitive.
• ○ The absence of alveolar edema effectively rules out elevated left-sided filling pressures due to the high sensitivity of this radiographic finding.
• ○ The lack of radiographic findings requires that the chest x-ray be used as the sole determinant to rule out the presence of heart failure.

Explanation. In patients presenting with acute heart failure, cardiomegaly may be entirely absent on an initial chest x-ray. Furthermore, while classic radiographic findings such as cephalization, interstitial edema, and alveolar edema are modestly specific for heart failure, they are relatively insensitive. Because of this limited sensitivity and specificity, the absence of these signs does not rule out the condition, and a chest x-ray should not be used as the sole determinant for the presence or specific cause of heart failure.

Question 32

A 58-year-old man with a long-standing history of hypertension and obesity presents with new-onset exertional fatigue and mild orthopnea. Physical examination is notable for a laterally displaced point of maximal impulse and trace pedal edema. He undergoes a transthoracic echocardiogram for the evaluation of suspected heart failure. During this evaluation, which of the following echocardiographic parameters is utilized specifically to identify subclinical left ventricular systolic dysfunction that portends a greater risk for developing heart failure or future hospitalizations?

• ✓ Global longitudinal strain
• ○ Tricuspid valve regurgitant gradient
• ○ Inferior vena cava diameter respiratory response
• ○ Left atrial pressure estimate

Explanation. Global longitudinal strain is an index of myocardial deformation that can identify subclinical left ventricular systolic dysfunction, a finding associated with a greater risk of developing clinical heart failure or experiencing recurrent heart failure hospitalizations.

Question 33

A 68-year-old woman with a history of heart failure with reduced ejection fraction (left ventricular ejection fraction of 35% measured 18 months ago) presents for a routine follow-up clinic visit. She reports feeling well, adheres strictly to her guideline-directed medical therapy, and denies any worsening dyspnea, orthopnea, or lower extremity edema. Vital signs are within normal limits. Her physical examination reveals clear lungs, normal heart sounds without new murmurs, and no jugular venous distention. The patient asks if she should have another echocardiogram to "check on her heart." Based on her current presentation, what is the most appropriate management regarding echocardiography?

• ○ Order an echocardiogram to evaluate for reverse remodeling given her strict adherence to therapy.
• ○ Order an echocardiogram to ensure no subclinical structural remodeling has occurred despite clinical stability.
• ✓ Defer echocardiography at this time, as serial imaging is not routinely indicated in clinically stable patients.
• ○ Schedule an echocardiogram annually to monitor for potential silent worsening of ventricular or valvular function.

Explanation. Serial echocardiograms to assess changes in ejection fraction, structural remodeling, and valvular function are not recommended routinely in clinically stable patients; however, they are useful and indicated when a patient experiences an unexplained, significant change in clinical status.

Question 34

A 58-year-old man presents to the clinic for follow-up of newly diagnosed non-ischemic heart failure with reduced ejection fraction. His baseline transthoracic echocardiogram (TTE) showed a left ventricular ejection fraction (LVEF) of 28%. He was recently initiated on guideline-directed medical therapy (GDMT). You are considering his potential need for a primary prevention implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT). What is the minimum recommended time frame to reevaluate his LVEF after the initiation of GDMT to determine device candidacy?

• ○ Greater than 14 days
• ○ Greater than 30 days
• ○ Greater than 40 days
• ✓ Greater than 90 days

Explanation. Reevaluation of ejection fraction to determine candidacy for an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT) is appropriate at a time point of greater than 90 days after the initiation of guideline-directed medical therapy (GDMT). This interval allows sufficient time to assess for potential recovery of left ventricular function in response to medical therapy before committing to device implantation.

Question 35

A 24-year-old female with a history of an uncharacterized childhood murmur presents with new-onset exertional dyspnea and fatigue. Initial transthoracic echocardiography is limited by poor acoustic windows, but the findings raise strong suspicion for an underlying congenital heart disease. The physician needs an imaging modality that provides high anatomic resolution of the heart and surrounding structures, as well as highly reproducible assessments of biventricular volumes, mass, and ejection fraction (EF). Which of the following imaging modalities is the most appropriate choice to achieve these goals while minimizing long-term risks for this young patient?

• ✓ Cardiac magnetic resonance (CMR) imaging
• ○ Electrocardiographic-gated cardiac computed tomography (CT)
• ○ Radionuclide ventriculography
• ○ Positron emission tomography (PET) scan

Explanation. Cardiac magnetic resonance (CMR) imaging provides an accurate and highly reproducible assessment of cardiac volumes, mass, and ejection fraction of the left and right ventricles. It also delivers high anatomic resolution of all aspects of the heart and surrounding structures without exposing the patient to ionizing radiation, making it the recommended modality for evaluating known or suspected congenital heart diseases.

Question 36

A 54-year-old man presents with progressive fatigue and exertional dyspnea. Echocardiography reveals a left ventricular ejection fraction of 35% with global hypokinesis. Coronary angiography shows normal coronary arteries, establishing a diagnosis of nonischemic cardiomyopathy. His history, physical examination, and initial echocardiogram lack specific features suggesting an infiltrative, inflammatory, or otherwise distinct etiology. The care team debates whether to order cardiac magnetic resonance (CMR) imaging to screen for a specific underlying cause. Which of the following is the most appropriate rationale regarding the use of CMR in this patient?

• ✓ Routine CMR screening is not indicated because it does not yield more specific heart failure causes than a selective approach guided by clinical and echocardiographic findings.
• ○ Routine CMR screening is indicated because it consistently identifies specific infiltrative causes of heart failure missed by selective screening approaches.
• ○ CMR is indicated specifically to utilize T-2 mapping techniques, which allow for the measurement of the extracellular volume fraction.
• ○ CMR is not indicated because late-gadolinium enhancement is exclusively useful for identifying acute or chronic myocardial infarction.

Explanation. A strategy of routine screening with cardiac magnetic resonance imaging in patients with nonischemic cardiomyopathy has not been shown to yield more specific causes of heart failure than a selective strategy based on specific echocardiographic and clinical findings.

Question 37

A 62-year-old man with a history of hypertension and type 2 diabetes is newly diagnosed with heart failure with reduced ejection fraction. He has no prior history of angina or myocardial infarction. To evaluate for ischemic heart disease as the underlying etiology of his heart failure, which of the following approaches is most appropriate for noninvasive identification of likely obstructive coronary artery disease?

• ✓ Stress imaging with echocardiography
• ○ Coronary artery calcium scoring without angiography
• ○ Resting transthoracic echocardiography
• ○ Pulmonary ventilation/perfusion (V/Q) scan

Explanation. Evaluation for ischemic heart disease is an important step in determining the etiology of heart failure, as coronary atherosclerosis is a frequent cause. Noninvasive stress imaging with echocardiography or nuclear scintigraphy is helpful in identifying patients who are likely to have obstructive coronary artery disease.

Question 38

A 62-year-old man with ischemic cardiomyopathy, a left ventricular ejection fraction (LVEF) of 25%, and severe triple-vessel coronary artery disease is being evaluated for coronary artery bypass grafting (CABG). He has no major comorbidities and his surgical risk is low. The multidisciplinary team is discussing whether to perform routine myocardial viability imaging using cardiac magnetic resonance (CMR) or positron emission tomography (PET) to predict if he will derive a long-term survival benefit from surgical revascularization. What is the most accurate statement regarding the role of viability testing for predicting outcomes in this clinical scenario?

• ○ Routine viability imaging significantly improves the guidance of revascularization, leading to a marked reduction in adverse cardiovascular outcomes.
• ✓ The presence of myocardial viability does not determine the long-term benefit from surgical revascularization in patients with ischemic cardiomyopathy.
• ○ Viability assessment is only useful for predicting outcomes if performed exclusively with single-photon emission computed tomography (SPECT).
• ○ Observational data and randomized controlled trials both demonstrate that identifying viable but dysfunctional myocardium is required to ensure a survival benefit from revascularization.

Explanation. Data from randomized controlled trials, notably the Surgical Treatment for Ischemic Heart Failure (STICH) trial, demonstrate that the presence of myocardial viability does not determine the long-term benefit from surgical revascularization in patients with ischemic cardiomyopathy, meaning viability imaging does not improve the guidance of revascularization to a reduction of adverse cardiovascular outcomes.

Question 39

A 68-year-old woman with a history of heart failure with reduced ejection fraction presents to the intensive care unit with acute respiratory distress, oliguria, and cool, mottled extremities. Her blood pressure is 78/52 mmHg, and her heart rate is 112 beats per minute. Clinical assessment of volume status is challenging, and her hemodynamics remain uncertain. Which of the following is the most appropriate next step in her evaluation to guide immediate treatment decisions?

• ✓ Hemodynamic evaluation with right heart catheterization
• ○ Routine endomyocardial biopsy
• ○ Repeat noninvasive echocardiography for routine surveillance
• ○ Left heart catheterization with coronary angiography

Explanation. Hemodynamic evaluation with right heart catheterization and monitoring is indicated to guide treatment decisions in the setting of acute respiratory distress, systemic hypoperfusion including cardiogenic shock, or when hemodynamics are uncertain.

Question 40

A 48-year-old female is admitted to the cardiac intensive care unit with a 3-week history of rapidly progressive heart failure (HF). Despite the initiation of appropriate medical treatment, her clinical status deteriorates, and echocardiography demonstrates worsening left ventricular dysfunction. Continuous telemetry reveals frequent ventricular arrhythmias. The clinical care team highly suspects active giant cell myocarditis. Which of the following is the most appropriate next diagnostic step to direct specific treatment?

• ✓ Endomyocardial biopsy
• ○ Cardiac magnetic resonance (CMR) imaging
• ○ Coronary computed tomography angiography (CCTA)
• ○ Fluorodeoxyglucose-positron emission tomography (FDG-PET) scan

Explanation. Endomyocardial biopsy is highly useful when seeking a specific diagnosis that directly influences treatment decisions. It is specifically indicated for patients with rapidly progressive clinical heart failure or worsening ventricular dysfunction that persists despite appropriate medical treatment, as well as those with unexplained cardiomyopathy in whom active myocarditis, especially giant cell myocarditis, is being considered.

Question 41

A 72-year-old woman with a history of ischemic cardiomyopathy (left ventricular ejection fraction 25%) and an implanted cardiac resynchronization therapy defibrillator (CRT-D) presents for a follow-up. She has experienced recurrent episodes of fluid overload requiring hospital admission over the last 12 months despite maximal tolerated guideline-directed medical therapy. The clinical team considers utilizing remote monitoring to anticipate and prevent future decompensations. Which of the following remote monitoring strategies is most supported by clinical evidence to reduce her risk of heart failure hospitalization?

• ○ Utilizing the existing CRT-D for remote monitoring of thoracic impedance
• ○ Providing a noninvasive telemonitoring system for daily symptom and weight tracking
• ✓ Implanting a permanent pulmonary artery pressure sensor
• ○ Monitoring patient activity and resting heart rate via the existing CRT-D

Explanation. Implantation of a pulmonary artery pressure sensor in selected patients with heart failure is supported by randomized trial and observational data to reduce the risk of heart failure hospitalization.

Question 42

A 68-year-old man with a history of New York Heart Association (NYHA) class III heart failure and a left ventricular ejection fraction of 55% presents to the clinic. He was hospitalized for a heart failure exacerbation four months ago and is currently on stable doses of a beta-blocker and an angiotensin II receptor blocker. The cardiology team considers the implantation of a pulmonary artery (PA) pressure monitor for hemodynamic-guided management. Based on the major trials evaluating this technology, which of the following best describes the expected clinical outcomes and current evidence regarding this device?

• ✓ It is associated with a significant reduction in heart failure-related hospitalizations, with clinical benefits observed in patients with both reduced and preserved ejection fraction.
• ○ It has been definitively proven to reduce the composite endpoint of mortality and total heart failure events across patients with NYHA class II to IV heart failure.
• ○ The clinical benefit of reducing hospitalizations was observed exclusively in patients with heart failure with reduced ejection fraction (HFrEF).
• ○ It provides similar clinical benefits to remote monitoring of thoracic impedance and heart rate via an implantable cardioverter-defibrillator.

Explanation. The CHAMPION trial demonstrated that in patients with NYHA class III heart failure and a recent heart failure hospitalization, an implanted pulmonary artery pressure monitor significantly reduced heart failure-related hospitalizations after 6 months. This benefit persisted during longer-term follow-up and was observed in subjects with both reduced and preserved left ventricular ejection fraction.

Question 43

A healthcare committee is evaluating the adoption of wireless pulmonary artery (PA) pressure monitoring (e.g., CardioMEMS) for patients with heart failure. Based on cost-effectiveness studies utilizing data from the CHAMPION-HF study, what is the anticipated economic and clinical impact of implementing this monitoring system?

• ○ It decreases overall healthcare costs by preventing recurrent heart failure hospitalizations, while leaving survival and quality-adjusted life years (QALYs) unchanged.
• ✓ It increases survival and quality-adjusted life years (QALYs) but concurrently increases healthcare costs, yielding intermediate to high economic value.
• ○ It provides low economic value due to an unclear effect on mortality and an overall decrease in QALYs over a 5-year period.
• ○ It provides high economic value by reducing mortality and decreasing long-term costs, as confirmed by cost-effectiveness models incorporating the GUIDE-HF trial.

Explanation. Analyses evaluating the cost-effectiveness of wireless PA pressure monitoring using data from the CHAMPION-HF study consistently estimated that the device increased survival and quality-adjusted life years (QALYs) while increasing costs, with studies classifying its overall economic value as intermediate to high.

Question 44

A 72-year-old man with a history of ischemic heart failure (HF) with a left ventricular ejection fraction of 25% presents for a routine follow-up. His current medications include sacubitril-valsartan, carvedilol, and spironolactone. During the interview, he reports feeling completely comfortable while sitting in his recliner or lying in bed. However, he notes that walking across the hallway to the bathroom—a task requiring less exertion than his ordinary daily activities—reliably provokes dyspnea and fatigue. He denies any shortness of breath while at rest. Based on this clinical presentation, which of the following best categorizes this patient's functional limitation?

• ○ New York Heart Association (NYHA) Class I
• ○ New York Heart Association (NYHA) Class II
• ✓ New York Heart Association (NYHA) Class III
• ○ New York Heart Association (NYHA) Class IV

Explanation. The New York Heart Association (NYHA) Class III functional classification specifically describes patients who are comfortable at rest but experience symptoms of heart failure (such as dyspnea or fatigue) with less than ordinary physical activity.

Question 45

A 62-year-old male with advanced ischemic cardiomyopathy is evaluated in the advanced heart failure clinic for potential heart transplant listing. His current medical regimen includes lisinopril, spironolactone, empagliflozin, and bisoprolol (a beta-blocker), all of which he has tolerated well for the past year. He is scheduled for a cardiopulmonary exercise test (CPET) for risk stratification. In this patient who is tolerating beta-blocker therapy, which of the following peak oxygen consumption (VO2) values is the suggested cutoff to consider listing him for a cardiac transplant?

• ○ Peak VO2 ≤ 10 mL/kg/min
• ✓ Peak VO2 ≤ 12 mL/kg/min
• ○ Peak VO2 ≤ 14 mL/kg/min
• ○ Peak VO2 ≤ 16 mL/kg/min

Explanation. In patients with heart failure who are tolerating beta-blocker therapy, a peak oxygen consumption (VO2) of less than or equal to 12 mL/kg/min is the suggested cutoff to consider listing for cardiac transplantation, because these patients have improved survival at an equivalent VO2 compared with patients who do not tolerate beta-blockers.

Question 46

A 65-year-old male with a history of non-ischemic cardiomyopathy and heart failure with reduced ejection fraction is evaluated in the clinic. The facility lacks the equipment and trained personnel required for cardiopulmonary exercise testing (CPET). Instead, a 6-minute walk test is administered to assess his exercise capacity. The patient completes a total distance of 275 meters on a flat course. Which of the following is the most accurate conclusion regarding this patient's clinical status and prognosis based on this assessment?

• ✓ His performance correlates with New York Heart Association (NYHA) class III to IV symptoms and is associated with a worse 3-year survival free of heart transplant.
• ○ He likely has New York Heart Association (NYHA) class I to II symptoms and an 82% 3-year survival free of heart transplant.
• ○ The test results are considered an invalid indicator of functional capacity because he walked less than 490 meters.
• ○ This distance correlates perfectly with a high peak oxygen consumption (VO2) and indicates a highly favorable prognosis.

Explanation. In patients with heart failure, a 6-minute walk test distance of less than 300 meters roughly correlates to New York Heart Association (NYHA) class III to IV symptoms and is associated with a worse 3-year survival free of heart transplant (approximately 62% versus 82% for those walking 300 meters or more).

Question 47

A 55-year-old man presents to the clinic with chronic, unexplained dyspnea on exertion. His past medical history is notable for obesity and mild hypertension. Resting echocardiography and baseline pulmonary function tests are unremarkable. He undergoes cardiopulmonary exercise testing (CPET) using a treadmill to further evaluate his symptoms. The results indicate a significantly diminished overall exercise capacity. However, his heart rate, blood pressure, electrocardiographic (ECG) findings, and ventilatory gas exchange measurements (including oxygen uptake, carbon dioxide output, and ventilation) demonstrate normal physiological responses to the level of exertion achieved. Which of the following is the most likely primary etiology of this patient's dyspnea?

• ○ Ischemic cardiomyopathy
• ✓ Physical deconditioning
• ○ Chronic obstructive pulmonary disease
• ○ Pulmonary arterial hypertension

Explanation. Cardiopulmonary exercise testing (CPET) provides a comprehensive assessment of multiple physiological measures that impact exercise capacity, integrating gas exchange analysis with standard exercise variables like heart rate, blood pressure, and electrocardiographic findings. When a patient demonstrates a diminished overall exercise capacity but normal cardiopulmonary responses to the exertion, it points away from primary cardiac or respiratory etiologies. Instead, this specific pattern indicates that the dyspnea is driven by other factors, such as physical deconditioning or metabolic abnormalities.

Question 48

A 72-year-old woman with chronic heart failure presents to the clinic for a routine follow-up. Her clinician wants to use a validated predictive risk model to guide discussions on her prognosis, goals of care, and future treatment decisions. When selecting a predictive model, the clinician should be aware of the performance characteristics of these tools. Which of the following best describes the accuracy of current predictive models for heart failure outcomes?

• ✓ The best performing models focus on predicting short- and long-term mortality.
• ○ Predictive models for hospital readmission demonstrate excellent discrimination.
• ○ Risk models for incident heart failure are discouraged in standard clinical evaluation.
• ○ Predictive models are equally accurate for mortality and hospital readmission.

Explanation. The best performing predictive models for patients with heart failure have focused on predicting short- and long-term mortality, whereas predictive models for hospitalization or readmission have generally demonstrated poor or modest discrimination.

Question 49

A 65-year-old male with chronic heart failure is seen in the cardiology clinic. His symptoms have been progressively worsening over the past few months despite being on maximally tolerated, guideline-directed medical therapy. The cardiologist considers using biomarker testing and multivariable clinical risk scores to objectively assess his prognosis. What is a primary clinical utility of applying these objective risk stratification methods in this scenario?

• ○ To determine the exact intravenous loop diuretic dosage required for acute symptomatic relief.
• ✓ To guide therapeutic decision-making, including a more rapid transition to advanced heart failure therapies.
• ○ To definitively identify the specific ischemic or nonischemic etiology of the patient's cardiomyopathy.
• ○ To substitute for routine echocardiographic assessment of left ventricular ejection fraction.

Explanation. Objective risk stratification using biomarker testing and multivariable clinical risk scores helps guide therapeutic decision-making, specifically by identifying high-risk patients who may benefit from a more rapid transition to advanced heart failure therapies.

Question 50

A 65-year-old male with chronic heart failure (HF) presents to the cardiology clinic for a routine ambulatory follow-up. He is currently stable on guideline-directed medical therapy. As part of a comprehensive assessment, the cardiologist wishes to estimate the patient's survival probability using a specific clinical risk model that is noted for being derived and validated across multiple clinical trials and cohorts, including more recent studies. Which of the following predictive models best fits this description?

• ○ Seattle Heart Failure Model
• ○ Heart Failure Survival score
• ✓ MAGGIC score
• ○ TIMI risk score

Explanation. The MAGGIC predictive model is commonly used to provide estimates of survival in patients with chronic heart failure and is particularly useful given its robust derivation and validation across multiple clinical trials and cohorts, including more recent studies.

Question 51

A 65-year-old woman with a history of type 2 diabetes mellitus, hypertension, and peripheral artery disease presents for a routine follow-up. She is fully active and denies any dyspnea, orthopnea, or lower extremity edema. Current medications include metformin, lisinopril, amlodipine, and atorvastatin. Her blood pressure is 126/78 mm Hg. Recent echocardiography shows a normal left ventricular ejection fraction of 60% with no structural abnormalities. Which of the following drug classes should be added to her regimen to improve survival and reduce the risk of future heart failure (HF) hospitalizations?

• ✓ Sodium-glucose cotransporter-2 inhibitor (SGLT2i)
• ○ Angiotensin receptor-neprilysin inhibitor (ARNI)
• ○ Mineralocorticoid receptor antagonist (MRA)
• ○ Dipeptidyl peptidase-4 (DPP-4) inhibitor

Explanation. In patients with diabetes mellitus and established cardiovascular disease who do not have clinical heart failure, the use of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) has been shown to improve overall survival and significantly reduce the rate of future heart failure hospitalizations.

Question 52

A 65-year-old man with hypertension, hyperlipidemia, and no history of diabetes or heart failure (HF) presents to the clinic for a routine follow-up. His home and in-office systolic blood pressure (SBP) readings consistently range between 134 and 138 mm Hg on his current regimen of lisinopril and amlodipine. His overall cardiovascular risk is considered elevated. You discuss intensifying his antihypertensive regimen to prevent incident HF and reduce overall mortality. Based on the findings of the SPRINT (Systolic Blood Pressure Intervention Trial), targeting an SBP goal of <120 mm Hg, rather than <140 mm Hg, is associated with which of the following relative reductions in incident HF and mortality?

• ✓ A 38% reduction in incident HF and a 23% reduction in mortality
• ○ A 23% reduction in incident HF and a 38% reduction in mortality
• ○ A 40% reduction in incident HF and a 40% reduction in mortality
• ○ A 30% reduction in incident HF and a 15% reduction in mortality

Explanation. Intensive blood pressure control to a systolic blood pressure goal of <120 mm Hg decreases incident heart failure by 38% and overall mortality by 23% compared with a standard systolic blood pressure goal of <140 mm Hg.

Question 53

A 62-year-old woman presents for a routine follow-up. She has a history of essential hypertension, type 2 diabetes mellitus, and peripheral vascular disease. She reports no shortness of breath, orthopnea, or edema. She exercises regularly without limitations. Based on study data from patients with similar risk profiles but no established left ventricular systolic dysfunction or symptomatic heart failure, which of the following screening strategies is associated with a reduction in the development of asymptomatic left ventricular dysfunction?

• ✓ Screening with B-type natriuretic peptide (BNP) testing and referring to a cardiovascular specialist with an echocardiogram if levels are 50 pg/mL or greater.
• ○ Routine annual echocardiography to monitor for early declines in left ventricular ejection fraction.
• ○ Screening with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and initiating an angiotensin receptor-neprilysin inhibitor if levels exceed 125 pg/mL.
• ○ Immediate implementation of a supervised cardiac rehabilitation program to preserve cardiac structure.

Explanation. In patients at risk of heart failure (identified by the presence of hypertension, diabetes, or known vascular disease) but without established left ventricular systolic dysfunction or symptomatic heart failure at baseline, screening with B-type natriuretic peptide (BNP) testing is beneficial. Intervening on those with BNP levels of 50 pg/mL or greater by performing echocardiography and referring to a cardiovascular specialist reduces the composite endpoint of asymptomatic left ventricular dysfunction.

Question 54

A 62-year-old man with type 2 diabetes mellitus and hypertension presents for a routine follow-up. He is asymptomatic and exercises daily without dyspnea or fatigue. His current medications include low-dose lisinopril and low-dose carvedilol. Recent laboratory screening reveals an elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) level. A comprehensive transthoracic echocardiogram demonstrates normal left ventricular systolic and diastolic function, with no evidence of structural cardiac disease. Which of the following management strategies has been shown to reduce future cardiac events in this specific patient population?

• ✓ Accelerated uptitration of renin-angiotensin-aldosterone system (RAAS) antagonists and beta blockers
• ○ Maintenance of current medication doses with repeat NT-proBNP testing in 12 months
• ○ Immediate transition from lisinopril to an angiotensin receptor-neprilysin inhibitor (ARNI)
• ○ Initiation of low-dose loop diuretic therapy to normalize NT-proBNP levels

Explanation. In patients with diabetes mellitus who have elevated NT-proBNP levels but no baseline cardiac disease, the accelerated uptitration of renin-angiotensin-aldosterone system (RAAS) antagonists and beta blockers reduces the incidence of future cardiac events.

Question 55

A 58-year-old man presents for a routine wellness exam. His past medical history is significant for essential hypertension and hyperlipidemia. His current medications include lisinopril and atorvastatin. His blood pressure is 134/82 mmHg, body mass index is 29 kg/m2, fasting glucose is 105 mg/dL, and total cholesterol is 190 mg/dL. He is a current smoker. The clinician decides to calculate the patient's 10-year risk of incident heart failure using the Pooled Cohort equations to Prevent HF (PCP-HF) model. Which additional parameter is required to complete this specific risk calculation?

• ✓ QRS duration
• ○ Left ventricular ejection fraction
• ○ N-terminal pro-B-type natriuretic peptide (NT-proBNP)
• ○ Left atrial volume index

Explanation. The Pooled Cohort equations to Prevent HF (PCP-HF) model provides race- and sex-specific 10-year risk equations for incident heart failure. The predictors included in this model are age, blood pressure (treated or untreated), fasting glucose (treated or untreated), body mass index, cholesterol, smoking status, and QRS duration.

Question 56

A 55-year-old male presents for a routine follow-up. He has a history of an anterior myocardial infarction 6 months ago. He reports no symptoms of dyspnea, orthopnea, or edema, and he exercises regularly without limitations. A recent echocardiogram reveals a left ventricular ejection fraction (LVEF) of 38%. His current medications include aspirin, atorvastatin, and metoprolol succinate. Which of the following medications should be added to his current regimen to prevent the development of symptomatic heart failure and reduce mortality?

• ✓ Angiotensin-converting enzyme inhibitor (ACEi)
• ○ Furosemide
• ○ Digoxin
• ○ Ivabradine

Explanation. In asymptomatic patients with a left ventricular ejection fraction of 40% or less (Stage B, or pre-heart failure), an angiotensin-converting enzyme inhibitor should be used to prevent the onset of symptomatic heart failure and reduce mortality.

Question 57

A 62-year-old asymptomatic woman undergoes an echocardiogram prior to an elective surgery, revealing a left ventricular ejection fraction (LVEF) of 34% and mild left ventricular enlargement. She denies any shortness of breath, orthopnea, or peripheral edema, and is able to walk three miles daily without difficulty. She has a medical history of hypertension and type 2 diabetes. What is the most appropriate pharmacological strategy to prevent or delay her transition to symptomatic heart failure?

• ✓ Initiation of an inhibitor of the renin-angiotensin system and a beta blocker
• ○ Initiation of a loop diuretic and a non-dihydropyridine calcium channel blocker
• ○ Continuation of current care with routine observation until symptomatic heart failure develops
• ○ Initiation of specific targeted therapy solely to improve asymptomatic diastolic dysfunction

Explanation. In patients with clinically asymptomatic structural cardiac abnormalities and depressed left ventricular ejection fraction (LVEF <35%-40%), the initiation of pharmacotherapy with inhibitors of the renin-angiotensin system and beta blockers is beneficial to prevent or delay the transition to symptomatic heart failure.

Question 58

A 62-year-old male presents for follow-up 2 weeks after an anterior myocardial infarction (MI) treated with primary percutaneous coronary intervention. His echocardiogram demonstrates a left ventricular ejection fraction (LVEF) of 36%. He is currently completely asymptomatic and reports no dyspnea, orthopnea, or edema, consistent with Stage B heart failure. You are contemplating his neurohormonal blockade regimen. Regarding the use of an angiotensin receptor-neprilysin inhibitor (ARNI) such as sacubitril/valsartan in this specific clinical scenario, which of the following statements is most accurate?

• ✓ ARNIs have not been well studied in stage B heart failure.
• ○ ARNIs have demonstrated superior mortality benefits over ACE inhibitors specifically in stage B heart failure.
• ○ ARNIs are contraindicated due to a high risk of symptomatic hypotension in stage B heart failure.
• ○ ARNIs are well established as first-line therapy for all patients with stage B heart failure.

Explanation. ARNIs have not been well studied in stage B heart failure. The efficacy and safety of sacubitril/valsartan in asymptomatic patients after an acute myocardial infarction with reduced ejection fraction are the subject of ongoing clinical investigation, such as the PARADISE-MI trial, which compares sacubitril/valsartan to an ACE inhibitor (ramipril).

Question 59

A 62-year-old woman is evaluated in the outpatient cardiology clinic 3 weeks after surviving an acute myocardial infarction (MI). She reports feeling well, has resumed her normal daily activities, and explicitly denies any dyspnea, orthopnea, paroxysmal nocturnal dyspnea, or peripheral edema. A resting transthoracic echocardiogram reveals a left ventricular ejection fraction (LVEF) of 34%. Which of the following therapeutic strategies has been shown to impede maladaptive ventricular remodeling and reduce her risk of mortality and progression to severe heart failure (HF)?

• ✓ Initiation of an angiotensin-converting enzyme inhibitor (ACEi)
• ○ Initiation of a non-dihydropyridine calcium channel blocker
• ○ Maintenance with isolated beta-blocker therapy without renin-angiotensin system antagonism
• ○ Prophylactic administration of a class Ic antiarrhythmic agent

Explanation. Angiotensin-converting enzyme inhibitors (ACEi) impede maladaptive ventricular remodeling after an acute myocardial infarction in patients with a reduced left ventricular ejection fraction. In survivors of an acute myocardial infarction who have asymptomatic left ventricular dysfunction, ACEi therapy significantly reduces mortality, heart failure hospitalizations, and the progression to severe symptomatic heart failure.

Question 60

A 58-year-old male is evaluated in the cardiology clinic 2 weeks after an acute myocardial infarction (MI). Echocardiography reveals a reduced left ventricular ejection fraction (LVEF) of 35%, though the patient reports no dyspnea, orthopnea, or edema. During his initial hospitalization, he was started on captopril, an angiotensin-converting enzyme inhibitor (ACEi), but he subsequently developed severe lip and tongue swelling consistent with angioedema, leading to the immediate discontinuation of the medication. You are considering initiating an angiotensin receptor blocker (ARB). Which of the following is the most appropriate strategy and consideration for this patient?

• ✓ Initiate valsartan, expecting comparable cardiovascular benefits to captopril, but counsel the patient to monitor closely for recurrent angioedema.
• ○ Initiate losartan at 50 mg daily, as this specific dose has been proven noninferior to captopril for reducing mortality after an MI.
• ○ Initiate valsartan, as this class of medication carries zero risk of cross-reactivity for angioedema in patients with prior ACEi-induced events.
• ○ Avoid initiating an ARB entirely, as there are no clinical trials evaluating their use in patients with asymptomatic reduced LVEF following an MI.

Explanation. Valsartan provides comparable benefits to captopril regarding mortality and adverse cardiovascular outcomes in patients who have asymptomatic left ventricular dysfunction following a myocardial infarction (MI). Furthermore, while angiotensin receptor blockers (ARBs) serve as a viable alternative for patients who have experienced angiotensin-converting enzyme inhibitor (ACEi)-induced angioedema, cautious administration and counseling are necessary because some patients may still develop angioedema with ARB therapy.

Question 61

A 60-year-old man presents for a follow-up 3 months after a myocardial infarction. He reports feeling well, walking 3 miles daily without fatigue or dyspnea, and denies any orthopnea or paroxysmal nocturnal dyspnea. His physical examination is unremarkable. Echocardiography demonstrates a left ventricular ejection fraction (LVEF) of 28%. He is currently adherent to maximally tolerated doses of lisinopril, carvedilol, aspirin, and atorvastatin. Which of the following interventions is indicated for this patient and has been shown to reduce all-cause mortality by approximately 31% in this clinical scenario?

• ✓ Prophylactic implantable cardioverter-defibrillator (ICD) placement
• ○ Initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor
• ○ Transitioning lisinopril to an angiotensin receptor-neprilysin inhibitor (ARNI)
• ○ Implantation of a cardiac resynchronization therapy defibrillator (CRT-D)

Explanation. In patients with a prior myocardial infarction and a left ventricular ejection fraction of 30% or less, prophylactic placement of an implantable cardioverter-defibrillator (ICD) provides a significant relative risk reduction in all-cause mortality compared with standard of care. This robust survival benefit justifies the broad adoption of ICDs for the primary prevention of sudden cardiac death in the post-myocardial infarction setting with reduced LVEF, even in the complete absence of heart failure symptoms.

Question 62

A 55-year-old woman is evaluated in the cardiology clinic. She has no symptoms of dyspnea, orthopnea, edema, or fatigue, and she walks two miles daily without difficulty. A recent echocardiogram, obtained to evaluate a newly detected systolic murmur, revealed a left ventricular ejection fraction (LVEF) of 35% with global hypokinesis. Subsequent coronary angiography showed normal coronary arteries. She was recently started on enalapril. Which of the following is the most appropriate next step in her pharmacological management?

• ✓ Initiate carvedilol
• ○ Initiate furosemide
• ○ Initiate ivabradine
• ○ Continue current therapy and monitor for symptom onset

Explanation. Beta-blocker therapy is recommended to prevent the development of symptomatic heart failure and adverse left ventricular remodeling in asymptomatic patients with a reduced left ventricular ejection fraction, including those with nonischemic etiologies. The use of a beta blocker in this population, particularly in combination with an angiotensin-converting enzyme inhibitor, is associated with a reduction in the risk of death and future hospitalizations for symptomatic heart failure.

Question 63

A 62-year-old woman with a history of type 2 diabetes mellitus and hypertension is evaluated after a recent anterior myocardial infarction. An echocardiogram reveals a left ventricular ejection fraction (LVEF) of 35%. She is currently asymptomatic regarding heart failure symptoms (New York Heart Association class I). Her physician is optimizing her medical regimen for both glycemic and blood pressure control. Based on her reduced LVEF, which of the following pairs of medications should be avoided?

• ✓ Pioglitazone and diltiazem
• ○ Empagliflozin and amlodipine
• ○ Glipizide and hydralazine
• ○ Metformin and chlorthalidone

Explanation. Thiazolidinediones (such as pioglitazone) are associated with fluid retention and an increased risk of heart failure hospitalization or worsening edema, and should be avoided in patients with reduced LVEF. Similarly, nondihydropyridine calcium channel blockers (such as diltiazem) are myocardial depressants with negative inotropic effects that can increase the risk of heart failure events in patients with low LVEF following a myocardial infarction.

Question 64

A 58-year-old African American male with a history of heart failure with reduced ejection fraction (HFrEF) is currently on foundational guideline-directed medical therapy (GDMT). He continues to experience marked limitation of physical activity, consistent with New York Heart Association (NYHA) class III symptoms. As part of his management, additional GDMT and device therapy are implemented as indicated for his demographic and symptom profile. What is the most appropriate next step in the sequential management of this patient prior to considering a referral for heart failure specialty care?

• ✓ Reassess symptoms, labs, health status, and left ventricular ejection fraction (LVEF)
• ○ Initiate an immediate referral for mechanical circulatory support evaluation
• ○ Temporarily discontinue foundational GDMT to establish a new clinical baseline
• ○ Maintain the current regimen indefinitely without further diagnostic testing unless acute decompensation occurs

Explanation. Following the implementation of additional guideline-directed medical therapy (GDMT) and device therapy—such as targeted therapies for African American patients with New York Heart Association (NYHA) class III-IV symptoms—the structured sequential approach requires reassessing the patient's symptoms, laboratory values, overall health status, and left ventricular ejection fraction (LVEF) before escalating to specialized heart failure care.

Question 65

A 58-year-old male is newly diagnosed with heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction 30%) after presenting with progressive dyspnea on exertion (New York Heart Association class II). He is euvolemic on examination. His heart rate is 78 bpm, blood pressure is 125/80 mmHg, and baseline laboratory results show normal renal function and electrolytes. The physician plans to initiate standard Step 1 medications, including a beta-blocker, an angiotensin receptor-neprilysin inhibitor (ARNi), a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose cotransporter 2 inhibitor (SGLT2i). What is the most appropriate approach to initiating and titrating these therapies?

• ○ Initiate one medication at a time, ensuring the target dose of the first is achieved before adding the next.
• ○ Initiate all four medications simultaneously at their target doses to rapidly reverse ventricular remodeling.
• ✓ Initiate the medications simultaneously at low doses or sequentially without needing to reach target doses before adding the next.
• ○ Start an ARNi and a beta-blocker at target doses, withholding the MRA and SGLT2i until LVEF is reassessed in 3 months.

Explanation. Step 1 medications for heart failure with reduced ejection fraction may be started simultaneously at initial, low doses. Alternatively, they may be started sequentially, with the sequence guided by clinical factors, without the need to achieve target dosing of one medication before initiating the next; all medication doses should then be increased to target as tolerated.

Question 66

A 72-year-old woman with a history of heart failure (HF) with reduced ejection fraction is prepared for discharge after a 5-day admission for acute decompensation. Her hospital course was complicated by severe volume overload requiring high-dose intravenous diuretics. She is transitioning to a complex oral regimen including an angiotensin receptor-neprilysin inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, a sodium-glucose cotransporter-2 inhibitor, and a loop diuretic. The hospital administration is evaluating structural outpatient programs to improve outcomes for patients with complex needs like hers. Which of the following care strategies has been shown to reduce all-cause mortality, all-cause readmission, and readmission for HF?

• ✓ Active management by case managers in an integrated care system and coordinated multidisciplinary interventions
• ○ Routine outpatient follow-up exclusively managed by a solitary primary care physician
• ○ Providing written educational materials focusing solely on dietary sodium and fluid restriction
• ○ Enrollment in an unsupervised, patient-directed progressive home exercise program

Explanation. Active case management, which involves the management of complex patients by case managers working within integrated care systems, along with coordinated multidisciplinary healthcare interventions and communications, are effective organizational strategies shown to significantly reduce all-cause mortality, all-cause readmission, and specific readmissions for heart failure.

Question 67

A 68-year-old male with recently exacerbated heart failure with reduced ejection fraction (HFrEF) is being discharged from the hospital. His care team decides to enroll him in a comprehensive intervention program focused on improving self-care knowledge, enhancing medication adherence, and providing structured telephone support. Based on established data regarding these interventions, what are the expected clinical outcomes for this patient?

• ✓ Significant reduction in heart failure-related hospitalization, all-cause hospitalization, and all-cause mortality, along with improved quality of life.
• ○ Improved quality of life and discharge preparedness, but no significant reduction in heart failure-related or all-cause hospitalizations.
• ○ Significant reduction in cardiac death and heart failure hospitalizations specifically when the intervention is delivered primarily via mobile health applications.
• ○ Improved self-care knowledge and skill without any significant effect on all-cause mortality or hospitalization rates.

Explanation. Interventions that aim to improve self-care knowledge and skills, enhance medication adherence, or reinforce self-care with structured telephone support are highly effective in patients with heart failure. These specific approaches significantly reduce the risk of heart failure-related hospitalization, all-cause hospitalization, and all-cause mortality, while also improving quality of life.

Question 68

A 65-year-old male with a history of heart failure with reduced ejection fraction (HFrEF) presents for a routine clinic visit in October. His current medications include sacubitril/valsartan, carvedilol, spironolactone, and dapagliflozin. When discussing preventive care, the patient expresses hesitation about receiving the seasonal influenza and pneumococcal vaccinations, asking if they provide any meaningful benefit for his heart condition. Which of the following is the most accurate statement regarding the cardiovascular benefits of these vaccinations for this patient?

• ✓ Both the influenza and pneumococcal vaccinations are associated with significant reductions in all-cause mortality and cardiovascular mortality.
• ○ Influenza vaccination decreases the risk of respiratory hospitalizations, but it does not significantly lower the risk of cardiovascular hospitalizations.
• ○ Pneumococcal vaccination is indicated to prevent severe pneumonia but has no demonstrated effect on reducing incident heart failure or all-cause mortality.
• ○ Influenza vaccination lowers the risk of major adverse cardiovascular events, but neither vaccine has been shown to reduce overall all-cause mortality in heart failure patients.

Explanation. In patients with cardiovascular disease and heart failure, influenza vaccination is associated with significant reductions in all-cause mortality, cardiovascular mortality, cardiovascular hospitalizations, and major adverse cardiovascular events. Furthermore, pneumococcal vaccination is associated with significant reductions in incident heart failure, all-cause mortality, and cardiovascular mortality.

Question 69

A 78-year-old male with a history of heart failure (HF) is seen in the cardiology clinic shortly after a hospital discharge for an acute exacerbation. Upon assessment, he reports feeling persistent sadness, loss of interest in daily activities, and scores highly on a standardized depression screening tool, consistent with moderate depression. He also exhibits signs of physical frailty. The multidisciplinary clinic team is discussing enrolling him in a targeted intervention program focused on improving his HF self-care skills. Which of the following is the most accurate expectation regarding the planned self-care intervention for this patient?

• ✓ Targeted interventions to improve HF self-care have been shown to be effective in reducing hospitalization and mortality risk in patients with moderate to severe depression.
• ○ Frailty is associated with impaired self-care and increased rehospitalization, but it does not significantly impact the overall all-cause mortality risk in HF.
• ○ Because of his moderate depression, self-care interventions are unlikely to be effective, and management should strictly focus on pharmacological up-titration.
• ○ The patient's comorbid depression and frailty indicate that he is unlikely to benefit from self-care education unless his social isolation is fully resolved first.

Explanation. Interventions that focus on improving heart failure (HF) self-care are effective among patients with moderate or severe depression, leading to significant reductions in both hospitalization and mortality risk.

Question 70

A 68-year-old male with a history of heart failure (HF) presents to the cardiology clinic for a follow-up visit. He recently experienced worsening symptomatic congestion and was advised to restrict his dietary sodium intake. During the visit, he reports that his overall dietary quality has declined significantly since starting the restriction, and he is concerned about potential micronutrient inadequacies. He asks whether he should begin taking routine supplements, such as oral iron, thiamine, zinc, vitamin D, or a daily multivitamin, to compensate. He is also interested in adopting a structured eating plan to safely lower his sodium intake. Which of the following is the most appropriate management strategy regarding his nutrition and supplementation?

• ○ Initiate routine supplementation with oral iron, thiamine, zinc, and vitamin D to counteract the nutritional inadequacies caused by sodium restriction.
• ✓ Advise that routine micronutrient supplementation is not beneficial, and instead recommend the Dietary Approaches to Stop Hypertension (DASH) diet to achieve sodium restriction without compromising nutritional adequacy.
• ○ Recommend a strict sodium reduction to less than 2300 mg/day as proven by robust heart failure clinical trials, alongside the initiation of a daily multivitamin.
• ○ Discontinue sodium restriction entirely to avoid macronutrient inadequacies, as no specific dietary patterns have been associated with improved clinical stability in heart failure.

Explanation. Routine supplementation of oral iron, thiamine, zinc, vitamin D, or multivitamins has not proven beneficial for addressing nutritional inadequacies in patients with heart failure. Instead, utilizing the Dietary Approaches to Stop Hypertension (DASH) diet provides a strategy that is rich in antioxidants and potassium, allowing patients to achieve sodium restriction without compromising nutritional adequacy when accompanied by dietary counseling. This dietary pattern may also be associated with reduced hospitalizations for heart failure.

Question 71

A 68-year-old man with a history of heart failure with reduced ejection fraction presents for a routine follow-up. He is currently asymptomatic while engaging in basic activities of daily living. His current medications include sacubitril-valsartan, carvedilol, dapagliflozin, and spironolactone at maximally tolerated doses. He is clinically stable and expresses interest in beginning an exercise routine to improve his stamina. Which of the following statements regarding the implementation of a comprehensive cardiac rehabilitation program is most accurate for this patient?

• ✓ He is an appropriate candidate for a program that includes exercise training, which will improve his functional capacity, exercise duration, and health-related quality of life.
• ○ He should defer the program until his left ventricular ejection fraction recovers to at least 40% due to the risk of exercise-induced arrhythmias.
• ○ The program should focus solely on aerobic physical training, as psychosocial support and dietary recommendations are not standard components of heart failure rehabilitation.
• ○ Exercise training is exclusively recommended for patients who have not yet achieved optimal doses of guideline-directed medical therapy to help delay disease progression.

Explanation. Patients with heart failure who are on optimal guideline-directed medical therapy, in a stable medical condition, and capable of participating are ideal candidates for an exercise rehabilitation program. Participation in comprehensive cardiac rehabilitation, which encompasses exercise training, leads to improved functional capacity, increased exercise duration, and enhanced health-related quality of life.

Question 72

A 62-year-old man with heart failure with reduced ejection fraction (HFrEF) and a left ventricular ejection fraction of 32% presents for a routine follow-up. He remains stable with New York Heart Association (NYHA) class II symptoms on optimal guideline-directed medical therapy. He inquires whether participating in a supervised exercise training program would be beneficial for him. Which of the following accurately describes the anticipated clinical and physiological effects of this intervention?

• ○ Increased catecholamine spillover and a significant improvement in resting ejection fraction
• ○ Significant reductions in all-cause mortality by unadjusted primary analysis
• ✓ Improved functional capacity, increased peripheral oxygen extraction, and blunted catecholamine spillover
• ○ Decreased peak oxygen consumption but improved health-related quality of life

Explanation. Exercise training in patients with heart failure is associated with improvements in functional capacity, exercise duration, and health-related quality of life, as well as reductions in heart failure hospitalizations. Additionally, physiological benefits of exercise training include improved endothelial function, blunted catecholamine spillover, increased peripheral oxygen extraction, and improvement in peak oxygen consumption.

Question 73

A 74-year-old male with a history of heart failure (HF) is currently hospitalized for acute decompensated HF. He has been stabilized with intravenous diuretics and is nearing discharge. To best improve his long-term physical function, exercise tolerance, and reduce his risk of future hospitalizations, which of the following approaches to cardiac rehabilitation should be recommended?

• ✓ An early, transitional, tailored, progressive rehabilitation intervention including multiple physical-function domains initiated during or early after hospitalization.
• ○ Delaying the initiation of exercise training until 6 weeks post-discharge to allow for complete myocardial recovery.
• ○ A formal cardiac rehabilitation program that focuses strictly on high-intensity aerobic endurance training to the exclusion of balance and strength training.
• ○ Usual care with generic discharge instructions to ambulate as tolerated without structured physical activity counseling.

Explanation. In older patients hospitalized for acute decompensated heart failure, an early, transitional, tailored, and progressive rehabilitation intervention that includes multiple physical-function domains (such as strength, balance, mobility, and endurance) initiated during or early after hospitalization and continued after discharge results in greater improvement in physical function. Exercise-based cardiac rehabilitation is associated with improvements in functional capacity, exercise tolerance, quality of life, and a reduction in both overall and heart failure-specific hospitalizations.

Question 74

A 65-year-old man with a history of chronic heart failure presents to the clinic with progressive weight gain, orthopnea, and severe pitting lower extremity edema. He is currently adherent to his guideline-directed medical therapy, which includes furosemide 80 mg twice daily, but his volume overload has become refractory to this regimen alone. The physician decides to add an additional diuretic, such as metolazone, to augment the diuresis. The class of diuretic added for this indication exerts its primary effect at which of the following anatomical sites in the nephron?

• ✓ Distal convoluting tubule
• ○ Thick ascending limb of the loop of Henle
• ○ Proximal convoluted tubule
• ○ Collecting duct

Explanation. Thiazide and thiazide-like diuretics, such as metolazone or chlorothiazide, act in the distal convoluting tubule and may be added to loop diuretics to achieve a synergistic effect in patients with refractory edema that is unresponsive to loop diuretics alone.

Question 75

A 72-year-old male with a history of heart failure is admitted for acute decompensated heart failure with severe volume overload. Despite initial treatment with a standard dose of intravenous furosemide, his urine output remains poor and he remains congested. The care team is considering two diuretic strategies to promote adequate natriuresis: adding oral metolazone to the current loop diuretic regimen versus significantly increasing the dose of the intravenous loop diuretic. What is the expected risk profile of adding metolazone compared to utilizing a higher dose of the intravenous loop diuretic in this patient?

• ✓ Adding metolazone increases the risk of hypokalemia, hyponatremia, worsening renal function, and mortality.
• ○ Increasing the dose of the intravenous loop diuretic is associated with a higher risk of mortality compared to adding metolazone.
• ○ Adding metolazone reduces the incidence of hyponatremia and worsening renal function while achieving similar diuresis.
• ○ Both strategies share an identical risk for mortality, though adding metolazone causes less hypokalemia.

Explanation. In patients hospitalized with heart failure, the addition of metolazone to loop diuretics increases the risk for hypokalemia, hyponatremia, worsening renal function, and mortality. Utilizing higher doses of intravenous loop diuretics is an optimized strategy for diuresis that does not adversely affect survival.

Question 76

A 72-year-old man with a history of heart failure with reduced ejection fraction is evaluated for worsening shortness of breath and lower extremity swelling. He was recently discharged from the hospital after a heart failure exacerbation and has been compliant with his prescribed regimen of lisinopril, carvedilol, spironolactone, and furosemide. He reports that his knee osteoarthritis has been bothering him lately, for which he started taking an over-the-counter medication, naproxen, a few days ago. His daily weight log shows an increase of 3 kg over the past week. Which of the following is the most likely reason for his lack of response to the prescribed diuretic?

• ✓ Blockade of the diuretic effect by the newly initiated nonsteroidal anti-inflammatory drug
• ○ Decreased oral bioavailability of furosemide due to a drug-drug interaction with spironolactone
• ○ Insufficient target weight loss goal, which should typically be 1.5 to 2.0 kg daily
• ○ Increased urinary sodium excretion leading to paradoxical fluid retention

Explanation. Patients with heart failure may become unresponsive to diuretic drugs if they are taking agents that can block the effects of diuretics, such as nonsteroidal anti-inflammatory drugs (NSAIDs) like naproxen. Other common causes of diuretic resistance include consuming large amounts of dietary sodium and having significant impairment of renal function or perfusion.

Question 77

A 68-year-old male with a history of heart failure with reduced ejection fraction (HFrEF) presents to the clinic with progressive shortness of breath and lower extremity swelling over the past two weeks. He is currently taking maximally tolerated doses of an angiotensin receptor-neprilysin inhibitor (ARNI), carvedilol, and spironolactone. His oral furosemide dose was recently escalated to 160 mg twice daily, but he continues to have significant signs of volume overload, including elevated jugular venous pressure and 3+ bilateral pitting edema. The physician decides to add oral metolazone to his regimen to address his diuretic resistance. What is the primary mechanism by which the addition of metolazone enhances diuresis in this patient?

• ✓ Inhibiting compensatory distal tubular sodium reabsorption
• ○ Increasing renal blood flow and glomerular filtration rate
• ○ Enhancing proximal tubular secretion of the loop diuretic
• ○ Antagonizing aldosterone at the mineralocorticoid receptors in the collecting duct

Explanation. The use of a thiazide or thiazide-like diuretic, such as metolazone, in combination with a loop diuretic overcomes diuretic resistance by inhibiting compensatory distal tubular sodium reabsorption, leading to enhanced overall sodium and water excretion.

Question 78

A 62-year-old male with Heart Failure with reduced Ejection Fraction (HFrEF) and New York Heart Association (NYHA) class II symptoms presents for a routine follow-up. He is currently taking carvedilol, spironolactone, and lisinopril (an Angiotensin-Converting Enzyme inhibitor ), which he tolerates well. To further improve his morbidity and mortality, the decision is made to switch his lisinopril to sacubitril/valsartan (an Angiotensin Receptor-Neprilysin Inhibitor ). Which of the following is the most appropriate strategy for transitioning this medication?

• ○ Discontinue lisinopril and initiate the ARNi 12 hours after the last dose.
• ✓ Discontinue lisinopril and initiate the ARNi at least 36 hours after the last dose.
• ○ Continue lisinopril and simultaneously initiate the ARNi at a low dose.
• ○ Discontinue lisinopril and initiate an Angiotensin II Receptor Blocker (ARB) for 1 week before transitioning to the ARNi.

Explanation. When transitioning a patient from an Angiotensin-Converting Enzyme inhibitor (ACEi) to an Angiotensin Receptor-Neprilysin Inhibitor (ARNi), there must be a washout period of at least 36 hours between the last dose of the ACEi and the first dose of the ARNi.

Question 79

A 62-year-old male with a history of symptomatic heart failure with reduced ejection fraction (HFrEF) is currently managed with enalapril, carvedilol, and spironolactone. He is tolerating his medications well but remains symptomatic. His physician plans to switch his enalapril to sacubitril-valsartan to further reduce his risk of cardiovascular events. When counseling the patient about the side effect profile of sacubitril-valsartan compared to his current regimen, which of the following should be communicated as occurring more frequently with the new medication?

• ✓ Symptomatic hypotension
• ○ Angioedema
• ○ Increased degradation of vasoactive peptides
• ○ Elevated incidence of heart failure hospitalization

Explanation. The use of an angiotensin receptor-neprilysin inhibitor (ARNi), such as sacubitril-valsartan, is more frequently associated with symptomatic hypotension when compared with enalapril.

Question 80

A 62-year-old male is admitted to the hospital with acute decompensated heart failure with reduced ejection fraction (HFrEF). His left ventricular ejection fraction is 28%. Over the past 48 hours, he has been stabilized with intravenous loop diuretics. A review of his medical records shows that he has never been treated with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB). His current blood pressure is 118/76 mmHg, and his renal function is at his baseline. Which of the following is the most appropriate approach regarding the initiation of an angiotensin receptor-neprilysin inhibitor (ARNi) for this patient?

• ✓ Initiate an ARNi prior to discharge, as it effectively reduces N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels without increasing adverse events in treatment-naïve patients.
• ○ Initiate an ACEi prior to discharge and wait at least 4 weeks in the outpatient setting before attempting a transition to an ARNi.
• ○ Avoid initiating an ARNi during the index hospitalization due to a significantly increased risk of worsening renal function in ACEi/ARB-naïve patients.
• ○ Delay the initiation of an ARNi until the patient has demonstrated tolerability to a target dose of an ARB for at least 3 months.

Explanation. Initiating an angiotensin receptor-neprilysin inhibitor (ARNi) in patients hospitalized for acute decompensated heart failure is safe and efficacious even in those who are ACEi/ARB-naïve. Early initiation of an ARNi in this stabilized population effectively reduces N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels without an increased rate of adverse events such as worsening renal function.

Question 81

A 65-year-old male is hospitalized for worsening acute heart failure. His echocardiogram demonstrates a left ventricular ejection fraction of 28%. After three days of intravenous diuretic therapy, his volume status has optimized, and he is preparing for discharge. His vital signs are stable with a blood pressure of 118/75 mmHg. Laboratory results show a serum creatinine of 1.1 mg/dL and a serum potassium of 4.3 mEq/L. He is currently not taking any renin-angiotensin system inhibitors. Which of the following is the most appropriate strategy for initiating neurohormonal blockade in this patient?

• ○ Initiate an angiotensin-converting enzyme inhibitor (ACEi) now, uptitrate as an outpatient, and later switch to an angiotensin receptor-neprilysin inhibitor (ARNi).
• ✓ Initiate an angiotensin receptor-neprilysin inhibitor (ARNi) de novo prior to hospital discharge.
• ○ Discharge the patient without renin-angiotensin system blockade and initiate an angiotensin receptor-neprilysin inhibitor (ARNi) at the first outpatient follow-up.
• ○ Initiate an angiotensin receptor-neprilysin inhibitor (ARNi) prior to discharge only if he has a documented history of a previous myocardial infarction.

Explanation. Initiating an angiotensin receptor-neprilysin inhibitor (ARNi) de novo prior to hospital discharge is the appropriate approach for patients hospitalized with acute heart failure with reduced ejection fraction in the absence of contraindications. Early in-hospital initiation simplifies patient management and is safe, removing the need to first initiate and uptitrate an angiotensin-converting enzyme inhibitor before later switching to an ARNi.

Question 82

A 62-year-old female presents for a follow-up of heart failure with reduced ejection fraction (HFrEF). She is currently taking enalapril, an angiotensin-converting enzyme inhibitor (ACEi), at the maximal target dose. She reports significant lightheadedness limiting her daily activities, and her blood pressure in the clinic is 90/60 mmHg. Laboratory results show a serum potassium of 4.8 mEq/L and stable renal function. Angiotensin receptor-neprilysin inhibitor (ARNi) therapy is deemed inappropriate for her. Because she cannot tolerate her current medication dose, which of the following is the most appropriate next step regarding her ACEi therapy?

• ✓ Decrease the enalapril to a tolerated intermediate dose.
• ○ Abruptly discontinue enalapril to prevent further hypotensive events.
• ○ Switch to a different ACEi to improve survival benefits and symptoms.
• ○ Abruptly discontinue enalapril and initiate an angiotensin receptor blocker (ARB).

Explanation. In patients with heart failure with reduced ejection fraction who cannot tolerate maximal doses of an angiotensin-converting enzyme inhibitor, intermediate doses should be utilized. Modifying the regimen to a tolerated intermediate dose maintains the beneficial therapy while mitigating adverse effects, as abrupt withdrawal of the medication can lead to clinical deterioration and must be avoided.

Question 83

A 62-year-old woman with a history of heart failure with reduced ejection fraction presents to the clinic for a follow-up. One month ago, she was hospitalized for lip and tongue swelling that occurred shortly after her dose of enalapril, an angiotensin-converting enzyme inhibitor (ACEi), was increased. The enalapril was discontinued at that time. She is currently taking bisoprolol and empagliflozin. Her blood pressure is 122/78 mmHg, serum potassium is 4.4 mEq/L, and creatinine is 1.1 mg/dL. Which of the following is the most appropriate next step regarding the management of her renin-angiotensin system inhibition?

• ✓ Initiate an angiotensin receptor blocker (ARB) at a low dose and titrate upward, exercising caution and advising the patient to monitor for recurrent angioedema.
• ○ Initiate an angiotensin receptor blocker (ARB) at the target dose immediately, as it does not inhibit kininase and carries zero risk of angioedema.
• ○ Avoid an angiotensin receptor blocker (ARB) entirely, as it is absolutely contraindicated in patients with a history of ACEi-induced angioedema.
• ○ Initiate an angiotensin receptor blocker (ARB) concurrently with a prophylactic course of systemic corticosteroids to prevent cross-reactive angioedema.

Explanation. Patients who are intolerant to angiotensin-converting enzyme inhibitors (ACEi) due to angioedema should be started on an angiotensin receptor blocker (ARB) as an alternative. ARBs should be started at low doses and titrated upward with an attempt to reach doses shown to reduce the risk of cardiovascular events. However, caution is advised during initiation because some patients who experienced ACEi-induced angioedema may also develop angioedema with the use of ARBs.

Question 84

A 65-year-old man with a recent anterior myocardial infarction (MI) is seen in the clinic. He reports no symptoms of heart failure and is fully active. Echocardiography demonstrates asymptomatic left ventricular (LV) dysfunction with an ejection fraction of 36%. The physician initiates an angiotensin-converting enzyme inhibitor (ACEi). When assessing the health economics and cost-effectiveness of starting this medication for this specific clinical presentation, which of the following accurately describes its value profile?

• ✓ ACEi therapy provides high value, as long-term outcome models demonstrate robust cost-effectiveness even in asymptomatic LV dysfunction following an MI.
• ○ ACEi therapy provides low value because cost-effectiveness is only established once the patient develops symptomatic chronic heart failure.
• ○ ACEi therapy provides intermediate value, as the high upfront cost of the medication outweighs the long-term reduction in hospitalizations.
• ○ ACEi therapy provides uncertain value in this setting, as cost-effectiveness data post-MI exclusively support the use of angiotensin receptor blockers (ARBs).

Explanation. Angiotensin-converting enzyme inhibitor (ACEi) therapy provides high economic value for patients across a range of clinical scenarios, specifically including asymptomatic left ventricular dysfunction and left ventricular dysfunction following a myocardial infarction. This high value is established through model-based analyses of long-term outcomes and is further supported by the low-cost generic availability of the medication class.

Question 85

A 65-year-old male with chronic stable heart failure with reduced ejection fraction (HFrEF) is evaluated in the clinic. He currently experiences mild dyspnea with moderate exertion. His medications include carvedilol 25 mg twice daily, spironolactone 25 mg daily, and enalapril 10 mg twice daily. His blood pressure is 118/75 mmHg, and his basic metabolic panel is unremarkable. You recommend switching his enalapril to sacubitril-valsartan (an angiotensin receptor-neprilysin inhibitor ). Which of the following statements accurately describes the expected outcomes and economic value of this pharmacological change?

• ✓ The switch will decrease hospitalizations and mortality, and is considered high economic value provided the treatment effectiveness extends beyond 27 months.
• ○ The switch will improve left ventricular remodeling but is considered intermediate economic value because the cost per quality-adjusted life year typically exceeds $60,000.
• ○ The switch is indicated to reduce hospitalizations, but inpatient initiation during future exacerbations should be avoided due to lower economic value compared to post-discharge initiation.
• ○ The switch will decrease hospitalizations and mortality but has no significant effect on left ventricular remodeling parameters compared to continuing enalapril.

Explanation. In patients with mild-to-moderate heart failure with reduced ejection fraction who tolerate a target dose of an angiotensin-converting enzyme inhibitor, switching to an angiotensin receptor-neprilysin inhibitor (ARNi) significantly decreases hospitalizations and mortality. Furthermore, economic models demonstrate that ARNi therapy provides high economic value (cost per quality-adjusted life year <$60,000) when the clinical benefits and treatment effectiveness are maintained beyond 27 months.

Question 86

A 62-year-old male with heart failure with reduced ejection fraction presents to the clinic for a routine follow-up. His current medications include lisinopril (an angiotensin-converting enzyme inhibitor ), carvedilol, and spironolactone. The cardiologist decides to transition the patient from lisinopril to sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNi). To minimize the risk of a potentially life-threatening complication, what is the most appropriate transition strategy?

• ○ Discontinue lisinopril and initiate sacubitril/valsartan immediately.
• ○ Discontinue lisinopril and initiate sacubitril/valsartan after a 12-hour washout period.
• ○ Discontinue lisinopril and initiate sacubitril/valsartan after a 24-hour washout period.
• ✓ Discontinue lisinopril and initiate sacubitril/valsartan after a 36-hour washout period.

Explanation. An angiotensin receptor-neprilysin inhibitor (ARNi) should not be administered within 36 hours of switching from or to an angiotensin-converting enzyme inhibitor (ACEi). Both ACE inhibitors and neprilysin inhibitors prevent the enzymatic breakdown of bradykinin. Utilizing an adequate 36-hour washout period is necessary to mitigate the risk of severe and potentially life-threatening angioedema caused by excess bradykinin accumulation.

Question 87

A 58-year-old Black man with heart failure with reduced ejection fraction (left ventricular ejection fraction 32%) and hypertension is evaluated in the clinic for optimization of his medical therapy. His past medical history is notable for a 30-pack-year smoking history. Five years ago, while taking enalapril for hypertension, he experienced an episode of severe facial and lip swelling requiring an emergency department visit. His current medications include bisoprolol, empagliflozin, and spironolactone. The clinician is considering adding an angiotensin receptor-neprilysin inhibitor (ARNi). What is the most appropriate decision regarding the initiation of ARNi therapy in this patient?

• ○ Initiate ARNi therapy, as his previous reaction was specific to angiotensin-converting enzyme (ACE) inhibitors.
• ✓ Do not initiate ARNi therapy, as it is contraindicated in patients with a history of angioedema.
• ○ Initiate ARNi therapy but at a reduced starting dose, monitoring closely for adverse reactions.
• ○ Do not initiate ARNi therapy because it is contraindicated in patients with a history of smoking.

Explanation. ARNi therapy should not be administered in patients with a history of angioedema because of the concern that it will increase the risk of a recurrent episode.

Question 88

A 64-year-old man is evaluated in the hospital for newly diagnosed heart failure with reduced ejection fraction (HFrEF) with a left ventricular ejection fraction (LVEF) of 30%. His medical history includes hypertension, type 2 diabetes mellitus, and a prior episode of severe lip and tongue swelling requiring intubation shortly after starting lisinopril. You are formulating his discharge medication regimen. Which of the following is the most appropriate approach regarding his medical therapy?

• ✓ Initiating an angiotensin receptor blocker (ARB) is acceptable because ARBs do not directly interfere with bradykinin metabolism and have low rates of angioedema.
• ○ Initiating an angiotensin-converting enzyme inhibitor (ACEi) at a low dose is appropriate since the mortality benefits in HFrEF outweigh the risks.
• ○ Deferring beta-blocker initiation until his first outpatient clinic visit is required, as they should only be started in the ambulatory setting.
• ○ Avoiding beta-blockers is recommended because their mortality benefits are exclusively observed in patients with concomitant coronary artery disease.

Explanation. Angiotensin receptor blockers (ARBs) do not interfere as directly with bradykinin metabolism as ACE inhibitors do, and they are associated with low rates of angioedema, making them a reasonable alternative for a patient with a history of ACE inhibitor-induced angioedema.

Question 89

A 65-year-old man is hospitalized for an acute exacerbation of heart failure with reduced ejection fraction (HFrEF). His left ventricular ejection fraction (LVEF) is 32%. After three days of treatment, he is clinically stabilized, resting comfortably, and requires no intravenous inotropic therapy. He is scheduled for discharge tomorrow. His current medications include lisinopril and oral furosemide, and his symptoms have completely resolved. Which of the following is the most appropriate approach to beta-blocker therapy for this patient?

• ✓ Initiate sustained-release metoprolol succinate prior to hospital discharge.
• ○ Initiate atenolol prior to hospital discharge to maintain his asymptomatic status.
• ○ Delay initiation of bisoprolol until his first outpatient follow-up to avoid recurrent decompensation.
• ○ Withhold beta-blocker therapy since his symptoms have resolved with the current regimen.

Explanation. Sustained-release metoprolol succinate is one of the specific beta-blockers shown to reduce the risk of death in patients with heart failure with reduced ejection fraction. It is safe and appropriate to initiate this therapy before hospital discharge because the patient is clinically stabilized and does not require intravenous inotropic therapy, and this treatment should not be delayed even when symptoms have completely resolved with other therapies.

Question 90

A 68-year-old male with heart failure with reduced ejection fraction (HFrEF) presents for a routine follow-up. His current medications include carvedilol, lisinopril, dapagliflozin, and spironolactone. He reports new-onset bilateral breast tenderness and enlargement. His laboratory results demonstrate an estimated glomerular filtration rate (eGFR) of 42 mL/min/1.73 m² and a serum potassium of 4.4 mEq/L. Which of the following is the most appropriate next step in managing this patient's symptoms while preserving the clinical benefits of his current drug class?

• ✓ Switch spironolactone to eplerenone, as it has higher selectivity for the aldosterone receptor.
• ○ Discontinue the mineralocorticoid receptor antagonist entirely, as his eGFR is an absolute contraindication to this class of medications.
• ○ Switch spironolactone to an alternative mineralocorticoid receptor antagonist because it has lower selectivity for the aldosterone receptor.
• ○ Maintain the current spironolactone dose, as alternative agents in this class do not reduce the risk of sudden cardiac death.

Explanation. Eplerenone has a higher selectivity for the aldosterone receptor compared to spironolactone, which results in a lower incidence of adverse endocrine effects such as gynecomastia while continuing to provide broad benefits in reducing all-cause mortality, heart failure hospitalizations, and sudden cardiac death for patients with heart failure with reduced ejection fraction.

Question 91

A 68-year-old male with a history of heart failure with reduced ejection fraction (HFrEF) and mild symptoms presents to the clinic. His left ventricular ejection fraction (LVEF) is 30%. Laboratory results show a serum potassium of 4.3 mEq/L and an estimated glomerular filtration rate (eGFR) of 42 mL/min/1.73 m². The physician decides to initiate eplerenone therapy. What is the most appropriate starting dose and initial monitoring strategy for this patient?

• ✓ Initiate eplerenone 12.5 mg orally daily and check serum potassium and renal function in 1 week.
• ○ Initiate eplerenone 25 mg orally daily and check serum potassium and renal function in 1 week.
• ○ Initiate eplerenone 12.5 mg orally daily and check serum potassium and renal function in 4 weeks.
• ○ Initiate eplerenone 25 mg orally daily and check serum potassium and renal function in 4 weeks.

Explanation. The standard starting dose of eplerenone for heart failure with reduced ejection fraction is 25 mg orally daily; however, for patients with an estimated glomerular filtration rate between 31 and 49 mL/min/1.73 m², this starting dose must be reduced by half to 12.5 mg daily. After initiating therapy with a mineralocorticoid receptor antagonist, serum potassium levels and renal function should be checked in approximately 1 week to ensure safety and clinical stability.

Question 92

A 72-year-old woman with heart failure is being evaluated in the clinic for optimization of her medical therapy. Her current medications include a beta-blocker, an angiotensin receptor-neprilysin inhibitor, and a loop diuretic. Her recent laboratory results reveal a serum potassium of 5.1 mEq/L and an estimated glomerular filtration rate (eGFR) of 28 mL/min/1.73 m2. You are considering the addition of a mineralocorticoid receptor antagonist (MRA) such as spironolactone or eplerenone. Which of the following is the most appropriate rationale regarding the use of MRA therapy in this patient?

• ✓ MRA therapy should be avoided because safety concerns are raised when the eGFR is ≤30 mL/min/1.73 m2 and when serum potassium is >5.0 mEq/L prior to initiation.
• ○ Eplerenone should be initiated because the incidence of clinically significant hyperkalemia is <1%, regardless of baseline renal function.
• ○ Spironolactone can be safely initiated because it is completely excreted by the hepatic system, preventing accumulation in severe renal impairment.
• ○ MRA therapy can be initiated safely but must be discontinued if the serum potassium reaches 5.2 mEq/L during follow-up.

Explanation. Spironolactone and eplerenone are partially excreted through the kidneys, which raises safety concerns in patients with an estimated glomerular filtration rate ≤30 mL/min/1.73 m2. These medications decrease renal potassium excretion, and the risk of hyperkalemia is elevated particularly when initiated in patients with a baseline serum potassium >5.0 mEq/L. Due to both the reduced renal function and the elevated baseline potassium, initiation of this drug class is contraindicated in this clinical scenario.

Question 93

A 62-year-old man with chronic heart failure with reduced ejection fraction (HFrEF) is seen in the outpatient clinic for routine follow-up. His current medications include bisoprolol, spironolactone, dapagliflozin, and enalapril (an angiotensin-converting enzyme inhibitor ). He has had borderline elevated serum potassium levels (5.1-5.3 mEq/L) over the last few months. His cardiologist recommends switching enalapril to sacubitril/valsartan (an angiotensin receptor-neprilysin inhibitor ). Which of the following statements best describes the expected impact of this medication change on the patient's risk of hyperkalemia?

• ✓ The risk of hyperkalemia is expected to be lower with the ARNi compared to the ACEi.
• ○ The risk of hyperkalemia is expected to be significantly higher with the ARNi compared to the ACEi.
• ○ The risk of hyperkalemia is expected to remain exactly the same as both therapies have identical effects on potassium excretion.
• ○ The risk of hyperkalemia is expected to decrease only if the mineralocorticoid receptor antagonist is temporarily held.

Explanation. In patients with chronic heart failure, the coadministration of a mineralocorticoid receptor antagonist with an angiotensin receptor-neprilysin inhibitor (ARNi) is associated with a lower risk of hyperkalemia compared to coadministration with an angiotensin-converting enzyme inhibitor (ACEi).

Question 94

A 68-year-old man with chronic heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction 34%) and New York Heart Association (NYHA) class III symptoms is evaluated in the clinic. He is currently on optimally titrated sacubitril/valsartan, metoprolol succinate, and spironolactone. His current blood pressure is 112/74 mm Hg. Laboratory studies show an N-terminal pro-B-type natriuretic peptide (NT-proBNP) of 1500 pg/mL and an estimated glomerular filtration rate (eGFR) of 26 mL/min/1.73 m2. He does not have diabetes mellitus. The clinician wishes to add a sodium-glucose cotransporter-2 inhibitor (SGLT2i) to his regimen. Based on the landmark clinical trials for HFrEF, which of the following is the most appropriate recommendation?

• ✓ Initiate empagliflozin
• ○ Initiate dapagliflozin
• ○ Withhold SGLT2i therapy due to the patient's current eGFR
• ○ Withhold SGLT2i therapy because the patient lacks a diagnosis of type 2 diabetes

Explanation. Empagliflozin is the appropriate choice for this patient because the landmark trial evaluating its efficacy in patients with symptomatic chronic HFrEF permitted enrollment of individuals with an estimated glomerular filtration rate (eGFR) down to 20 mL/min/1.73 m2. Additionally, the clinical benefits of SGLT2 inhibitors in reducing heart failure outcomes are independent of their glucose-lowering effects, meaning they are efficacious and indicated irrespective of whether the patient has a concurrent diagnosis of type 2 diabetes.

Question 95

A 68-year-old man presents to the cardiology clinic for a routine follow-up of heart failure with reduced ejection fraction. His left ventricular ejection fraction is 35%. He is currently treated with maximally tolerated doses of sacubitril-valsartan, carvedilol, and spironolactone. He has no history of diabetes mellitus, and his recent hemoglobin A1c is 5.4%. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, is added to his medical regimen. Which of the following best describes the anticipated outcomes of adding this medication?

• ✓ A reduction in the composite of cardiovascular death or heart failure hospitalization, and a slower rate of decline in estimated glomerular filtration rate.
• ○ A reduction in heart failure hospitalization, but an increased rate of decline in estimated glomerular filtration rate over time.
• ○ A reduction in cardiovascular death and heart failure hospitalization, but only if the patient concurrently develops type 2 diabetes mellitus.
• ○ A reduction in heart failure hospitalization, with a proportional increase in the frequency of serious renal adverse outcomes.

Explanation. Dapagliflozin reduces the composite of cardiovascular death or heart failure hospitalization, as well as all-cause mortality, in patients with heart failure with reduced ejection fraction. These clinical benefits are observed irrespective of baseline diabetes status. Additionally, treatment with sodium-glucose co-transporter 2 inhibitors results in less frequent serious renal outcomes and a slower rate of decline in estimated glomerular filtration rate over time.

Question 96

A health system's cardiovascular therapeutics committee is assessing the economic viability of incorporating dapagliflozin into their standard treatment protocols for patients with heart failure. They are evaluating model-based analyses derived from the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial to determine the cost per quality-adjusted life year (QALY). According to these economic models, which parameter is the most critical driver of cost-effectiveness, requiring a specific threshold of benefit to maintain a cost per QALY below $150,000?

• ✓ The magnitude of reduction in cardiovascular mortality, requiring at least an 8% reduction.
• ○ The magnitude of reduction in heart failure hospitalizations, requiring at least a 15% reduction.
• ○ The reduction in overall annual drug costs, requiring a decrease to a maximum of $5,000.
• ○ The improvement in functional capacity, requiring at least a 10-point increase on standardized quality-of-life questionnaires.

Explanation. The economic value and cost per quality-adjusted life year (QALY) of dapagliflozin therapy are most sensitive to the magnitude of cardiovascular mortality reduction. A reduction in cardiovascular mortality of 8% or greater is necessary to achieve a cost per QALY below the $150,000 threshold.

Question 97

A 60-year-old self-identified African American man with heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction 30%) remains symptomatic despite optimal medical therapy with an angiotensin-converting enzyme inhibitor (ACEi), an evidence-based beta-blocker, and a mineralocorticoid receptor antagonist. The clinician plans to initiate a combination of hydralazine and isosorbide dinitrate. When prescribing this regimen to replicate the benefits demonstrated in established clinical trials, which of the following describes the necessary dosing strategy and formulation?

• ○ Utilizing long-acting nitrate formulations to enhance medication adherence and minimize drug-related adverse effects.
• ○ Utilizing lower starting and target doses of both agents than those used in general clinical practice to prevent medication intolerance.
• ✓ Utilizing short-acting nitrate therapy and titrating to doses that are generally higher than those typically used in standard clinical practice.
• ○ Utilizing standard clinical practice doses combined with an angiotensin receptor-neprilysin inhibitor (ARNi) to maximize synergistic vasodilation.

Explanation. The established benefits of the hydralazine and isosorbide dinitrate combination in self-identified African Americans with heart failure with reduced ejection fraction (HFrEF) were observed specifically when utilizing short-acting nitrate therapy and achieving doses that are higher than those typically prescribed in routine clinical practice.

Question 98

A 58-year-old self-identified African American man with heart failure with reduced ejection fraction (HFrEF) is evaluated in the clinic for persistent dyspnea and fatigue with minimal exertion. His current medical regimen consists of maximally tolerated doses of lisinopril (an angiotensin-converting enzyme inhibitor), carvedilol (a beta blocker), and spironolactone (a mineralocorticoid receptor antagonist). His vital signs are stable, and physical examination reveals no evidence of volume overload. What is the most appropriate next step in managing this patient's pharmacological therapy to improve survival?

• ✓ Initiate a fixed-dose combination of hydralazine and isosorbide dinitrate.
• ○ Discontinue lisinopril and initiate hydralazine and isosorbide dinitrate.
• ○ Add an angiotensin receptor-neprilysin inhibitor (ARNI) to the current regimen.
• ○ Add digoxin to the current regimen.

Explanation. The addition of a fixed-dose combination of hydralazine and isosorbide dinitrate to standard therapy with an angiotensin-converting enzyme inhibitor, a beta blocker, and a mineralocorticoid receptor antagonist offers significant survival benefit and is the appropriate therapeutic step for self-identified African American patients with heart failure with reduced ejection fraction who remain symptomatic.

Question 99

A 62-year-old self-identified African American male with heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction 28%) presents to the clinic. He remains symptomatic (New York Heart Association class III) despite maximally tolerated medical therapy, including a beta-blocker, an angiotensin receptor-neprilysin inhibitor, and a mineralocorticoid receptor antagonist. The physician initiates combination therapy with hydralazine and isosorbide dinitrate. Based on the primary trial evaluating the economic and clinical value of this therapy (A-HeFT), what is the anticipated impact?

• ✓ It increases survival and reduces health care costs in the short term, remaining a high-value intervention over a lifetime with a favorable cost per life-year.
• ○ It increases survival but dramatically increases short-term health care costs, leading to a cost per life-year exceeding $150,000.
• ○ It improves symptoms and quality of life without increasing overall survival, while maintaining a cost-neutral economic profile over a lifetime.
• ○ It reduces health care costs by decreasing hospitalizations but has no significant impact on overall survival or lifetime cost-effectiveness.

Explanation. The A-HeFT trial demonstrated that the combination of hydralazine and isosorbide dinitrate increases survival and reduces health care costs. Furthermore, extrapolations demonstrate that this combination remains of high economic value over a lifetime, maintaining a cost per life-year of less than $60,000.

Question 100

A 72-year-old Caucasian male with heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction 28%) is evaluated in the cardiology clinic. He is currently treated with bisoprolol, spironolactone, and bumetanide. Two weeks ago, an attempt to initiate sacubitril-valsartan (an angiotensin receptor-neprilysin inhibitor ) was discontinued due to symptomatic hypotension and an acute rise in serum creatinine from 1.3 mg/dL to 2.9 mg/dL. A previous trial of lisinopril (an angiotensin-converting enzyme inhibitor ) was also poorly tolerated due to similar renal insufficiency. He continues to experience New York Heart Association class III symptoms. Which of the following is an appropriate pharmacological consideration for this patient's heart failure management?

• ✓ Initiation of hydralazine and isosorbide dinitrate
• ○ Initiation of verapamil
• ○ Re-initiation of lisinopril at a micro-dose
• ○ Initiation of minoxidil

Explanation. In patients with heart failure with reduced ejection fraction who are unable to tolerate first-line agents such as angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers due to drug intolerance, hypotension, or renal insufficiency, the combined use of hydralazine and isosorbide dinitrate may be considered as a therapeutic option for further management.

Question 101

A 68-year-old man with a history of a prior myocardial infarction (MI) and symptomatic chronic heart failure with reduced left ventricular ejection fraction (LVEF) presents for a routine follow-up. He is adherent to his maximally tolerated evidence-based medical therapy. His clinician considers adding an adjunctive oral therapy to further reduce his risk of all-cause mortality and hospitalization for cardiovascular events. Which of the following daily regimens has been shown to reduce death from any cause in this specific patient population?

• ✓ 1 g of omega-3 polyunsaturated fatty acids (850-882 mg of eicosapentaenoic acid and docosahexaenoic acid)
• ○ 4 g of omega-3 polyunsaturated fatty acids (isolated eicosapentaenoic acid)
• ○ 1 g of omega-6 polyunsaturated fatty acids (linoleic acid and arachidonic acid)
• ○ 850 mg of isolated docosahexaenoic acid (DHA)

Explanation. Supplementation with 1 g daily of omega-3 polyunsaturated fatty acids (containing 850-882 mg of eicosapentaenoic acid and docosahexaenoic acid) reduces death from any cause and the combined outcome of death or admission to the hospital for a cardiovascular event in symptomatic patients with heart failure. Furthermore, this specific therapy provides a concentrated reduction in mortality and sudden cardiac death for patients with a prior myocardial infarction and reduced left ventricular ejection fraction.

Question 102

A 62-year-old man with type 2 diabetes mellitus, hypertension, and a prior myocardial infarction (MI) is evaluated in the clinic. His medications include aspirin, lisinopril, metoprolol, and rosuvastatin. To further reduce his risk of major adverse cardiovascular events, he is started on icosapent ethyl (a highly purified eicosapentaenoic acid) 2 grams twice daily. During follow-up, which of the following dose-related adverse events should this patient be monitored for as a known risk of this specific therapy?

• ✓ Atrial fibrillation (AF)
• ○ Symptomatic bradycardia
• ○ Ventricular tachycardia
• ○ Complete heart block

Explanation. In patients with cardiovascular risk factors who are treated with omega-3 fatty acid therapies, such as icosapent ethyl, there is an established dose-related risk of developing atrial fibrillation (AF).

Question 103

A 72-year-old man with chronic heart failure with reduced ejection fraction and chronic kidney disease presents for a routine follow-up. His medications include sacubitril/valsartan, carvedilol, dapagliflozin, and spironolactone. Laboratory tests reveal a serum potassium level of 5.7 mEq/L. To avoid down-titrating his renin-angiotensin-aldosterone system inhibitors and maintain their cardio-renal benefits, the physician initiates a gastrointestinal potassium binder that removes potassium by exchanging it for sodium and hydrogen. Which of the following adverse effects is associated with the initiated agent?

• ✓ Edema
• ○ Hypomagnesemia
• ○ Hypercalcemia
• ○ Gastrointestinal bleeding

Explanation. The initiated agent is sodium zirconium cyclosilicate, which lowers serum potassium levels by exchanging potassium for sodium and hydrogen cations in the gastrointestinal tract. A recognized adverse effect associated with this specific potassium binder is edema.

Question 104

A 68-year-old man with a history of coronary artery disease (CAD), a prior anterior myocardial infarction, and heart failure with reduced ejection fraction (HFrEF) with a left ventricular ejection fraction (LVEF) of 25% presents for a routine follow-up. He is currently asymptomatic and his ECG shows normal sinus rhythm. He has no history of atrial fibrillation, venous thromboembolism, or stroke. His current medications include lisinopril, metoprolol succinate, empagliflozin, spironolactone, and aspirin. He asks if he should be taking a stronger blood thinner like warfarin or rivaroxaban to prevent future strokes or heart attacks. Based on clinical trial evidence, what is the most appropriate management regarding anticoagulation for this patient?

• ○ Initiate warfarin, as it significantly reduces the combined outcome of death, ischemic stroke, and myocardial infarction compared to aspirin in this patient population.
• ○ Add rivaroxaban to his current regimen to reduce mortality and stroke risk, given his concurrent CAD and HFrEF.
• ✓ Continue current therapy without adding an oral anticoagulant, as routine anticoagulation in this setting provides no cardiovascular benefit and increases the risk of bleeding.
• ○ Switch aspirin to clopidogrel, as it has been shown to be superior to both aspirin and warfarin in reducing thromboembolic events in HFrEF.

Explanation. There is no evidence of cardiovascular benefit for anticoagulation in heart failure patients without a specific indication, such as venous thromboembolism, atrial fibrillation, a previous thromboembolic event, or a cardioembolic source. Clinical trials comparing warfarin to aspirin or rivaroxaban to placebo in patients with reduced left ventricular ejection fraction and normal sinus rhythm have shown no significant differences in primary outcomes like death, stroke, or myocardial infarction, but have demonstrated a significant increase in major bleeding with oral anticoagulation.

Question 105

A 64-year-old woman with a history of ischemic cardiomyopathy (left ventricular ejection fraction of 30%) and type 2 diabetes mellitus presents to the clinic for a routine follow-up. Her current medications include sacubitril/valsartan, carvedilol, spironolactone, and metformin. Her hemoglobin A1c is 8.1%, and her primary care physician wishes to add a new oral antihyperglycemic agent. Which of the following medication classes has potential for harm or unproven value in this patient and should be avoided?

• ✓ Thiazolidinediones
• ○ Sodium-glucose cotransporter-2 (SGLT2) inhibitors
• ○ Glucagon-like peptide-1 (GLP-1) receptor agonists
• ○ Sulfonylureas

Explanation. Thiazolidinediones are medications used for the treatment of type 2 diabetes that have either unproven value or potential for harm in the management of patients with heart failure with reduced ejection fraction.

Question 106

A 64-year-old man with a history of nonischemic cardiomyopathy and a left ventricular ejection fraction of 30% presents to the clinic for a routine evaluation. He has no symptoms of congestion at rest. His current medication regimen includes maximally tolerated doses of sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Vital signs show a heart rate of 66 bpm and a blood pressure of 162/94 mm Hg. Optimization of his current guideline-directed medical therapy (GDMT) has already been achieved, but his blood pressure remains poorly controlled. Which of the following medications is the most appropriate addition to control his hypertension?

• ✓ Amlodipine
• ○ Diltiazem
• ○ Verapamil
• ○ Hormonal therapy

Explanation. Second-generation dihydropyridine calcium channel blockers, including amlodipine, have greater selectivity for calcium channels in vascular smooth muscle cells and less myocardial depressant activity. They may be safely used for the treatment of hypertension in patients with heart failure who have elevated blood pressure despite the optimization of guideline-directed medical therapy.

Question 107

A 64-year-old man with a history of ischemic heart disease and heart failure with reduced ejection fraction (HFrEF) following a recent acute myocardial infarction presents to the cardiology clinic. He continues to experience mild exertional angina despite optimal medical therapy with a beta-blocker, an angiotensin receptor-neprilysin inhibitor, a mineralocorticoid receptor antagonist, and a sodium-glucose cotransporter-2 inhibitor. The patient asks if a calcium channel blocker such as verapamil could be added to his regimen to help manage his angina. What is the most appropriate response regarding the use of verapamil in this clinical context?

• ○ Verapamil is a suitable addition as it has been shown to improve survival post-myocardial infarction in patients with HFrEF.
• ✓ Verapamil should be avoided because it acts as a myocardial depressant and is generally not well tolerated in patients with heart failure.
• ○ Verapamil can be safely used if combined with coenzyme Q10 supplementation to offset its negative inotropic effects.
• ○ Verapamil is indicated because it significantly reduces the incidence of major adverse cardiovascular events at 2 years in ischemic heart failure.

Explanation. Nondihydropyridine calcium channel blockers, such as diltiazem and verapamil, are myocardial depressants and are generally not well tolerated in patients with heart failure. Verapamil has been shown to have no impact on survival or major cardiac events post-myocardial infarction, including in patients who develop HFrEF after an acute myocardial infarction.

Question 108

A 72-year-old male with a history of severe ischemic cardiomyopathy (left ventricular ejection fraction of 25%) and a recent hospitalization for decompensated heart failure is evaluated in the clinic. He reports frequent palpitations and worsening fatigue. An electrocardiogram (ECG) confirms the presence of highly symptomatic atrial fibrillation. Rate control strategies have been exhausted, and he is deemed a candidate for rhythm control with an antiarrhythmic medication. Which of the following agents is the safest to initiate in this patient due to its neutral effect on mortality in patients with heart failure with reduced ejection fraction (HFrEF)?

• ○ Flecainide
• ○ Dronedarone
• ✓ Dofetilide
• ○ Mexiletine

Explanation. Dofetilide is one of the few antiarrhythmic agents, along with amiodarone, that has been demonstrated to have neutral effects on mortality in clinical trials involving patients with heart failure with reduced ejection fraction (HFrEF).

Question 109

A 68-year-old female with type 2 diabetes mellitus presents to the clinic with progressive exertional dyspnea, a recent weight gain of 12 lbs, and bilateral pitting edema up to the knees. Echocardiography is consistent with new-onset heart failure (HF). Her primary care physician recently prescribed a thiazolidinedione to improve her glycemic control. Through which of the following mechanisms does this class of medication most likely contribute to the patient's fluid retention and clinical presentation?

• ✓ Activation of nuclear peroxisome proliferator-activated receptor gamma (PPAR-y) increasing sodium reabsorption in the renal collecting ducts
• ○ Inhibition of dipeptidyl peptidase-4 (DPP-4) resulting in enhanced glucose-dependent insulin secretion and secondary volume expansion
• ○ Direct myocardial toxicity leading to increased ventricular stiffness and elevated left ventricular filling pressures
• ○ Activation of glucagon-like peptide 1 (GLP-1) receptors causing peripheral vasodilation and subsequent reflex fluid retention

Explanation. Thiazolidinediones increase insulin sensitivity by activating nuclear peroxisome proliferator-activated receptor gamma (PPAR-y), which is expressed in virtually all tissues and specifically regulates sodium reabsorption in the collecting ducts of the kidney, ultimately leading to an increased incidence of fluid retention and heart failure events.

Question 110

A 58-year-old male with heart failure with reduced ejection fraction (HFrEF) returns for a follow-up clinic visit. Two months ago, he was initiated on low-dose medical therapy including an angiotensin receptor-neprilysin inhibitor (ARNi) and a beta blocker. Today, he reports feeling excellent with complete resolution of his shortness of breath and fatigue. His blood pressure is 122/78 mmHg, heart rate is 68 bpm, and serum creatinine and potassium are within normal limits. He asks if his medication doses can be kept at their current low levels since his symptoms have completely resolved. What is the most appropriate next step in the dosing management of his medications?

• ○ Maintain the current medication doses since further increases may provoke adverse effects without added benefit in an asymptomatic patient.
• ✓ Uptitrate the medications to specific target doses, provided the patient continues to tolerate the dose increases.
• ○ Taper and discontinue the ARNi since his symptoms have resolved, but maintain the beta blocker at the current low dose.
• ○ Increase the medication doses only if his heart failure symptoms recur or his ejection fraction declines further.

Explanation. Even if symptoms improve or other indicators of clinical response are shown at lower doses, heart failure medication doses should still be increased to the trial-defined target doses, if tolerated, because these specific target doses established the efficacy and safety of the medications in improving patient outcomes.

Question 111

A 65-year-old man with a history of heart failure with reduced ejection fraction (HFrEF) presents for a routine follow-up. He is currently asymptomatic, denying any dyspnea, orthopnea, or lower extremity edema. His medications include lisinopril 5 mg daily and carvedilol 6.25 mg twice daily. His blood pressure is 130/80 mmHg, heart rate is 72 bpm, and recent laboratory tests show normal renal function and electrolytes. He has no history of adverse effects from his current medical regimen. Based on clinical trials evaluating dose-response outcomes in HFrEF, which of the following is the most appropriate approach regarding his medication dosing?

• ○ Maintain the current medication doses since the patient is currently asymptomatic and hemodynamically stable.
• ✓ Up-titrate the current medications toward established target doses, as tolerated, to maximize clinical benefit.
• ○ Decrease the medication doses to minimize the risk of future adverse events while preserving symptom control.
• ○ Switch his current regimen to hydralazine-nitrate therapy, as it provides universal incremental benefit over ACE inhibitors across all demographic groups.

Explanation. In trials evaluating dose response for outcomes in patients with heart failure with reduced ejection fraction (HFrEF), composite event rates were lower in patients receiving target doses compared to those on lower doses. There is no direct evidence to suggest that lower doses produce the same degree of clinical benefit as higher target doses in patients who can tolerate them; therefore, up-titration toward target doses is indicated.

Question 112

A 68-year-old man with a history of heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction of 30%) is evaluated in the clinic. He was recently started on carvedilol 3.125 mg twice daily and lisinopril 5 mg daily. His blood pressure is 118/76 mmHg, and his heart rate is 72 beats per minute. He is currently asymptomatic, and his renal function and electrolytes are within normal limits. The cardiologist plans to systematically uptitrate his heart failure medications. Which of the following represents the most appropriate rationale for pursuing target doses of his beta-blocker?

• ✓ Beta-blockers provide dose-dependent improvements in left ventricular ejection fraction, reduction in heart failure hospitalizations, and reduction in all-cause mortality.
• ○ Beta-blockers provide dose-dependent improvements in renal function and electrolyte stability during the uptitration phase.
• ○ Maximizing the beta-blocker dose enables a safe reduction in the target dose of concurrent angiotensin-converting enzyme inhibitors.
• ○ Achieving target doses of beta-blockers is primarily beneficial for symptom control and does not significantly impact long-term mortality.

Explanation. In patients with heart failure with reduced ejection fraction, beta-blockers provide dose-dependent improvements in left ventricular ejection fraction, reduction in heart failure hospitalizations, and reduction in all-cause mortality, which justifies the clinical effort to carefully uptitrate these medications to trial-defined target doses.

Question 113

A 68-year-old man with a history of Stage C heart failure with reduced ejection fraction (HFrEF) is seen in the cardiology clinic. He remains symptomatic despite optimization of his guideline-directed medical therapy. A medication that acts as a sinoatrial node modulator is added to his regimen. Which of the following describes the specific mechanism of action of this drug and its demonstrated clinical benefit?

• ✓ It selectively inhibits the If current and reduces the composite endpoint of cardiovascular death or heart failure hospitalization.
• ○ It inhibits the Na+/K+ ATPase pump and reduces the composite endpoint of all-cause mortality or heart failure hospitalization.
• ○ It blocks beta-1 adrenergic receptors and reduces the composite endpoint of cardiovascular death or heart failure hospitalization.
• ○ It acts as a non-dihydropyridine calcium channel blocker and reduces the composite endpoint of all-cause mortality or heart failure hospitalization.

Explanation. Ivabradine is a sinoatrial node modulator that selectively inhibits the If current. This mechanism reduces heart rate, which is a strong predictor of cardiovascular outcomes, and has been shown to reduce the composite endpoint of cardiovascular death or heart failure hospitalization in patients with heart failure.

Question 114

A 68-year-old man with heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction 32%) presents for a routine follow-up. He was hospitalized for a heart failure exacerbation 4 months ago. He currently experiences New York Heart Association (NYHA) class II symptoms. His medications include sacubitril-valsartan 97/103 mg twice daily, dapagliflozin 10 mg daily, spironolactone 25 mg daily, and metoprolol succinate 50 mg daily. His blood pressure is 118/76 mm Hg, and his electrocardiogram (ECG) shows normal sinus rhythm with a resting heart rate of 78 beats per minute. The physician is considering adding ivabradine to his regimen. What is the most appropriate next step in management?

• ○ Initiate ivabradine 5 mg twice daily to reduce the risk of heart failure hospitalization.
• ✓ Uptitrate metoprolol succinate to the maximum tolerated target dose before reassessing the heart rate.
• ○ Discontinue metoprolol succinate and initiate ivabradine due to inadequate heart rate control.
• ○ Add digoxin to achieve a target resting heart rate of less than 70 beats per minute.

Explanation. Beta-blocker therapy has well-proven mortality benefits in patients with heart failure with reduced ejection fraction. Therefore, these agents must be initiated and uptitrated to target doses, as tolerated, before assessing the resting heart rate to consider ivabradine initiation. Although ivabradine is beneficial for reducing heart failure hospitalizations in patients with an ejection fraction of 35% or less, sinus rhythm, and a resting heart rate of 70 beats per minute or greater, maximizing the beta-blocker dose to achieve its full mortality benefit is the required preceding step.

Question 115

A 68-year-old male with a history of non-ischemic cardiomyopathy and a left ventricular ejection fraction of 28% presents for a follow-up visit. He continues to experience fatigue and dyspnea with mild physical activity, consistent with New York Heart Association (NYHA) class III heart failure. He is currently on maximally tolerated guideline-directed medical therapy (GDMT), including sacubitril/valsartan, bisoprolol, spironolactone, and dapagliflozin. His heart rate is 74 bpm in normal sinus rhythm. To address his persistent symptoms, the addition of digoxin is considered. Which of the following outcomes is the most established benefit of initiating digoxin in this clinical scenario?

• ○ Prolonged overall survival
• ✓ Reduction in the risk of heart failure hospitalization
• ○ Significant improvement in overall health-related quality of life
• ○ Reversal of adverse left ventricular remodeling

Explanation. In patients with mild to moderate heart failure who remain symptomatic despite optimization of guideline-directed medical therapy, the addition of digoxin provides a modest reduction in the combined risk of death and hospitalization, driven primarily by a decrease in hospitalizations.

Question 116

A 68-year-old man with a history of Heart Failure with reduced Ejection Fraction (HFrEF) (left ventricular ejection fraction 25%) presents for a follow-up visit. He was recently hospitalized for acute decompensated heart failure and has experienced progression of his symptoms despite adherence to optimal Guideline-Directed Medical Therapy (GDMT). His cardiologist decides to initiate vericiguat to further manage his worsening HFrEF. Which of the following best describes the intracellular mechanism and corresponding beneficial cardiac effect of this medication?

• ✓ It directly stimulates soluble guanylyl cyclase (sGC) to increase cyclic guanosine monophosphate (cGMP) production, resulting in decreased myocardial fibrosis and cardiac remodeling.
• ○ It increases cyclic adenosine monophosphate (cAMP) production through phosphodiesterase inhibition, leading to increased cardiac inotropy.
• ○ It inhibits the degradation of natriuretic peptides, increasing circulating cyclic guanosine monophosphate (cGMP) to promote vasodilation and diuresis.
• ○ It competitively binds to the angiotensin receptor, preventing the production of profibrotic downstream messengers and reversing cardiac remodeling.

Explanation. Vericiguat is an oral soluble guanylyl cyclase (sGC) stimulator that directly binds to and stimulates sGC, which increases the intracellular production of cyclic guanosine monophosphate (cGMP). The increased levels of cGMP mediate several beneficial downstream effects in patients with heart failure, including vasodilation, improvement in endothelial function, and a decrease in both myocardial fibrosis and structural remodeling of the heart.

Question 117

A 72-year-old male with heart failure with reduced left ventricular ejection fraction (LVEF 35%) and New York Heart Association (NYHA) class III symptoms is evaluated in the cardiology clinic. He was hospitalized for a heart failure exacerbation 3 months ago. His current medical therapy includes sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. His blood pressure is 108/72 mm Hg, and his estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73 m^2. His current N-terminal pro-B-type natriuretic peptide (NT-proBNP) level is 6,500 pg/mL. The addition of vericiguat is being considered. Which of the following best describes the expected outcome or appropriateness of adding vericiguat for this patient?

• ○ He is expected to have a significant reduction in all-cause mortality.
• ✓ He is unlikely to derive clinical benefit from vericiguat due to his markedly elevated NT-proBNP level.
• ○ Vericiguat is contraindicated because his systolic blood pressure is less than 110 mm Hg.
• ○ He is ineligible for vericiguat because it is only beneficial for patients without a heart failure hospitalization in the past 6 months.

Explanation. Subgroup analysis of trial data evaluating vericiguat in heart failure with reduced ejection fraction demonstrated heterogeneity in treatment response based on natriuretic peptide levels. Specifically, patients in the highest quartile of NT-proBNP (levels greater than 5314 pg/mL) did not derive a clinical benefit from the addition of vericiguat compared to placebo. Given this patient's NT-proBNP level of 6,500 pg/mL, he falls into this highest quartile and is unlikely to experience a reduction in cardiovascular death or heart failure hospitalization.

Question 118

A 58-year-old man is newly diagnosed with heart failure with reduced ejection fraction (HFrEF). An echocardiogram reveals a left ventricular ejection fraction (LVEF) of 28%. His electrocardiogram demonstrates normal sinus rhythm with a left bundle branch block and a QRS duration of 155 ms. He is currently taking low-dose lisinopril and metoprolol succinate. He reports New York Heart Association (NYHA) class II symptoms. The patient inquires about his eligibility for an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. What is the most appropriate next step in the management of this patient?

• ○ Immediate implantation of a CRT-defibrillator (CRT-D) device.
• ✓ Optimize guideline-directed medical therapy (GDMT) to assess whether the LVEF improves.
• ○ Schedule an electrophysiology study to determine the necessity of an ICD.
• ○ Wait 3 months and re-evaluate LVEF without changing his current medication regimen.

Explanation. Guideline-directed medical therapy (GDMT) must be optimized prior to the implantation of an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT) device to properly assess whether the left ventricular ejection fraction (LVEF) improves with medical management alone.

Question 119

A 62-year-old male is evaluated in the cardiology clinic. He has a history of an anterior myocardial infarction 5 years ago. His current echocardiogram demonstrates a left ventricular ejection fraction (LVEF) of 25%. He has no history of sustained ventricular arrhythmias, and a recent 24-hour Holter monitor reveals no premature ventricular contractions or non-sustained ventricular tachycardia. Based on landmark clinical trials, which of the following statements describes the expected outcome of implantable cardioverter-defibrillator (ICD) therapy for this patient?

• ✓ It provides a mortality benefit despite the absence of an arrhythmia qualifier.
• ○ It provides a mortality benefit only if he develops documented non-sustained ventricular tachycardia.
• ○ It shows a trend toward mortality benefit, but does not achieve statistical significance in ischemic populations.
• ○ It is inferior to prophylactic amiodarone therapy for sudden cardiac death prevention in this specific population.

Explanation. Patients with a history of a previous myocardial infarction and a severely reduced left ventricular ejection fraction (LVEF <30%) derive a significant mortality benefit from an implantable cardioverter-defibrillator (ICD) even in the absence of any arrhythmia qualifier.

Question 120

A 60-year-old man with nonischemic dilated cardiomyopathy, normal sinus rhythm, and a left ventricular ejection fraction (LVEF) of 32% is evaluated in the clinic. He is on maximally tolerated guideline-directed medical therapy. He has a wide QRS complex (160 ms) with a left bundle branch block pattern, and you are planning a device strategy. When considering the addition of an implantable cardioverter-defibrillator (ICD) to his treatment plan, what do findings from the DANISH trial indicate regarding the expected outcomes?

• ✓ ICD implantation reduces the risk of sudden cardiac death but does not significantly reduce total mortality, a finding that may be influenced by concurrent cardiac resynchronization therapy (CRT) use.
• ○ ICD implantation significantly reduces total mortality but has no measurable effect on the overall incidence of sudden cardiac death in nonischemic patients.
• ○ The addition of an ICD to standard care significantly increases total mortality due to a high rate of inappropriate shocks when paired with CRT.
• ○ ICD implantation significantly reduces both total mortality and the risk of sudden cardiac death regardless of baseline CRT use.

Explanation. In patients with nonischemic cardiomyopathy and a left ventricular ejection fraction ≤35%, utilizing an implantable cardioverter-defibrillator (ICD) alongside standard care reduces the specific risk of sudden cardiac death without producing a significant reduction in total mortality. A high baseline rate of concurrent cardiac resynchronization therapy (CRT) in this population can potentially mitigate the observable survival benefit of the ICD.

Question 121

A 58-year-old male with a history of an anterior myocardial infarction 50 days ago presents for follow-up. He has been on maximally tolerated guideline-directed medical therapy (GDMT) for heart failure for 4 months. An echocardiogram shows a left ventricular ejection fraction (LVEF) of 28%. An electrocardiogram (ECG) reveals sinus rhythm with a left bundle branch block (LBBB) and a QRS duration of 155 ms. The clinical team considers device therapy for the primary prevention of sudden cardiac death (SCD). In evaluating the health economic outcomes for such devices, what projected minimum increase in life expectancy is associated with a consistently high economic value (incremental cost-effectiveness ratio <$60,000 per year of life added)?

• ○ 0.5 years
• ✓ 1.4 years
• ○ 2.5 years
• ○ 5.0 years

Explanation. The value provided by an implantable cardioverter-defibrillator (ICD) for the primary prevention of sudden cardiac death is consistently high, defined as an incremental cost-effectiveness ratio of less than $60,000 per year of life added, when life expectancy is projected to increase by at least 1.4 years.

Question 122

A 62-year-old man presents for a routine follow-up. He has a history of a myocardial infarction 3 years ago. He is currently entirely asymptomatic and has no limitations in his physical activity (New York Heart Association class I). A recent echocardiogram reveals a left ventricular ejection fraction (LVEF) of 28%. His electrocardiogram demonstrates normal sinus rhythm with a QRS duration of 98 ms. Based on seminal clinical trials, what is the most appropriate consideration regarding device therapy for this patient?

• ✓ Placement of an implantable cardioverter-defibrillator (ICD) is indicated as it has been shown to reduce mortality.
• ○ He is not a candidate for device therapy because mortality benefits from such devices are restricted to those with symptomatic heart failure.
• ○ Placement of a cardiac resynchronization therapy defibrillator (CRT-D) is indicated to improve his functional capacity.
• ○ Placement of a cardiac resynchronization therapy pacemaker (CRT-P) is indicated to decrease the risk of future hospitalizations.

Explanation. The MADIT-II trial demonstrated that patients with a previous myocardial infarction and a left ventricular ejection fraction <30% experience a reduction in mortality with the placement of an implantable cardioverter-defibrillator (ICD), regardless of their heart failure symptom class. This mortality benefit applies even to asymptomatic patients, as a significant portion of the cohort in the trial had class I heart failure.

Question 123

A 58-year-old woman with non-ischemic cardiomyopathy is evaluated in the heart failure clinic. Despite optimization of guideline-directed medical therapy, she remains limited by NYHA class II symptoms. Echocardiography reveals a left ventricular ejection fraction (LVEF) of 28%. An electrocardiogram (ECG) shows normal sinus rhythm with a QRS duration of 150 ms and a left bundle branch block morphology. If this patient were treated with a cardiac resynchronization therapy-defibrillator (CRT-D) rather than an implantable cardioverter-defibrillator (ICD) alone, which of the following outcomes is most anticipated based on the MADIT-CRT trial?

• ✓ A reduction in the primary composite endpoint of death or heart failure
• ○ A reduction in appropriate ICD therapies without impacting overall survival
• ○ An increase in left ventricular ejection fraction to >40% within 6 months
• ○ A reduction in all-cause mortality with no significant effect on heart failure hospitalizations

Explanation. The MADIT-CRT trial enrolled patients with NYHA class I and II heart failure with a left ventricular ejection fraction ≤30% and a QRS duration ≥130 ms. In this population, comparing CRT-D with ICD therapy demonstrated a significant reduction in the primary composite endpoint of death or heart failure events.

Question 124

A 65-year-old man with a history of nonischemic cardiomyopathy and New York Heart Association (NYHA) class III heart failure symptoms is being evaluated for device therapy. His current left ventricular ejection fraction (LVEF) is 25% despite guideline-directed medical therapy. Which of the following baseline electrocardiogram (ECG) findings predicts the greatest clinical benefit from cardiac resynchronization therapy (CRT) in this patient?

• ○ Left bundle branch block (LBBB) with a QRS duration of 135 ms
• ✓ Left bundle branch block (LBBB) with a QRS duration of 160 ms
• ○ Non-LBBB pattern with a QRS duration of 160 ms
• ○ Non-LBBB pattern with a QRS duration of 135 ms

Explanation. Patients with a left bundle branch block (LBBB) morphology and a QRS duration greater than 150 ms derive the greatest benefit from cardiac resynchronization therapy, as both LBBB morphology and wider QRS durations are the strongest predictors of positive clinical response and remodeling.

Question 125

A 38-year-old woman with a family history of sudden cardiac death presents with progressive fatigue and palpitations. An echocardiogram reveals a left ventricular ejection fraction (LVEF) of 38%. Genetic testing identifies a pathogenic mutation in the LMNA/C gene. She was initiated on guideline-directed medical therapy (GDMT) 2 weeks ago. What is the most appropriate clinical decision regarding implantable cardioverter-defibrillator (ICD) therapy for primary prevention in this patient?

• ✓ Proceed with ICD implantation now, as her genetic variant carries a high risk of sudden death regardless of an LVEF >35% or short GDMT duration.
• ○ Defer ICD implantation until she has completed at least 3 months of GDMT to assess for left ventricular functional recovery.
• ○ Withhold ICD implantation, as primary prevention devices are only indicated when the LVEF falls to 35% or below.
• ○ Withhold ICD implantation, as patients with this specific mutation typically progress strictly to pump failure rather than arrhythmogenic death.

Explanation. Identification of specific arrhythmogenic genetic variants, such as LMNA/C mutations, carries significant implications for the implantation of implantable cardioverter-defibrillators (ICDs) for the primary prevention of sudden cardiac death. In these specific high-risk populations, ICD implantation is indicated even in patients who have a left ventricular ejection fraction (LVEF) greater than 35% or who have received guideline-directed medical therapy (GDMT) for less than 3 months, as their disease course is frequently complicated by refractory, life-threatening arrhythmias.

Question 126

A 65-year-old man with non-ischemic cardiomyopathy presents to the clinic with persistent New York Heart Association (NYHA) class III heart failure symptoms despite optimally titrated medical therapy. His recent echocardiogram shows a left ventricular ejection fraction (LVEF) of 32% and significant mechanical dyssynchrony. His electrocardiogram (ECG) demonstrates a normal sinus rhythm with a QRS duration of 125 ms. Based on the ECHO-CRT (Echocardiography Guided Cardiac Resynchronization Therapy) trial, which of the following statements is true regarding the use of cardiac resynchronization therapy (CRT) for this patient?

• ✓ CRT provides no clinical benefit for patients with NYHA class III to IV heart failure, LVEF ≤35%, a QRS duration ≤130 ms, and mechanical dyssynchrony.
• ○ CRT provides a substantial mortality benefit because echocardiographic mechanical dyssynchrony is a stronger predictor of response than QRS duration.
• ○ CRT is strongly indicated because the patient's QRS duration falls between 120 and 130 ms, a subgroup universally proven to benefit.
• ○ CRT improves clinical composite scores primarily in patients with a narrow QRS who have non-ischemic cardiomyopathy.

Explanation. The ECHO-CRT trial evaluated patients with NYHA class III to IV heart failure, an LVEF ≤35%, a QRS duration ≤130 ms, and mechanical dyssynchrony on echocardiography, demonstrating that there is no clinical benefit to cardiac resynchronization therapy in this specific patient population.

Question 127

A 65-year-old male with non-ischemic cardiomyopathy and a left ventricular ejection fraction (LVEF) of 30% presents for follow-up. He is on maximally tolerated guideline-directed medical therapy, including sacubitril/valsartan, carvedilol, spironolactone, and dapagliflozin. Despite this, he continues to experience New York Heart Association (NYHA) class III symptoms. His electrocardiogram (ECG) shows normal sinus rhythm with a QRS duration of 95 ms, making him unsuited for cardiac resynchronization therapy (CRT). Which of the following device therapies is currently approved for the improvement of symptoms, quality of life, and exercise capacity in this patient?

• ○ Implantable vagus nerve stimulator
• ○ Multisite left ventricular pacemaker
• ✓ Carotid artery baroreceptor stimulator
• ○ Spinal cord stimulator

Explanation. An implantable device that electrically stimulates the baroreceptors of the carotid artery has been approved for the improvement of symptoms, quality of life, and exercise capacity in patients with advanced heart failure who are unsuited for treatment with other heart failure devices, such as cardiac resynchronization therapy.

Question 128

A 68-year-old man with non-ischemic cardiomyopathy presents for a follow-up visit. He reports persistent shortness of breath with mild activities, consistent with New York Heart Association (NYHA) class III heart failure, despite being on maximally tolerated guideline-directed medical therapy. His recent echocardiogram reveals a left ventricular ejection fraction (LVEF) of 40%. An electrocardiogram shows normal sinus rhythm with a QRS duration of 90 ms. The patient is inquiring about additional device-based therapies. Which of the following interventions is approved to improve exercise capacity and quality of life in this patient?

• ✓ Cardiac contractility modulation (CCM)
• ○ Cardiac resynchronization therapy (CRT)
• ○ Implantable cardioverter-defibrillator (ICD)
• ○ Phrenic nerve stimulation

Explanation. Cardiac contractility modulation (CCM) involves applying relatively high-voltage, long-duration electric signals to the right ventricular septal wall during the absolute myocardial refractory period to augment left ventricular contractile performance. It is FDA-approved for patients with New York Heart Association (NYHA) class III heart failure and a left ventricular ejection fraction (LVEF) of 25% to 45% who are not candidates for cardiac resynchronization therapy (CRT), such as those with a narrow QRS complex. This therapy has been shown to improve exercise capacity and quality of life in this specific patient population.

Question 129

A 65-year-old man with type 2 diabetes mellitus and ischemic cardiomyopathy presents to the cardiology clinic to discuss treatment options. His current left ventricular ejection fraction (LVEF) is 30%. Coronary angiography demonstrates severe multi-vessel coronary artery disease. He is highly compliant with maximum tolerated guideline-directed medical therapy (GDMT) but continues to experience mild exertional angina and dyspnea. The multidisciplinary team recommends coronary artery bypass grafting (CABG). When counseling the patient on the expected long-term outcomes of adding CABG to his GDMT regimen compared to continuing medical therapy alone, which of the following is most accurate?

• ✓ The addition of coronary artery bypass grafting provides a significant reduction in all-cause mortality, cardiovascular mortality, and hospitalizations at 10 years.
• ○ The addition of coronary artery bypass grafting offers an immediate survival benefit within the first 5 years that plateaus by 10 years.
• ○ The addition of coronary artery bypass grafting provides no significant long-term reduction in all-cause mortality but significantly reduces recurrent angina.
• ○ The addition of coronary artery bypass grafting offers comparable 10-year all-cause mortality and hospitalization outcomes to percutaneous coronary intervention.

Explanation. In patients with ischemic cardiomyopathy and a left ventricular ejection fraction of 35% or less, the addition of coronary artery bypass grafting to optimal guideline-directed medical therapy results in significant long-term reductions in all-cause mortality, cardiovascular mortality, and both first and recurrent cardiovascular and heart failure hospitalizations at a 10-year follow-up.

Question 130

A 62-year-old man with a history of anterior myocardial infarction presents with progressive dyspnea on exertion. Echocardiography demonstrates a left ventricular ejection fraction (LVEF) of 25% with anterior wall scarring, but no large thrombus, well-defined aneurysm, or evidence of persistent arrhythmias. Coronary angiography reveals severe three-vessel disease. He is optimized on guideline-directed medical therapy (GDMT) and referred for coronary artery bypass grafting (CABG). The cardiothoracic surgeon considers adding surgical ventricular remodeling at the time of the procedure. What is the expected clinical outcome of adding surgical ventricular remodeling to CABG for this patient?

• ✓ It will not reduce death, hospitalization, or improve symptoms compared to CABG alone.
• ○ It will provide a significant long-term reduction in all-cause mortality compared to CABG alone.
• ○ It will decrease the rate of heart failure hospitalizations but increase perioperative mortality.
• ○ It will significantly improve his quality of life and heart failure symptoms compared to CABG alone.

Explanation. In patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting, the addition of surgical ventricular remodeling does not reduce death or hospitalization, nor does it improve symptoms compared to bypass surgery alone. Its utility is reserved for specific complicated cases involving intractable heart failure, a large thrombus, or persistent arrhythmias resulting from a well-defined aneurysm or scar.

Question 131

A 68-year-old male with a history of heart failure with reduced ejection fraction (HFrEF) presents for follow-up of worsening exertional dyspnea. His current left ventricular ejection fraction is 28%. He is currently treated with low-dose lisinopril and carvedilol. A recent transthoracic echocardiogram reveals severe secondary mitral regurgitation (MR) with significant left ventricular dilation. Which of the following is the most appropriate next step in the management of this patient's mitral regurgitation?

• ○ Refer the patient for immediate surgical mitral valve repair.
• ○ Refer the patient for transcatheter mitral valve edge-to-edge repair (TEER).
• ✓ Optimize guideline-directed medical therapy (GDMT) and reassess the MR severity.
• ○ Schedule an isolated surgical mitral valve replacement.

Explanation. Optimization of guideline-directed medical therapy can improve secondary mitral regurgitation associated with left ventricular dysfunction and potentially obviate the need for surgical or transcatheter intervention. Re-assessing the severity of the mitral regurgitation after medical therapy has been maximized is an essential step before considering any structural mitral valve interventions.

Question 132

A 68-year-old man with non-ischemic cardiomyopathy presents with persistent New York Heart Association (NYHA) class III symptoms despite maximally tolerated guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy (CRT). A transesophageal echocardiogram confirms severe secondary mitral regurgitation (MR) with appropriate valve anatomy for intervention. You are considering transcatheter edge-to-edge mitral valve repair (TEER) for this patient. Which of the following echocardiographic parameter profiles indicates that he is an optimal candidate who would derive a mortality and hospitalization benefit from TEER?

• ○ Left ventricular ejection fraction (LVEF) 15%, LV end-systolic dimension (LVESD) 75 mm, and pulmonary artery systolic pressure (PASP) 60 mm Hg
• ✓ Left ventricular ejection fraction (LVEF) 30%, LV end-systolic dimension (LVESD) 60 mm, and pulmonary artery systolic pressure (PASP) 55 mm Hg
• ○ Left ventricular ejection fraction (LVEF) 40%, LV end-systolic dimension (LVESD) 65 mm, and pulmonary artery systolic pressure (PASP) 75 mm Hg
• ○ Left ventricular ejection fraction (LVEF) 55%, LV end-systolic dimension (LVESD) 45 mm, and pulmonary artery systolic pressure (PASP) 40 mm Hg

Explanation. Transcatheter edge-to-edge mitral valve repair (TEER) is beneficial in patients with severe secondary mitral regurgitation who have persistent symptoms despite guideline-directed medical therapy, appropriate valve anatomy, a left ventricular ejection fraction (LVEF) between 20% and 50%, a left ventricular end-systolic dimension (LVESD) of 70 mm or less, and a pulmonary artery systolic pressure of 70 mm Hg or less.

Question 133

A 72-year-old male with a history of heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction 32%) presents for a routine follow-up. He reports stable, mild exertional dyspnea. A recent transthoracic echocardiogram reveals moderate, nonsevere aortic stenosis with an aortic valve area of 1.4 cm² and a mean transvalvular gradient of 28 mm Hg. He is currently on a stable regimen of heart failure medications, including a beta-blocker, a mineralocorticoid receptor antagonist, and an angiotensin receptor-neprilysin inhibitor. What is the most appropriate approach to managing this patient's concurrent nonsevere aortic stenosis and HFrEF?

• ✓ Continue guideline-directed medical therapy (GDMT) in conjunction with clinical surveillance and serial imaging.
• ○ Refer the patient for immediate transcatheter aortic valve implantation.
• ○ Refer the patient for surgical aortic valve replacement to improve left ventricular function.
• ○ Discontinue the angiotensin receptor-neprilysin inhibitor to prevent excessive afterload reduction.

Explanation. In patients who have nonsevere aortic stenosis and a reduced ejection fraction, standard management involves continuing guideline-directed medical therapy (GDMT) alongside regular clinical surveillance and serial imaging.

Question 134

A 72-year-old male with a history of non-ischemic cardiomyopathy and atrial fibrillation presents with severe, persistent dyspnea on exertion. He has been receiving optimal guideline-directed medical therapy and appropriate medical management for atrial fibrillation for the past year. Echocardiography reveals a left ventricular ejection fraction of 32%, a left ventricular end-systolic dimension of 62 mm, and a pulmonary artery systolic pressure of 58 mm Hg. Severe mitral regurgitation is present with a regurgitant volume of 65 mL and an effective regurgitant orifice of 0.42 cm2. Transesophageal echocardiography confirms that the mitral valve anatomy is favorable for percutaneous intervention. Which of the following is the most appropriate next step in the management of this patient's valvular disease?

• ✓ Transcatheter edge-to-edge mitral valve repair
• ○ Surgical mitral valve replacement
• ○ Surgical mitral valve repair with an annuloplasty ring
• ○ Percutaneous balloon mitral valvotomy

Explanation. Transcatheter edge-to-edge mitral valve repair is indicated for patients with severe stage D mitral regurgitation (characterized by a regurgitant volume of 60 mL or greater and an effective regurgitant orifice of 0.40 cm2 or greater) who have severe persistent symptoms despite optimal guideline-directed medical therapy and atrial fibrillation management, provided they have favorable mitral anatomy, a left ventricular ejection fraction between 20% and 50%, a left ventricular end-systolic dimension of 70 mm or less, and a pulmonary artery systolic pressure of 70 mm Hg or less.

Question 135

A 68-year-old man with heart failure with reduced ejection fraction (HFrEF) is evaluated in the cardiology clinic. An echocardiogram reveals left ventricular (LV) dilatation with secondary mitral regurgitation (MR) that is proportionate to the LV dilatation. He is currently treated with valsartan and a beta-blocker. His heart rate is 70 bpm and blood pressure is 120/75 mmHg. Which of the following medication adjustments would be expected to yield a significant reduction in both the effective regurgitant area and regurgitant volume of his secondary MR?

• ✓ Switching valsartan to sacubitril-valsartan
• ○ Replacing the beta-blocker with a non-dihydropyridine calcium channel blocker
• ○ Adding an alpha-blocker to the current regimen
• ○ Switching valsartan to an angiotensin-converting enzyme (ACE) inhibitor

Explanation. In patients with heart failure with reduced ejection fraction and secondary mitral regurgitation, treatment with sacubitril-valsartan results in a significant reduction in both the effective regurgitant area and the regurgitant volume when compared with valsartan alone. Optimizing guideline-directed medical therapy improves mitral regurgitation and left ventricular dimensions in this patient population.

Question 136

A 68-year-old male with non-ischemic cardiomyopathy and severe secondary mitral regurgitation (MR) presents to the clinic. He reports persistent shortness of breath with minimal exertion, consistent with New York Heart Association (NYHA) class III symptoms. He has been closely followed by a heart failure cardiologist and is on maximally tolerated guideline-directed medical therapy (GDMT) for the past 8 months, including an angiotensin receptor-neprilysin inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and a sodium-glucose cotransporter 2 inhibitor. Recent imaging and right heart catheterization demonstrate a left ventricular ejection fraction (LVEF) of 30%, a left ventricular end-systolic diameter (LVESD) of 62 mm, and a pulmonary artery systolic pressure (PASP) of 60 mm Hg. Medical options for heart failure have been effectively exhausted. Which of the following interventions is the most appropriate consideration for this patient's mitral regurgitation?

• ✓ Transcatheter edge-to-edge repair (TEER)
• ○ Surgical mitral valve replacement
• ○ Percutaneous mitral balloon valvuloplasty
• ○ Addition of an angiotensin-converting enzyme inhibitor (ACEi)

Explanation. This patient is an appropriate candidate for transcatheter edge-to-edge repair (TEER) because he meets all the necessary anatomical and clinical criteria, which include the presence of severe secondary mitral regurgitation, a left ventricular ejection fraction between 20% and 50%, a left ventricular end-systolic diameter of 70 mm or less, a pulmonary artery systolic pressure of 70 mm Hg or less, and persistent New York Heart Association class II to IV symptoms despite exhaustively optimized guideline-directed medical therapy.

Question 137

A 62-year-old woman presents with progressive dyspnea on exertion and lower extremity edema. An echocardiogram reveals a left ventricular ejection fraction (LVEF) of 42%, establishing a diagnosis of heart failure with mildly reduced ejection fraction (HFmrEF). She is currently treatment-naïve for heart failure and asks about her options for disease-modifying medications. Which of the following is the most appropriate approach to her pharmacological management?

• ✓ Initiate guideline-directed medical therapy used for heart failure with reduced ejection fraction (HFrEF), as patients at the lower end of the HFmrEF spectrum respond similarly.
• ○ Limit treatment strictly to symptomatic relief with loop diuretics, as there is no data regarding the use of neurohormonal blockade in this LVEF range.
• ○ Prescribe therapies solely based on the results of prospective randomized controlled trials specifically designed for the HFmrEF population.
• ○ Defer all disease-modifying medical therapy until her LVEF drops below 40%, as therapies have only demonstrated efficacy in strict HFrEF.

Explanation. LVEF represents a continuous clinical spectrum, and patients with heart failure with mildly reduced ejection fraction (HFmrEF), particularly those at the lower end of the 41% to 49% range, appear to respond to medical therapies similarly to patients with heart failure with reduced ejection fraction (HFrEF). Therefore, it is reasonable to treat these patients with the same guideline-directed medical therapy (GDMT) used for the treatment of HFrEF.

Question 138

A 72-year-old woman with a history of hypertension and obesity presents with progressive exertional dyspnea and orthopnea. Transthoracic echocardiogram demonstrates a left ventricular ejection fraction (LVEF) of 55% with diastolic dysfunction. Laboratory testing reveals an elevated N-terminal pro-B-type natriuretic peptide level. She has normal fasting blood glucose and no history of diabetes mellitus. Initiation of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), is planned. Which of the following represents an expected outcome of adding this therapy?

• ○ A significant reduction in all-cause mortality after one year of treatment
• ✓ A reduction in the composite of cardiovascular death or heart failure hospitalization, driven primarily by reduced hospitalizations
• ○ A significant reduction in cardiovascular death as the primary driver of the composite endpoint benefit
• ○ Minimal cardiovascular benefit since the patient does not have a diagnosis of diabetes mellitus

Explanation. In patients with symptomatic heart failure, a left ventricular ejection fraction greater than 40%, and elevated natriuretic peptides, empagliflozin significantly reduces the primary composite endpoint of time to heart failure hospitalization or cardiovascular death. This combined clinical benefit is driven predominantly by a significant reduction in the time to heart failure hospitalization.

Question 139

A 64-year-old man with a history of hypertension and a prior anterior myocardial infarction is evaluated in the clinic for heart failure management. His recent echocardiogram reveals an estimated left ventricular ejection fraction (LVEF) of 45%. An electrocardiogram (ECG) demonstrates normal sinus rhythm. Based on meta-analysis data evaluating heart failure patients with an LVEF of 40% to 49% in sinus rhythm, the initiation of which of the following therapies is specifically associated with a reduction in both all-cause and cardiovascular mortality?

• ✓ Beta-blockers
• ○ Sacubitril-valsartan
• ○ Spironolactone
• ○ Ivabradine

Explanation. In patients with heart failure and a mildly reduced ejection fraction (LVEF 40% to 49%) who are in normal sinus rhythm, meta-analysis data has demonstrated that the use of beta-blockers significantly reduces the primary outcomes of all-cause and cardiovascular mortality.

Question 140

A 65-year-old female with a history of heart failure with mildly reduced ejection fraction (HFmrEF) presents to the cardiology clinic for a follow-up. A recent echocardiogram reveals a left ventricular ejection fraction (LVEF) of 46%. Her current medical regimen includes bisoprolol and dapagliflozin. During the visit, her blood pressure is noted to be consistently elevated at 158/94 mm Hg despite lifestyle modifications. Which of the following medications is most preferred to add to her current regimen?

• ✓ Spironolactone
• ○ Candesartan
• ○ Hydralazine
• ○ Ivabradine

Explanation. Spironolactone is the preferred pharmacological agent for patients with heart failure with mildly reduced ejection fraction (HFmrEF) who also have poorly controlled hypertension. Evidence supports its use for effective blood pressure management while simultaneously reducing the risk of cardiovascular mortality and heart failure hospitalization in this specific ejection fraction range.

Question 141

A 52-year-old male with a history of dilated cardiomyopathy (DCM) presents for a routine follow-up. Three years ago, his left ventricular ejection fraction (LVEF) was 32%, and he was highly symptomatic. He was placed on comprehensive medical therapy for heart failure. Today, he is completely asymptomatic. His most recent echocardiogram reveals an LVEF of 54% with a normalized left ventricular end-diastolic volume (LVEDV). Laboratory studies show an N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration of 110 ng/L. He inquires whether he can begin tapering off his heart failure medications. What is the most appropriate management regarding his pharmacologic therapy?

• ○ Phased withdrawal of his heart failure medications can be safely initiated because his LVEF is now ≥50% and he is asymptomatic.
• ✓ He should continue his current heart failure medications, as withdrawal carries a significant risk of cardiomyopathy relapse within 6 months.
• ○ He should discontinue all heart failure medications and have his NT-proBNP monitored for a 2-fold rise to >400 ng/L before restarting.
• ○ He should undergo phased withdrawal of his medications because successful withdrawal without relapse is achieved in over 90% of similar patients.

Explanation. In patients with a history of dilated cardiomyopathy who become asymptomatic, improve their LVEF to ≥50%, normalize their LVEDV, and achieve an NT-proBNP concentration <250 ng/L, the phased withdrawal of heart failure medications results in a relapse of cardiomyopathy and clinical heart failure in approximately 40% of cases within 6 months. Relapse is characterized by a reduction in LVEF by >10% and to <50%, an increase in LVEDV to above the normal range, a 2-fold rise in NT-proBNP concentration to >400 ng/L, or the return of clinical heart failure symptoms. Continuing medical therapy is necessary to maintain improved cardiac function and prevent substantial reductions in LVEF and worsening of the patient's clinical status.

Question 142

A 58-year-old man with a history of heart failure with reduced ejection fraction (HFrEF) presents for a routine follow-up. Two years ago, his left ventricular ejection fraction (LVEF) was 28% and he experienced New York Heart Association (NYHA) class III symptoms. He was optimized on guideline-directed medical therapy (GDMT), including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Today, he is completely asymptomatic and exercises daily without limitation. His most recent echocardiogram demonstrates an LVEF of 52%, and his N-terminal pro-B-type natriuretic peptide (NT-proBNP) level is within normal limits. The patient asks if he can stop his heart medications since he feels his heart condition is cured. What is the most appropriate recommendation?

• ○ Discontinue the current regimen as the patient no longer meets the criteria for heart failure.
• ○ Discontinue sacubitril-valsartan and spironolactone, but maintain carvedilol indefinitely.
• ✓ Continue the current guideline-directed medical therapy regimen without interruption.
• ○ Halve the doses of all medications and plan to discontinue them if he remains asymptomatic in 6 months.

Explanation. Resolution of heart failure symptoms and improvement in left ventricular ejection fraction and biomarker levels on medical therapy indicate a state of remission rather than a full, sustained recovery. Maintaining the current treatment regimen is required because withdrawal of these medications frequently leads to clinical relapse and recurrence of structural abnormalities.

Question 143

A 68-year-old man with a history of hypertension and type 2 diabetes mellitus is evaluated for worsening exertional dyspnea and lower extremity edema. He is diagnosed with heart failure with preserved ejection fraction (HFpEF) and is currently taking a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and a loop diuretic. You are considering the addition of an angiotensin receptor-neprilysin inhibitor (ARNi), an angiotensin receptor blocker (ARB), or a mineralocorticoid receptor antagonist (MRA) to his regimen to further optimize his therapy. Which of the following documented left ventricular ejection fraction (LVEF) values on his echocardiogram would suggest the greatest expected therapeutic benefit from these additional agents?

• ✓ 51%
• ○ 62%
• ○ 68%
• ○ 74%

Explanation. In the management of heart failure with preserved ejection fraction, patients derive a greater therapeutic benefit from medications such as angiotensin receptor-neprilysin inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists when their left ventricular ejection fraction is closer to 50%.

Question 144

A 72-year-old woman presents with exertional dyspnea, orthopnea, and significant bilateral lower extremity edema. Her medical history includes hypertension, obesity, and atrial fibrillation. An echocardiogram reveals a left ventricular ejection fraction (LVEF) of 55%, left atrial enlargement, and normal valvular function. Which of the following represents the most appropriate initial management approach for this patient's heart failure?

• ✓ Use of diuretics to relieve congestion and optimization of her hypertension and atrial fibrillation
• ○ Initiation of a beta-blocker and an angiotensin-converting enzyme (ACE) inhibitor to significantly reduce mortality
• ○ Routine administration of positive inotropic agents to augment diastolic filling
• ○ Immediate evaluation for an implantable cardioverter-defibrillator (ICD) to prevent sudden cardiac death

Explanation. The recommended management for heart failure with preserved ejection fraction (HFpEF) focuses on the use of diuretics to reduce congestion and improve symptoms, alongside the identification and treatment of specific causes and the active management of contributing comorbidities such as hypertension, atrial fibrillation, and coronary artery disease.

Question 145

A 72-year-old male with heart failure with preserved ejection fraction (HFpEF) and a prior myocardial infarction (MI) presents with poorly controlled hypertension. To manage his blood pressure and underlying coronary disease, his physician initiates a beta-blocker. Four weeks later, the patient reports new-onset profound fatigue and difficulty climbing a single flight of stairs, despite an improved resting blood pressure of 128/78 mmHg and a stable volume status. Which of the following is the most likely mechanism contributing to this patient's new exercise intolerance?

• ✓ Impaired chronotropic response to exertion
• ○ Rebound activation of the renin-angiotensin-aldosterone system (RAAS)
• ○ Direct enhancement of left ventricular myocardial stiffness
• ○ Increased intrapulmonary right-to-left shunting

Explanation. Beta-blockers can induce or exacerbate chronotropic incompetence, which is an inability of the heart to adequately increase its rate during exertion, leading directly to restricted cardiac output and worsened exercise intolerance during physical activity.

Question 146

A 70-year-old man presents to the clinic for follow-up of symptomatic heart failure. He reports New York Heart Association (NYHA) class III symptoms. His recent echocardiogram demonstrates a left ventricular ejection fraction (LVEF) of 45%. Laboratory studies reveal an elevated N-terminal pro-b-type natriuretic peptide (NT-proBNP) and a normal hemoglobin A1c. You decide to add the sodium-glucose cotransporter-2 inhibitor (SGLT2i) empagliflozin to his medical regimen. When considering the expected clinical outcomes of this therapy for this specific patient population, which of the following is most accurate?

• ✓ A reduction in the composite of heart failure hospitalization or cardiovascular death, predominantly driven by a decrease in heart failure hospitalizations.
• ○ A significant reduction in all-cause mortality accompanied by an acceleration in the slope of estimated glomerular filtration rate (eGFR) decline.
• ○ A substantial decrease in cardiovascular death, with the magnitude of benefit progressively increasing as the LVEF exceeds 62.5%.
• ○ A clinical benefit on heart failure hospitalizations that is strictly dependent on the future development of clinical diabetes mellitus.

Explanation. The administration of empagliflozin in symptomatic heart failure patients with an ejection fraction greater than 40% and elevated natriuretic peptides results in a significant reduction in the primary composite endpoint of time to heart failure hospitalization or cardiovascular death. This overall composite benefit is predominantly driven by a significant 29% reduction in the time to heart failure hospitalization, as the isolated reduction in cardiovascular death is statistically nonsignificant and there is no observed benefit on all-cause mortality.

Question 147

An 82-year-old woman with a history of heart failure with preserved ejection fraction (HFpEF) presents with palpitations and worsening dyspnea on exertion. Her electrocardiogram reveals atrial fibrillation with a ventricular rate of 115 beats per minute. Echocardiography shows a left ventricular ejection fraction of 60%. A decision is made to initiate a rate control strategy, and the physician is weighing the choice between bisoprolol and digoxin. Based on trial data comparing these agents in elderly patients with atrial fibrillation and heart failure symptoms, which of the following outcomes is most likely expected at 12 months?

• ✓ Digoxin will be favored for functional capacity and reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP), with fewer adverse events such as hypotension compared to bisoprolol.
• ○ Bisoprolol will achieve a significantly greater reduction in resting heart rate compared to digoxin.
• ○ Bisoprolol will demonstrate superior secondary quality of life endpoints and fewer instances of lethargy.
• ○ Digoxin will achieve superior reduction in heart rate but with higher rates of dizziness and lethargy compared to bisoprolol.

Explanation. In elderly patients with atrial fibrillation and heart failure symptoms (predominantly with preserved ejection fraction), the use of digoxin compared to a beta-blocker like bisoprolol is favored at 12 months for secondary quality of life endpoints, functional capacity, and reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP). Additionally, both agents provide a similar reduction in heart rate, but beta-blockers are associated with a higher incidence of adverse events such as dizziness, lethargy, and hypotension.

Question 148

A 68-year-old woman with a history of symptomatic heart failure with preserved ejection fraction (HFpEF) is evaluated in the clinic. She was hospitalized for a heart failure exacerbation 4 months ago. A recent echocardiogram reveals a left ventricular ejection fraction (LVEF) of 47%. Laboratory studies show a serum potassium of 4.5 mEq/L, serum creatinine of 1.8 mg/dL, and an estimated glomerular filtration rate (eGFR) of 38 mL/min/1.73 m². Her physician considers initiating spironolactone, a mineralocorticoid receptor antagonist (MRA). Which of the following describes the most likely clinical outcome of adding this therapy and the appropriate management strategy?

• ○ A significant reduction in the composite of all-cause mortality and aborted cardiac death, requiring monitoring of hepatic transaminases.
• ✓ A reduction in heart failure hospitalizations, with the greatest potential efficacy seen because her LVEF is at the lower end of the preserved spectrum, requiring careful monitoring of potassium and renal function.
• ○ A significant reduction in mortality with no effect on heart failure hospitalizations, with the greatest efficacy expected in patients with an LVEF greater than 60%.
• ○ No anticipated clinical benefit because spironolactone is contraindicated in patients with an eGFR less than 45 mL/min/1.73 m².

Explanation. Spironolactone, a mineralocorticoid receptor antagonist (MRA), has been shown to reduce the rate of heart failure hospitalizations in appropriately selected patients with symptomatic heart failure with preserved ejection fraction (HFpEF). Efficacy is particularly noted to be greatest at the lower end of the left ventricular ejection fraction (LVEF) spectrum. Patients who have an elevated B-type natriuretic peptide or a heart failure admission within the past year, an estimated glomerular filtration rate (eGFR) greater than 30 mL/min/1.73 m², creatinine less than 2.5 mg/dL, and potassium less than 5.0 mEq/L are appropriate candidates for this therapy. Because MRAs can cause hyperkalemia and increase creatinine levels, careful monitoring of serum potassium, renal function, and diuretic dosing is essential at initiation and during follow-up.

Question 149

A 70-year-old man with a history of hypertension and heart failure with preserved ejection fraction (HFpEF) (LVEF 52%) presents for a routine follow-up. He is currently euvolemic on a loop diuretic and his blood pressure is well controlled on a calcium channel blocker. The physician is considering the addition of candesartan, an angiotensin receptor blocker (ARB), to improve his long-term prognosis. Based on the findings of the CHARM-Preserved trial, what is the expected outcome of adding this medication?

• ○ A significant reduction in overall mortality and cardiovascular death.
• ○ Substantial clinical benefit equivalent to that seen in patients with heart failure with reduced ejection fraction (HFrEF).
• ○ Marked improvement in renal function and a reduced risk of hyperkalemia.
• ✓ Little to no substantial clinical benefit, as clinical trials with RAAS inhibition have not shown much benefit in patients with HFpEF.

Explanation. Although renin-angiotensin-aldosterone system (RAAS) inhibition strategies have been highly successful in the treatment of heart failure with reduced ejection fraction (HFrEF), clinical trials evaluating RAAS inhibition (such as the CHARM-Preserved trial using candesartan in patients with an LVEF >40%) have not shown much benefit in patients with HFpEF, while carrying risks such as hyperkalemia and worsening renal function.

Question 150

A 72-year-old woman with a history of hypertension presents with progressive exertional dyspnea, orthopnea, and bilateral lower extremity edema. Transthoracic echocardiography reveals a left ventricular ejection fraction (LVEF) of 62% with evidence of severe diastolic dysfunction and left atrial enlargement. She is diagnosed with heart failure with preserved ejection fraction (HFpEF). Her current medications include furosemide and amlodipine. The addition of an angiotensin receptor blocker (ARB) is considered. Based on meta-analyses of trials evaluating ARBs in patients with HFpEF, what is the expected impact of this drug class on her long-term outcomes?

• ○ A significant reduction in cardiovascular mortality and all-cause mortality.
• ○ A significant reduction in heart failure hospitalizations with no effect on mortality.
• ○ A significant reduction in all-cause mortality with no effect on heart failure hospitalizations.
• ✓ No significant benefit on cardiovascular mortality, all-cause mortality, or heart failure hospitalizations.

Explanation. Meta-analyses of trials evaluating angiotensin receptor blockers in patients with heart failure with preserved ejection fraction have demonstrated no signal for benefit regarding cardiovascular mortality, all-cause mortality, or heart failure hospitalizations.

Question 151

A 72-year-old woman with a history of hypertension and heart failure with preserved ejection fraction (HFpEF, LVEF 58%) presents to the clinic complaining of fatigue and dyspnea on exertion. She has no history of coronary artery disease (CAD) or angina. Her current medications include lisinopril, amlodipine, and torsemide. Her physician considers adding isosorbide mononitrate or sildenafil to her regimen to improve her activity tolerance. What is the most appropriate expectation regarding the effect of these therapies on her exercise capacity?

• ○ Isosorbide mononitrate is expected to significantly improve her activity levels and quality of life.
• ○ Sildenafil is expected to significantly improve her peak oxygen consumption and exercise tolerance.
• ✓ Neither isosorbide mononitrate nor sildenafil has been shown to improve exercise tolerance or activity levels in this patient population.
• ○ Isosorbide mononitrate is expected to reduce her NT-proBNP levels, although without improving her quality of life.

Explanation. Clinical trials have shown a lack of benefit for both of these therapies regarding exercise tolerance in patients with HFpEF. The NEAT-HFpEF trial demonstrated that isosorbide mononitrate does not improve activity levels, quality of life, exercise tolerance, or NT-proBNP levels in this population. Similarly, the RELAX trial showed that phosphodiesterase-5 inhibition with sildenafil does not improve oxygen consumption or exercise tolerance in patients with HFpEF.

Question 152

A 74-year-old man with a history of bilateral carpal tunnel syndrome and lumbar spinal stenosis presents with progressive fatigue, exertional dyspnea, and lower extremity edema. An electrocardiogram (ECG) demonstrates low QRS voltage in the limb leads. A transthoracic echocardiogram reveals a left ventricular ejection fraction of 55% and a left ventricular wall thickness of 15 mm. Which of the following best describes the fundamental pathophysiological mechanism underlying this patient's cardiac condition?

• ✓ Extracellular myocardial protein deposition
• ○ Sarcomere gene mutations leading to myocyte hypertrophy and disarray
• ○ Intracellular accumulation of globotriaosylceramide
• ○ Left ventricular pressure overload leading to concentric hypertrophy

Explanation. The patient presents with heart failure symptoms, a left ventricular wall thickness of ≥14 mm, discordance between echocardiographic wall thickness and electrocardiogram (ECG) QRS voltage, and a supportive history of carpal tunnel syndrome and spinal stenosis, which is highly characteristic of cardiac amyloidosis. Cardiac amyloidosis is a restrictive cardiomyopathy defined by extracellular myocardial protein deposition, most commonly involving monoclonal immunoglobulin light chains or transthyretin.

Question 153

A 75-year-old man with a history of bilateral carpal tunnel syndrome and lumbar spinal stenosis presents with progressive fatigue and lower extremity edema. Echocardiography reveals a left ventricular wall thickness of 16 mm with apical sparing of longitudinal strain, while his electrocardiogram demonstrates low QRS voltage. A technetium pyrophosphate (99mTc-PYP) scan is ordered to evaluate for transthyretin cardiac amyloidosis (ATTR-CM). Which of the following is the most appropriate concurrent laboratory testing strategy?

• ✓ Serum free light chain concentration, serum immunofixation electrophoresis, and urine immunofixation electrophoresis.
• ○ Serum plasma electrophoresis and urine plasma electrophoresis.
• ○ Serum free light chain concentration and a bone scintigraphy scan without further testing.
• ○ Endomyocardial biopsy followed by serum plasma electrophoresis.

Explanation. To accurately diagnose transthyretin cardiac amyloidosis (ATTR-CM) using a technetium pyrophosphate (99mTc-PYP) scan, concurrent testing with serum free light chain concentration, serum immunofixation electrophoresis, and urine immunofixation electrophoresis is required to rule out light chain (AL) amyloidosis. This specific combination of laboratory tests provides greater than 99% sensitivity for AL amyloidosis. Because 99mTc-PYP scans can also be positive in AL amyloidosis, the scan results can only be interpreted to diagnose ATTR-CM in the context of a negative monoclonal light chain screen.

Question 154

A 74-year-old man with progressive dyspnea and lower extremity edema undergoes echocardiography, which reveals severe left ventricular hypertrophy with a speckled myocardial appearance. Laboratory testing, including serum free light chains and serum and urine immunofixation, demonstrates the absence of any monoclonal light-chain abnormality. A planar technetium-99m pyrophosphate (99mTc-PYP) scan is performed and demonstrates grade 3 cardiac uptake with a heart-to-contralateral ratio of 1.7. Which of the following is required to correctly validate the findings of this scan?

• ✓ Single-photon emission computed tomography (SPECT) imaging
• ○ Endomyocardial biopsy for histological confirmation
• ○ Hematology-oncology consultation to evaluate for multiple myeloma
• ○ Repeat imaging utilizing hydromethylene diphosphonate

Explanation. Single-photon emission computed tomography (SPECT) must be assessed in all positive planar radiotracer scans to confirm that the observed signal represents true myocardial retention of the tracer rather than residual blood pool or overlapping rib uptake.

Question 155

A 72-year-old man with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) presents for follow-up. He also reports a one-year history of bilateral numbness and tingling in his feet, and neurologic evaluation confirms a sensorimotor polyneuropathy. To determine whether he is a candidate for therapies such as inotersen or patisiran, and to guide counseling for his family members, which of the following is the most appropriate next step?

• ✓ Genetic sequencing of the TTR gene
• ○ Serum and urine immunofixation electrophoresis
• ○ Endomyocardial biopsy with Congo red staining
• ○ Cardiac magnetic resonance imaging

Explanation. Once transthyretin amyloid cardiomyopathy is identified, genetic sequencing of the transthyretin (TTR) gene is required to differentiate between a pathological variant and wild-type disease. Confirming a pathological variant triggers genetic counseling, potential screening of family members, and identifies patients who are eligible for specific therapies such as inotersen and patisiran, which are approved specifically for variant transthyretin amyloidosis presenting with polyneuropathy.

Question 156

A 74-year-old man recently diagnosed with transthyretin cardiac amyloidosis (ATTR-CM) and a left ventricular ejection fraction of 35% presents to the clinic complaining of worsening fatigue, dyspnea, and lightheadedness upon standing. His home medications include carvedilol, sacubitril/valsartan, and bumetanide. His blood pressure is 90/60 mmHg and heart rate is 72 bpm. Which of the following statements best explains his intolerance to his current neurohormonal blockade regimen?

• ✓ Patients with ATTR-CM rely on heart rate response to maintain cardiac output, and autonomic dysfunction exacerbates the hypotensive effects of vasodilators.
• ○ Accumulation of misfolded light chain proteins increases the risk of complete heart block, which is unmasked by beta-blockers.
• ○ Myocardial deposition of amyloid fibrils prevents the binding of angiotensin receptor-neprilysin inhibitors (ARNi) to their target receptors.
• ○ Left ventricular hypertrophy in ATTR-CM causes dynamic left ventricular outflow tract obstruction that is exacerbated by vasodilators.

Explanation. In patients with ATTR-CM and a reduced ejection fraction (≤40%), standard neurohormonal therapies are often poorly tolerated. The vasodilating effects of angiotensin receptor-neprilysin inhibitors (ARNi), angiotensin-converting enzyme inhibitors (ACEi), and angiotensin receptor blockers (ARB) can exacerbate hypotension, particularly due to amyloid-associated autonomic dysfunction. Additionally, beta-blockers can worsen heart failure symptoms because these patients have a restricted stroke volume and heavily depend on an adequate heart rate response to maintain their cardiac output.

Question 157

A 72-year-old man with confirmed transthyretin cardiac amyloidosis (ATTR-CM) presents to the clinic. His echocardiogram reveals a severely thickened left ventricle, and he reports worsening dyspnea. He brings a list of potential off-label and supplement-based therapies he found online, specifically inquiring about diflunisal, a combination of doxycycline plus tauroursodeoxycholic acid (TUDCA), and epigallocatechin gallate (EGCG). He wants to know if taking these will improve his chances of survival and reduce cardiovascular events. What is the most accurate information to provide regarding these agents?

• ✓ They have limited benefit on surrogate endpoints such as left ventricular mass, and their impact on cardiovascular morbidity and mortality has not been assessed.
• ○ They have demonstrated substantial reductions in cardiovascular mortality and are recommended as first-line therapy.
• ○ They significantly improve autonomic dysfunction and arrhythmias, directly reducing cardiovascular mortality.
• ○ They are highly effective at reducing left ventricular mass, which reliably translates to decreased cardiovascular morbidity.

Explanation. While agents such as diflunisal, doxycycline plus TUDCA, and EGCG have been studied, they have shown only limited benefit on surrogate endpoints like left ventricular mass, and their actual impact on cardiovascular morbidity and mortality has not yet been evaluated.

Question 158

A 74-year-old man is diagnosed with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM). He currently experiences fatigue and mild dyspnea with moderate exertion, consistent with New York Heart Association (NYHA) class II heart failure. His past medical history includes mild aortic stenosis and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 55 mL/min/1.73 m². You are discussing the initiation of tafamidis therapy to improve cardiovascular outcomes. Which of the following is the most appropriate counseling to provide regarding the expected mechanism and clinical benefit of this medication?

• ○ The medication reverses existing amyloid deposits, leading to rapid symptom improvement within the first 3 months.
• ✓ The medication prevents further amyloid deposition, and survival benefits typically become apparent after approximately 18 months of therapy.
• ○ The medication significantly reduces cardiovascular hospitalizations, but is strictly contraindicated in patients with any degree of aortic stenosis.
• ○ The medication provides the greatest mortality benefit in patients who have progressed to NYHA class IV heart failure.

Explanation. Tafamidis exerts its effect by binding the thyroxin-binding site of transthyretin, which prevents further amyloid deposition but does not reverse existing amyloid deposits. Because of this preventive mechanism, it is expected to have the greatest benefit when administered early in the disease course. The survival benefits take time to accrue; survival curves between treated patients and those not on therapy separate after 18 months of treatment, highlighting the importance of selecting patients whose noncardiac comorbidities are not expected to limit survival within this timeframe.

Question 159

A 74-year-old man with a recent diagnosis of wild-type transthyretin cardiac amyloidosis presents for follow-up. He reports mild exertional dyspnea consistent with New York Heart Association (NYHA) class II heart failure. A recent 14-day ambulatory electrocardiogram monitor demonstrates normal sinus rhythm with no evidence of atrial fibrillation. His medical history is otherwise unremarkable, yielding a CHA2DS2-VASc score of 1 due to his age. Which of the following best describes his risk profile for intracardiac thrombosis?

• ○ His risk is primarily determined by his CHA2DS2-VASc score, which currently indicates a low risk of thrombosis.
• ○ He is at low risk because intracardiac thrombosis in this condition strictly occurs in the setting of documented atrial fibrillation.
• ✓ He is at significant risk, as intracardiac thrombosis occurs in approximately one-third of patients with this condition, regardless of atrial fibrillation or CHA2DS2-VASc score.
• ○ He has a low risk of intracardiac thrombosis as long as his left ventricular ejection fraction remains preserved.

Explanation. Intracardiac thrombosis occurs in approximately one-third of patients with cardiac amyloidosis. This high risk of thrombus formation is a distinct feature of the disease process itself and is present even in the absence of diagnosed atrial fibrillation and regardless of the patient's baseline CHA2DS2-VASc score.

Question 160

A 68-year-old woman with heart failure with preserved ejection fraction (HFpEF) continues to experience severe, refractory dyspnea at rest despite maximum guideline-directed medical therapy (GDMT). Her most recent echocardiogram demonstrates a left ventricular ejection fraction of 55% with severe diastolic dysfunction. A medical student on the team suggests she cannot be classified as having "advanced" heart failure because her ejection fraction is not severely reduced. Which of the following represents the most accurate clinical understanding of the criteria for advanced heart failure?

• ✓ Advanced heart failure is fundamentally defined by refractory symptoms despite maximum GDMT and can occur in patients with preserved ejection fraction.
• ○ Advanced heart failure criteria mandate the presence of a severely reduced left ventricular ejection fraction in addition to refractory symptoms.
• ○ The definition of advanced heart failure requires classification into INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profile 1 or 2 before HFpEF can be included.
• ○ Patients with preserved ejection fraction must have concomitant uncorrectable congenital heart disease to meet the clinical definition of advanced heart failure.

Explanation. The definition of advanced heart failure focuses primarily on the presence of refractory symptoms despite maximum guideline-directed medical therapy rather than an absolute threshold of cardiac function. Advanced heart failure is recognized to occur in patients without severely reduced ejection fraction, including those with heart failure with preserved ejection fraction, mildly reduced ejection fraction, isolated right ventricular dysfunction, or uncorrectable valvular and congenital heart disease.

Question 161

A 65-year-old male with known heart failure with reduced ejection fraction presents for a follow-up visit. He reports increasing shortness of breath with minimal exertion. His vital signs show a systolic blood pressure of 88 mm Hg and a resting heart rate of 105 bpm. Due to recurrent symptomatic hypotension over the past two months, his previously optimized doses of guideline-directed medical therapy (GDMT) have been progressively down-titrated. Medication adherence is confirmed, and a recent workup revealed no concomitant pulmonary disorders. Which of the following is the most appropriate next step in management?

• ✓ Referral to an advanced heart failure specialist
• ○ Initiate a pulmonary rehabilitation program
• ○ Up-titrate his guideline-directed medical therapy back to target doses
• ○ Switch his loop diuretic from furosemide to torsemide

Explanation. The patient demonstrates key clinical indicators of advanced heart failure, specifically a low systolic blood pressure (≤90 mm Hg), a high resting heart rate, and progressive intolerance requiring the down-titration of prognostic medications. These features signify a declining clinical trajectory, making timely referral for review and consideration of advanced heart failure therapies crucial to achieving optimal patient outcomes.

Question 162

A 58-year-old woman with advanced non-ischemic dilated cardiomyopathy and a left ventricular ejection fraction of 18% continues to experience New York Heart Association (NYHA) class III symptoms despite optimal guideline-directed medical therapy. Her general cardiologist is considering a referral to an advanced heart failure (HF) center for evaluation for durable mechanical circulatory support or heart transplantation. The patient has not yet undergone a complete multidisciplinary assessment of her comorbid conditions, nor has she had a formal psychosocial evaluation. Which of the following is the most appropriate approach regarding her referral?

• ✓ Refer her immediately to an advanced HF center, as a complete comprehensive assessment will be routinely performed as part of their evaluation.
• ○ Complete a comprehensive multidisciplinary assessment of her comorbidities and psychosocial status locally before initiating the referral.
• ○ Wait until she develops early signs of end-organ dysfunction or cardiogenic shock to clearly establish the clinical need for advanced therapies.
• ○ Delay the referral until she fails intermittent outpatient inotropic therapy, at which point an advanced HF evaluation becomes mandatory.

Explanation. A complete assessment of the patient is not required before referral to an advanced heart failure center, because a comprehensive, multidisciplinary assessment of cardiac disease and comorbid conditions is routinely performed when evaluating patients for advanced therapies at the receiving center. Timely referral is also essential because patients may no longer qualify for advanced therapies if they are allowed to progress to end-organ dysfunction or cardiogenic shock.

Question 163

A 74-year-old female with advanced heart failure is admitted for acute decompensation. Her weight has increased by 5 kg over the past week, and she has marked orthopnea and 3+ bilateral lower extremity edema. Current laboratory results show a serum sodium level of 129 mEq/L. She is receiving high-dose intravenous loop diuretics but continues to exhibit diuretic-refractory congestion. The medical team considers implementing a strict fluid restriction to manage her hyponatremia. Which of the following best describes the expected impact of this intervention?

• ○ It will significantly improve long-term clinical outcomes and reduce the need for high-dose diuretics.
• ✓ It will provide only a modest improvement in her hyponatremia with limited-to-no effect on clinical outcomes or diuretic use.
• ○ It will dramatically increase her serum sodium levels and fully reverse the diuretic-refractory state.
• ○ It is strongly supported by high-quality evidence specifically evaluating patients with advanced heart failure.

Explanation. Fluid restriction is commonly prescribed for patients with hyponatremia in acute heart failure but only improves hyponatremia modestly, and it has limited-to-no effect on clinical outcomes or diuretic use.

Question 164

A 68-year-old man with a history of heart failure with reduced ejection fraction (HFrEF) is admitted for acute decompensated heart failure. He presents with worsening dyspnea, 3+ pitting edema in his lower extremities, and a serum sodium of 131 mEq/L. His physician considers prescribing a strict fluid restriction strategy. Compared to free fluid consumption, what is the most likely impact of this intervention?

• ○ A marked decrease in the duration of required intravenous diuretic therapy
• ○ A significant improvement and correction of the patient's serum sodium levels
• ✓ No significant reduction in subsequent hospitalization or mortality rates
• ○ A profound decrease in patient-reported thirst during the hospitalization

Explanation. In patients with heart failure, restricted fluid intake compared with free fluid consumption does not result in reduced hospitalization or mortality rates, nor does it significantly change thirst, the duration of intravenous diuretic use, serum creatinine, or serum sodium levels.

Question 165

A 65-year-old man with a history of severe systolic dysfunction is hospitalized for decompensated heart failure. He presents with a blood pressure of 78/52 mm Hg, a cardiac index of 1.5 L/min/m2, and rising serum creatinine, indicating end-organ hypoperfusion. He is initiated on short-term, continuous intravenous dobutamine to maintain systemic perfusion. After several days of continuous support, his perfusion indices and urine output begin to worsen despite maintaining the same continuous infusion rate. What is the most likely pharmacological explanation for this decline, and what is an appropriate adjustment to his therapy?

• ✓ Development of tachyphylaxis; the choice of inotropic agent may need to be changed.
• ○ Accumulation of active metabolites leading to toxicity; the dobutamine dose should be halved.
• ○ Increased parasympathetic tone overriding the inotrope; intravenous atropine should be administered.
• ○ Irreversible end-organ failure; all parenteral inotropes must be discontinued immediately to prevent mortality.

Explanation. During longer periods of continuous intravenous inotropic support, patients may develop tachyphylaxis, which manifests as a diminished hemodynamic response to the same dose of the drug. When this occurs, the choice of inotropic agent may need to be changed to maintain systemic perfusion and preserve end-organ performance.

Question 166

A 58-year-old female with end-stage heart failure is being managed with a continuous dobutamine infusion for palliative purposes. She has a history of recurrent ventricular arrhythmias and has an active implantable cardioverter-defibrillator (ICD). She is concerned about receiving inappropriate shocks for sinus tachycardia and the overall risks of the continuous infusion. What is the most appropriate counseling to provide regarding her therapy?

• ○ She should have her ICD deactivated immediately because the rate of inappropriate shocks for sinus tachycardia is exceptionally high with dobutamine.
• ✓ The use of inotropes carries a risk for arrhythmias, but her ICD decreases mortality associated with these arrhythmias, and the rate of inappropriate shocks for sinus tachycardia is relatively low.
• ○ The continuous inotrope infusion will eliminate the need for her ICD by reversing her underlying heart failure and reducing pulmonary vascular resistance.
• ○ The risk of catheter-related infections is mitigated by the presence of an ICD, making the continuous infusion safe for long-term palliation without risk.

Explanation. The use of inotropes for palliation carries inherent risks for arrhythmias and catheter-related infections; however, the presence of an implantable cardioverter-defibrillator (ICD) decreases the mortality associated with these arrhythmias. Furthermore, the rate of inappropriate shocks for sinus tachycardia in this setting is relatively low, and the concomitant use of beta-blockers may provide further benefit in managing sinus tachycardia.

Question 167

A 60-year-old man with end-stage heart failure with reduced ejection fraction (HFrEF) and a severely dilated left ventricle is admitted with refractory cardiogenic shock. The heart failure team recommends the initiation of temporary mechanical circulatory support (MCS). Recognizing that MCS devices will eventually be turned off—whether for explant, recovery, or withdrawal of life support in the setting of terminal non-cardiac illness—when is the most appropriate time to discuss the potential need to discontinue or escalate support with the patient and his family?

• ✓ Before discussions about initiating MCS, or at the time of implantation.
• ○ Once the patient's hemodynamics have completely stabilized post-implantation.
• ○ Only if the patient develops a catastrophic neurologic event or metastatic malignancy.
• ○ At the time the temporary device is being evaluated for transition to a durable device.

Explanation. The eventual need to turn off a mechanical circulatory support device should be addressed a priori with patients before discussions about MCS. Particularly with temporary devices, the potential need to either discontinue or to escalate support should be addressed at the time of implantation to ensure goals of care are clearly established.

Question 168

A 62-year-old male with advanced ischemic cardiomyopathy is evaluated for durable mechanical circulatory support (MCS). He has New York Heart Association (NYHA) class IV symptoms despite optimal medical therapy and is dependent on a continuous intravenous milrinone infusion. His medical history is notable for recurrent, severe gastrointestinal bleeding from intestinal angiodysplasias, which has resulted in an inability to tolerate any systemic anticoagulation after repeated attempts. His central venous pressure is 12 mm Hg. What is the most significant concern regarding the implantation of a durable MCS device in this patient?

• ✓ His inability to tolerate anticoagulation is associated with excess morbidity, including pump thrombosis and ischemic neurologic events.
• ○ His dependence on continuous intravenous inotropes indicates he is too clinically advanced to derive a survival advantage from the device.
• ○ His elevated central venous pressure is an absolute contraindication that guarantees a poor outcome after implantation.
• ○ His symptom burden corresponds to an ambulatory profile that is generally considered too well to derive significant benefit from the intervention.

Explanation. In patients who are unable to tolerate anticoagulation after repeated challenges, the implantation of a durable mechanical circulatory support device is associated with excess morbidity. The inability to maintain therapeutic anticoagulation is directly linked to severe, life-threatening incidents of pump thrombosis, hemolysis, and ischemic neurologic events.

Question 169

A 62-year-old male with advanced heart failure is being evaluated for a left ventricular assist device (LVAD) as destination therapy. During a multidisciplinary committee meeting to discuss hospital resource allocation, a healthcare administrator expresses hesitation, citing historical studies from 2012 to 2017 that demonstrated low economic value for device implantation, with incremental cost-effectiveness ratios of approximately $200,000 per quality-adjusted life year. As the consulting cardiologist, which of the following is the most accurate statement regarding the contemporary economic value and outcome trends of LVAD implantation to share with the committee?

• ✓ Recent limited data suggest an improvement to intermediate economic value due to lower complication rates, increased survival, and higher quality of life, though overall value remains uncertain.
• ○ Contemporary studies confirm that LVAD therapy continues to offer low economic value exclusively in patients who are ineligible for subsequent heart transplantation.
• ○ Recent data demonstrate that LVADs have definitively achieved high economic value primarily due to the complete elimination of post-implant rehospitalizations.
• ○ The economic value of LVAD therapy has worsened in recent years due to significantly higher initial implant costs associated with newer generation devices.

Explanation. Recent data indicate an improvement in health care costs and intermediate economic value for left ventricular assist device therapy among patients with advanced heart failure. This positive shift is driven by lower complication rates, increased survival, lower implant costs, and higher estimated quality of life associated with newer devices and better care, even though the definitive overall value remains uncertain due to conflicting historical and contemporary data.

Question 170

A 58-year-old man is admitted to the cardiac intensive care unit with acute myocardial infarction complicated by severe cardiogenic shock and a brief out-of-hospital cardiac arrest. Despite escalating doses of intravenous inotropes and vasopressors, he exhibits signs of impending multiorgan failure, including oliguria and rising serum lactate. His neurologic status is uncertain due to the recent cardiac arrest, and he remains unresponsive off sedation. Which of the following is an appropriate rationale for initiating temporary mechanical circulatory support (MCS) in this patient?

• ○ To serve as permanent destination therapy since his uncertain neurologic status makes him ineligible for advanced therapies.
• ✓ To stabilize hemodynamics and allow time to determine the recovery of his neurologic status before deciding on durable therapies.
• ○ To immediately bridge the patient to cardiac transplantation regardless of his neurologic recovery.
• ○ To provide long-term outpatient support while he awaits spontaneous myocardial recovery.

Explanation. Temporary mechanical circulatory support (MCS) is indicated to stabilize patients in cardiogenic shock that cannot be managed solely with intravenous inotropes, specifically allowing time to determine the recovery of neurologic status and to permit patients to engage in decision-making for definitive management, such as durable MCS or cardiac transplantation.

Question 171

A 54-year-old female with stage D (refractory) heart failure is admitted to the cardiac intensive care unit. Despite optimal medical therapy and cardiac resynchronization therapy, she continues to experience resting dyspnea and is increasingly dependent on intravenous inotropes. The advanced heart failure team is consulted to discuss long-term options, including left ventricular assist device (LVAD) implantation and cardiac transplantation. When counseling the patient on the expected outcomes of her condition and the proposed advanced therapies, which of the following is the most accurate statement?

• ✓ The median survival for this patient without advanced therapies is less than 2 years.
• ○ The risk of death becomes greater than survival between 5 and 6 years after LVAD implantation.
• ○ The median survival for adult cardiac transplant recipients is currently estimated to be approximately 7 years.
• ○ Treated rejection rates in the first year following cardiac transplantation typically exceed 20%.

Explanation. Patients with stage D (refractory, advanced) heart failure face a very poor prognosis, with a median survival of less than 2 years in the absence of advanced therapies such as a left ventricular assist device or cardiac transplantation.

Question 172

A 54-year-old female presents with progressive shortness of breath and fatigue. She has a history of cardiac sarcoidosis leading to stage D heart failure. She is currently refractory to maximal guideline-directed medical therapy (GDMT) and biventricular pacing. Her right heart catheterization reveals mild pulmonary hypertension that is completely reversible with vasodilator testing. She is being evaluated for cardiac transplantation. Her care team is integrating her comorbidity burden, caretaker status, and goals of care to determine her transplant candidacy. Which of the following investigations should be utilized to further refine her prognosis and aid in appropriate candidate selection?

• ✓ Cardiopulmonary exercise testing (CPET)
• ○ Pharmacologic nuclear stress testing
• ○ Serial endomyocardial biopsies
• ○ Ambulatory continuous electrocardiographic (ECG) monitoring

Explanation. Cardiopulmonary exercise testing (CPET) is utilized to refine candidate prognosis and candidate selection for cardiac transplantation in patients with advanced heart failure.

Question 173

A 58-year-old male with a history of severe ischemic cardiomyopathy and advanced heart failure (HF) is currently hospitalized. He has been dependent on a continuous milrinone infusion for the past 4 weeks to maintain adequate end-organ perfusion. The multidisciplinary team is discussing his candidacy for heart transplantation versus ongoing medical therapy. When discussing the health economics and cost-effectiveness of heart transplantation compared with medical therapy in this specific patient population (inotrope-dependent advanced HF), which of the following accurately reflects its economic value?

• ○ Heart transplantation is of high value, demonstrating significant cost savings over long-term medical therapy.
• ✓ Heart transplantation is of intermediate value, with results remaining consistent across various patient ages and wait-list durations.
• ○ Heart transplantation is of low value due to the extremely high initial procedural costs and subsequent lifelong immunosuppression expenses.
• ○ Heart transplantation is of intermediate value, but only in younger patients with a very short expected wait-list duration.

Explanation. An analysis evaluating the cost-effectiveness of heart transplantation compared with medical therapy among patients with inotrope-dependent advanced heart failure found that transplantation is of intermediate economic value. These results remain similar across a broad range of patient ages, wait-list durations, and monthly mortality risks associated with medical therapy.

Question 174

A 68-year-old man with a history of chronic heart failure with reduced ejection fraction (HFrEF) is admitted to the cardiac intensive care unit with worsening dyspnea, orthopnea, and increasing lower extremity edema over the past week. On physical examination, his blood pressure is 125/80 mmHg, heart rate is 92 beats per minute, and oxygen saturation is 94% on room air. He has jugular venous distension up to the angle of the jaw, bilateral pulmonary crackles, and 3+ pitting edema in both legs. His extremities are warm to the touch and capillary refill is less than 2 seconds. A pulmonary artery catheter is placed to further assess his hemodynamics and guide therapy. Which of the following statements best describes the expected relationship between his cardiac filling pressures?

• ✓ Right- and left-sided cardiac filling pressures are expected to be proportionally elevated, although a mismatch between the two occurs in up to 25% of such patients.
• ○ A severe mismatch between right- and left-sided filling pressures is the expected finding, occurring in the vast majority of decompensated patients.
• ○ Right-sided filling pressures are typically normal while left-sided filling pressures are markedly elevated.
• ○ Left-sided filling pressures are typically normal while right-sided filling pressures are markedly elevated due to secondary right ventricular dysfunction.

Explanation. Most patients admitted with heart failure have clinical evidence of congestion without apparent hypoperfusion. During the decompensation of chronic heart failure with a low ejection fraction, elevations of right- and left-sided cardiac filling pressures are usually proportional, but up to 1 in 4 patients can present with a mismatch between these right- and left-sided filling pressures.

Question 175

A 65-year-old woman with a body mass index (BMI) of 38 kg/m2 and a known history of heart failure with preserved ejection fraction (HFpEF) presents to the emergency department with worsening shortness of breath on exertion. On physical examination, her blood pressure is 140/80 mmHg, heart rate is 88 bpm, and oxygen saturation is 94% on ambient air. She has no jugular venous distention and no lower extremity edema. Her extremities are warm and well-perfused. Suspecting that disproportionate elevation of left-sided filling pressures may be the cause of her dyspnea, you order a B-type natriuretic peptide (BNP) level. Which of the following is true regarding the diagnostic utility of natriuretic peptide testing in this specific patient?

• ✓ It has decreased sensitivity for identifying heart failure.
• ○ It has decreased specificity for identifying heart failure.
• ○ It is highly sensitive but lacks specificity due to the absence of right-sided congestion.
• ○ It has increased sensitivity for identifying heart failure.

Explanation. Elevated natriuretic peptides can help identify heart failure in the urgent care setting, but their utility is limited by decreased sensitivity in certain patient populations, specifically those with obesity and heart failure with preserved ejection fraction (HFpEF).

Question 176

A 68-year-old male with a history of heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction 30%) is admitted to the hospital with acute decompensated heart failure. On presentation, he had severe orthopnea, elevated jugular venous pressure, and marked lower extremity edema. Intravenous loop diuretics were administered. On hospital day 3, his weight has decreased by 5 kg, his jugular venous pressure is approaching normal, and his edema is significantly improved, demonstrating effective diuresis. What is the most appropriate approach regarding his disease-modifying medical therapies?

• ○ Wait until an outpatient clinic visit 2 weeks post-discharge to initiate or up-titrate therapies to prevent inpatient adverse events.
• ✓ Initiate or increase recommended medical therapies toward target doses during the hospitalization, since the efficacy of diuresis has been shown.
• ○ Maintain only his admission doses of medical therapies, as hospitalization should focus strictly on achieving optimal volume status.
• ○ Delay any medication adjustments until his residual congestion is completely resolved at home, focusing exclusively on assessing precipitating factors.

Explanation. The disease trajectory for patients hospitalized with heart failure with reduced ejection fraction is markedly improved by optimization of recommended medical therapies. These therapies should be initiated or increased toward target doses once the efficacy of diuresis has been established during the hospitalization.

Question 177

A 68-year-old male with a history of heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction 30%) is admitted to the hospital with acute decompensated heart failure, presenting with worsening dyspnea and lower extremity edema. He is currently taking lisinopril 5 mg daily and carvedilol 6.25 mg twice daily. During his hospital stay, he is treated with intravenous loop diuretics, and his volume status improves. His blood pressure remains stable at 115/75 mmHg, and his renal function is at his baseline. Which of the following is the most appropriate strategy regarding his guideline-directed medical therapy (GDMT)?

• ○ Discontinue lisinopril and carvedilol during hospitalization to avoid hemodynamic compromise, with a plan to resume them upon discharge.
• ✓ Continue his current oral GDMT and use the hospitalization as an opportunity to further optimize and up-titrate his therapies.
• ○ Maintain his current doses of GDMT but defer any optimization or addition of new therapies, such as a mineralocorticoid receptor antagonist, until his first outpatient follow-up.
• ○ Stop lisinopril and carvedilol, and initiate intravenous inotropes to facilitate diuresis prior to resuming oral therapies.

Explanation. Continuation of oral guideline-directed medical therapy (GDMT) during hospitalization for heart failure with reduced ejection fraction lowers the risk of postdischarge death and readmission compared with discontinuation. Hospitalization is a critical opportunity to continue, initiate, and further optimize GDMT, as reliance solely on the outpatient setting often leads to prolonged periods of suboptimal dosing or lack of appropriate therapeutic initiation.

Question 178

A 72-year-old woman with a history of heart failure with reduced ejection fraction (LVEF 25%) presents to the hospital with progressive dyspnea and lower extremity edema. Her home medications include sacubitril-valsartan, bisoprolol, empagliflozin, and spironolactone. On examination, her blood pressure is 98/62 mmHg (baseline 110/70 mmHg) and heart rate is 75 bpm. She has mild volume overload but no signs of marginal low cardiac output or cardiogenic shock. Laboratory studies reveal a serum creatinine of 1.4 mg/dL (baseline 1.1 mg/dL) and potassium of 4.6 mEq/L. Which of the following is the most appropriate management of her heart failure medications during this hospitalization?

• ✓ Continue her current oral guideline-directed medical therapies.
• ○ Discontinue bisoprolol to improve cardiac output.
• ○ Withhold sacubitril-valsartan due to the reduction in blood pressure.
• ○ Discontinue spironolactone to prevent further worsening of renal function.

Explanation. Oral guideline-directed medical therapy should not be withheld for mild or transient reductions in blood pressure or mild deteriorations in renal function in patients hospitalized with heart failure with reduced ejection fraction. Furthermore, withholding or reducing beta-blockers is specifically reserved for patients with marked volume overload or marginal low cardiac output.

Question 179

A 72-year-old male is preparing for discharge following a hospitalization for acutely decompensated heart failure with reduced ejection fraction. His current vital signs include a heart rate of 78 beats per minute and a systolic blood pressure (SBP) of 106 mm Hg. Laboratory results reveal an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2, representing a 22% decrease from his baseline eGFR upon admission. The medical team is finalizing his oral guideline-directed medical therapy. Which of the following is the most appropriate pharmacological approach for this patient?

• ✓ Initiate or continue therapies such as carvedilol and sacubitril-valsartan, as their clinical benefits are maintained irrespective of the lower systolic blood pressure, and the mild decline in eGFR does not indicate true acute kidney injury.
• ○ Delay the initiation of beta-blockers and sacubitril-valsartan until the systolic blood pressure is consistently >120 mm Hg to prevent therapy-induced morbidity.
• ○ Substitute sacubitril-valsartan with enalapril due to the superiority and better tolerance of enalapril in heart failure patients presenting with a systolic blood pressure <110 mm Hg.
• ○ Discontinue spironolactone and beta-blockers immediately, as the >20% decrease in eGFR directly correlates with acute kidney injury exacerbated by these agents.

Explanation. In patients with heart failure, evidence demonstrates that agents like sacubitril-valsartan maintain the same tolerance and relative clinical benefits even in those with lower systolic blood pressures. Discharge use of carvedilol is strongly associated with a reduction in short-term mortality and composite mortality risk. Additionally, during the administration of oral guideline-directed medical therapy, a small to moderate worsening of renal function (such as a ≥20% decrease in estimated glomerular filtration rate) is not associated with acute kidney injury, and medications like beta-blockers and spironolactone may actually confer protective effects in this context.

Question 180

A 62-year-old male is hospitalized for acute decompensated heart failure with reduced ejection fraction (HFrEF). After aggressive intravenous diuresis, he is now hemodynamically stable and nearing discharge. The cardiology team plans to initiate an angiotensin receptor-neprilysin inhibitor (ARNi) rather than an angiotensin-converting enzyme inhibitor (ACEi). Based on trial data evaluating this specific comparison in patients hospitalized for acute decompensated heart failure, what is the expected outcome of initiating an ARNi compared with enalapril?

• ✓ Reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels without increased rates of worsening renal function, hyperkalemia, symptomatic hypotension, or angioedema.
• ○ Reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, but with an increased risk of symptomatic hypotension.
• ○ Similar N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, but with a significant reduction in 30-day all-cause readmission.
• ○ Improved 30-day mortality, but with significantly increased rates of worsening renal function and hyperkalemia.

Explanation. Initiating an angiotensin receptor-neprilysin inhibitor (ARNi) in patients hospitalized for acute decompensated heart failure is associated with significantly reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared with enalapril, without an increased rate of adverse events such as worsening renal function, hyperkalemia, symptomatic hypotension, or angioedema.

Question 181

A 68-year-old man with a history of heart failure with reduced ejection fraction (HFrEF) is evaluated in the outpatient clinic 6 months after hospitalization for acute decompensated heart failure. His current medications include lisinopril 5 mg daily and metoprolol succinate 25 mg daily. His blood pressure is 124/78 mmHg, heart rate is 72 bpm, and he has no signs of fluid overload. His renal function and potassium levels are normal. You plan to increase his lisinopril and add a mineralocorticoid receptor antagonist (MRA) to optimize his guideline-directed medical therapy (GDMT). When considering real-world prescribing patterns for patients with HFrEF following an index hospitalization, which of the following accurately describes the expected rate of achieving target doses of comprehensive GDMT (including an angiotensin-converting enzyme inhibitor , angiotensin II receptor blocker , angiotensin receptor-neprilysin inhibitor , beta blocker, and MRA) at 12 months?

• ✓ Less than 1% of patients are on target doses of an ACEi/ARB/ARNi, beta blocker, and MRA.
• ○ Approximately 18% of patients are on target doses of an ACEi/ARB/ARNi, beta blocker, and MRA.
• ○ Nearly 46% of patients achieve target doses of an ACEi/ARB/ARNi, beta blocker, and MRA.
• ○ Over 50% of patients have successful initiation or dose increases of an ACEi/ARB/ARNi, beta blocker, and MRA.

Explanation. Despite the graded improvement in the risk of death or rehospitalization associated with multi-drug guideline-directed medical therapy, clinical inertia remains highly prevalent, resulting in less than 1% of patients with heart failure with reduced ejection fraction being on target doses of an ACEi/ARB/ARNi, beta blocker, and MRA within 12 months of an index hospitalization.

Question 182

A 72-year-old woman with a history of heart failure with reduced ejection fraction (HFrEF) is admitted with worsening dyspnea, orthopnea, and marked lower extremity edema. She is started on intravenous loop diuretics. After 3 days of therapy, her breathing has subjectively improved, but physical examination reveals persistent elevated jugular venous pressure and 2+ pitting edema in both legs. The patient requests to be discharged home. Which of the following is the most appropriate approach regarding her discharge and diuretic management?

• ○ Discharge the patient with a prescription for a higher dose of oral loop diuretics to manage the remaining congestion as an outpatient.
• ○ Discharge the patient and add an oral thiazide diuretic to her home regimen to facilitate outpatient diuresis.
• ✓ Continue hospitalization and adjust diuretic therapy to achieve complete resolution of signs and symptoms of congestion before discharge.
• ○ Discharge the patient on her pre-admission oral diuretic regimen, as her subjective dyspnea has resolved.

Explanation. A major goal of therapy for patients hospitalized with heart failure is the resolution of the signs and symptoms of congestion before discharge. Persistent congestion at the time of discharge has been associated with higher rates of rehospitalization and mortality.

Question 183

A 68-year-old male is admitted to the hospital with acute decompensated heart failure (HF). On presentation, he exhibits marked jugular venous distention (JVD), severe orthopnea, and 3+ bilateral lower extremity edema. His admission serum creatinine is 1.4 mg/dL. He is started on intravenous (IV) loop diuretics. On hospital day 3, his weight has decreased by 3.5 kg, but he continues to have notable JVD and 2+ lower extremity edema. His morning laboratory tests reveal a serum creatinine of 1.7 mg/dL. Which of the following is the most appropriate management strategy regarding his diuresis?

• ○ Discontinue intravenous diuresis to prevent further worsening of renal function.
• ✓ Continue diuresis to achieve resolution of congestive signs despite the mild elevation in serum creatinine.
• ○ Withhold loop diuretics until serum creatinine returns to the admission baseline.
• ○ Switch from intravenous to oral diuresis and prepare for early hospital discharge.

Explanation. In patients hospitalized for heart failure, achieving complete resolution of signs and symptoms of congestion is a primary goal before hospital discharge. Diuresis should not be discontinued prematurely due to small changes in serum creatinine. Elevations in the range of 0.3 mg/dL during active diuresis do not predict worse outcomes, except in cases where patients are discharged with persistent congestion. Persistent congestion at discharge is strongly associated with higher rates of mortality, readmission, and worsening renal dysfunction, making it imperative to continue decongestive therapy until signs of congestion resolve.

Question 184

A 68-year-old man with a history of heart failure with reduced ejection fraction (HFrEF) is admitted to the hospital with acute decompensated heart failure. He has been compliant with his home medications, which include sacubitril-valsartan, carvedilol, spironolactone, empagliflozin, and furosemide 40 mg orally twice daily. On examination, he has elevated jugular venous pressure, bilateral crackles at the lung bases, and 3+ pitting edema in his lower extremities. The physician plans to initiate intravenous loop diuretic therapy to achieve net diuresis. Based on established protocols for diuretic titration in hospitalized patients, what is the most appropriate initial intravenous diuretic strategy for this patient?

• ○ Furosemide 40 mg IV twice daily
• ✓ Furosemide 80 mg IV twice daily
• ○ Furosemide 20 mg IV twice daily
• ○ Furosemide 160 mg IV twice daily

Explanation. Titration of diuretics for patients hospitalized with heart failure is often initiated with at least 2 times the daily home diuretic dose (mg to mg) administered intravenously. For a patient on a home dose of furosemide 40 mg orally twice daily (80 mg total daily dose), the initial intravenous dose should be at least 160 mg per day, which can be achieved with a regimen such as furosemide 80 mg IV twice daily.

Question 185

A 65-year-old man presents to the emergency department with acute decompensated heart failure (HF). He reports severe dyspnea and orthopnea. Examination reveals a respiratory rate of 28 breaths per minute, oxygen saturation of 88% on room air, and diffuse bilateral crackles. His blood pressure is 160/95 mm Hg. The clinical team initiates an intravenous vasodilator to manage his pulmonary congestion. Regarding the expected outcomes of this intervention, which of the following is true?

• ✓ It will acutely relieve symptoms of pulmonary congestion but has no proven durable effect on rehospitalization or mortality.
• ○ It will acutely relieve dyspnea and provides a demonstrated reduction in 30-day all-cause mortality.
• ○ It will mitigate pulmonary congestion and significantly decrease the rate of heart failure-related readmissions.
• ○ It is primarily indicated to reverse signs of end-organ hypoperfusion such as worsening renal function.

Explanation. Vasodilators are utilized in acute heart failure to acutely mitigate dyspnea and relieve pulmonary congestion, but these medications have not been shown to produce durable, long-term benefits in reducing either rehospitalization rates or overall mortality.

Question 186

A 65-year-old female with a history of non-ischemic cardiomyopathy presents to the emergency department with severe orthopnea and paroxysmal nocturnal dyspnea. Her blood pressure is 170/105 mmHg, and her heart rate is 105 bpm. Physical examination reveals bilateral pulmonary crackles and a loud holosystolic murmur at the apex. A bedside echocardiogram demonstrates severe mitral regurgitation (MR) complicating severe left ventricular (LV) dysfunction. The intensive care team plans to initiate an intravenous sodium nitroprusside infusion for the relief of her dyspnea. Which of the following is a critical requirement or characteristic of utilizing this specific therapy in this patient?

• ✓ Continuous invasive hemodynamic blood pressure monitoring is typically required due to the risk of marked hypotension.
• ○ The infusion is associated with a demonstrated improvement in long-term clinical outcomes for hospitalized heart failure patients.
• ○ The medication is strictly contraindicated due to the presence of severe mitral regurgitation complicating her LV dysfunction.
• ○ Tachyphylaxis and medication resistance are expected to develop within the first 24 hours of initiating the infusion.

Explanation. Sodium nitroprusside has a strong potential to produce marked hypotension; consequently, its use typically requires continuous invasive hemodynamic blood pressure monitoring, such as an arterial line, and administration within an intensive care setting.

Question 187

A 68-year-old female with a body mass index of 42 kg/m² is admitted to the hospital for acute decompensated heart failure. Her laboratory results reveal an estimated creatinine clearance of 65 mL/min. The medical team decides to initiate pharmacological venous thromboembolism (VTE) prophylaxis during her hospitalization. Which of the following is the most appropriate prophylactic regimen for this patient?

• ○ Enoxaparin 40 mg subcutaneously once daily
• ✓ Enoxaparin 60 mg subcutaneously once daily
• ○ Unfractionated heparin 5000 units subcutaneously once daily
• ○ Rivaroxaban 10 mg daily continued for 30 days post-discharge

Explanation. For obese patients hospitalized for medical illnesses such as decompensated heart failure who have adequate renal function, a higher prophylactic dose of enoxaparin 60 mg subcutaneously once daily successfully achieves the target range of thromboprophylaxis without increasing bleeding events.

Question 188

A 72-year-old woman with a history of chronic stable heart failure (HF) is admitted to the medical ward for a severe exacerbation of chronic obstructive pulmonary disease. During her stay, her HF symptoms remain at baseline. She is being discharged to a rehabilitation facility, and the medical team considers prophylactic measures for venous thromboembolic disease. Regarding the expected risk trajectory for venous thromboembolism in this patient following hospitalization, when is her risk the greatest?

• ✓ Within the first 30 days following hospitalization.
• ○ Between 3 and 6 months following hospitalization.
• ○ Between 12 and 24 months following hospitalization.
• ○ The risk remains uniformly elevated over the entire 2-year period following hospitalization.

Explanation. When patients with chronic stable heart failure are hospitalized for other reasons, they are at an increased risk for venous thromboembolic disease. This elevated risk may extend for up to 2 years after hospitalization, but it is greatest during the first 30 days.

Question 189

A 62-year-old man presents to the emergency department with severe acute chest pain and diaphoresis. An electrocardiogram (ECG) reveals ST-segment elevations in the anterior leads. Upon evaluation, his systolic blood pressure (SBP) is 82 mm Hg and his heart rate is 115 beats per minute. He is newly confused, with cool, mottled extremities and markedly decreased urine output. Invasive hemodynamics demonstrate a cardiac index of 1.8 L/min/m² and elevated pulmonary capillary wedge (PCW) pressures. Based on this patient's clinical presentation, what is the paramount initial management strategy?

• ✓ Urgent coronary revascularization
• ○ Initiation of intravenous milrinone
• ○ Administration of an intravenous fluid bolus
• ○ Immediate continuous renal replacement therapy

Explanation. In cases where cardiogenic shock is caused by an acute myocardial infarction, urgent revascularization is the paramount intervention to address the underlying acute myocardial dysfunction. The patient exhibits the hallmark diagnostic criteria for cardiogenic shock, which requires a systolic blood pressure less than 90 mm Hg, a cardiac index less than 2.0 L/min/m², and the presence of end-organ hypoperfusion (manifesting here as altered mental status, cool extremities, and oliguria) resulting directly from cardiac dysfunction.

Question 190

A 62-year-old woman is admitted to the cardiac intensive care unit with cardiogenic shock complicating an acute myocardial infarction. Despite initial measures including appropriate volume loading and intravenous inotropes, she shows insufficient clinical improvement, with ongoing oliguria, cold extremities, and rising lactate levels. The clinical team proceeds with invasive hemodynamic assessment and considers the initiation of temporary mechanical circulatory support (MCS) to optimize end-organ perfusion. When considering the specific temporary MCS device to employ, which of the following best characterizes the evidence base supporting this choice?

• ✓ Evidence is primarily derived from observational retrospective datasets, with few randomized trials limited by small sample sizes and surrogate endpoints.
• ○ The choice of specific devices is supported by multiple large, double-blind randomized controlled trials with long-term mortality endpoints.
• ○ Prospective cohort studies with extended follow-up have consistently demonstrated the superiority of specific temporary MCS devices over others.
• ○ Randomized clinical trials specifically powered for long-term survival have established definitive, widely accepted algorithms for device selection.

Explanation. The evidence supporting the use of specific pharmacologic therapies and the choice of temporary mechanical circulatory support (MCS) devices is primarily gleaned from observational retrospective datasets. The limited number of randomized trials that have been conducted in this area are constrained by small sample sizes, inherent open-label study designs, short follow-up periods, and the use of surrogate endpoints rather than hard clinical outcomes.

Question 191

A 68-year-old man is admitted to the intensive care unit with acute myocardial infarction complicated by cardiogenic shock. Despite adequate empiric volume replacement and the initiation of vasopressor therapy, he continues to exhibit signs of severe organ hypoperfusion, including anuria and cool, mottled extremities. The critical care team decides to add intravenous inotropic support to increase his cardiac output and improve hemodynamics. How should the specific inotropic agent be selected for this patient?

• ✓ The selection should be guided by clinical factors such as blood pressure, concurrent arrhythmias, and drug availability.
• ○ Dobutamine is universally preferred as the first-line agent because prospective randomized trials have proven its mortality benefit.
• ○ Milrinone is the agent of choice because it reliably increases cardiac output without carrying a risk of systemic hypotension.
• ○ An inotropic agent should only be selected if a pulmonary artery catheter demonstrates a preserved systemic vascular resistance.

Explanation. There is a lack of robust evidence or prospective randomized trials to suggest a clear benefit of one inotropic agent over another in the management of cardiogenic shock. Consequently, the choice of a specific inotrope should be individualized and guided by the patient's blood pressure, the presence of concurrent arrhythmias, and the availability of the drug.

Question 192

A 72-year-old woman is admitted to the cardiac intensive care unit with profound cardiogenic shock secondary to an acute anterior myocardial infarction. Despite optimal medical therapy and escalating doses of multiple vasopressors, her hemodynamic status continues to deteriorate. The interventional cardiology team is evaluating the potential insertion of a percutaneous short-term mechanical circulatory support (MCS) device. Given the clinical scenario, which of the following represents the most appropriate principle regarding the initiation of this therapy?

• ○ The choice of the specific device should be strictly based on extensive head-to-head randomized comparative trials demonstrating a clear survival benefit.
• ✓ An understanding of the patient's wishes, overall prognosis, and an assessment of therapeutic risk should precede the use of the invasive temporary device.
• ○ The device should be deployed immediately without further discussion, as short-term MCS is generally devoid of significant vascular and neurologic complications.
• ○ The deployment of the device should be delayed indefinitely until ongoing randomized clinical trials confirm the exact hemodynamic benefits of one modality over another.

Explanation. Prior to the deployment of invasive temporary mechanical circulatory support, an understanding of the patient's wishes, overall prognosis and trajectory, along with a careful assessment of therapeutic risks, should be established. This shared decision-making process is critical because the use of such devices carries a known risk of common adverse events, including vascular, bleeding, and neurologic complications.

Question 193

A 62-year-old female is admitted to the cardiac intensive care unit following an acute anterior ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. She is currently hypotensive, oliguric, and cool to the touch despite initial empiric measures, including intravenous fluids and norepinephrine. The multidisciplinary shock team is contemplating the initiation of short-term mechanical circulatory support (MCS). Assuming time allows, which of the following is the most appropriate next step to guide the escalation of therapy?

• ✓ Placement of a pulmonary artery (PA) catheter to obtain invasive hemodynamic data.
• ○ Empirical deployment of an intra-aortic balloon pump based on clinical markers of hypoperfusion.
• ○ Non-invasive assessment of cardiac output utilizing impedance cardiography.
• ○ Maximization of multiple vasoactive agents to achieve a target mean arterial pressure prior to considering device therapy.

Explanation. In patients with shock who are not responding to initial empiric measures, the escalation to mechanical circulatory support should be guided by invasively obtained hemodynamic data, such as that provided by a pulmonary artery catheter, provided time allows. Invasive hemodynamic monitoring aids in resolving diagnostic uncertainty regarding the cause of hypotension and end-organ dysfunction, and its use is associated with improved clinical outcomes, particularly in conjunction with short-term mechanical circulatory support.

Question 194

A 58-year-old man with a history of anterior myocardial infarction and ischemic cardiomyopathy presents to a community hospital with progressive dyspnea, confusion, and oliguria. His blood pressure is 82/50 mm Hg, heart rate is 115 bpm, and respiratory rate is 26/min. Laboratory tests show a serum lactate of 4.5 mmol/L and creatinine of 2.1 mg/dL (baseline 1.0 mg/dL). Despite initiation of intravenous inotropic support with milrinone and a norepinephrine infusion, his lactate continues to rise, and his urine output remains minimal over the next 4 hours. Which of the following is the most appropriate next step in the management of this patient?

• ○ Increase the dose of norepinephrine and observe for another 12 hours.
• ✓ Initiate early transfer to a center capable of providing advanced mechanical circulatory support and definitive therapies.
• ○ Start an oral angiotensin receptor-neprilysin inhibitor to improve forward flow.
• ○ Administer intravenous beta-blocker therapy to control the heart rate and reduce myocardial oxygen demand.

Explanation. In patients with cardiogenic shock demonstrating a trajectory of worsening end-organ malperfusion despite initial therapy, early transfer to a center capable of providing advanced support should be considered. This allows for temporizing strategies such as mechanical circulatory support to maintain end-organ perfusion while definitive solutions, such as a durable left ventricular assist device or cardiac transplantation, can be accomplished or evaluated.

Question 195

A 72-year-old woman is preparing for discharge after a 5-day hospitalization for acute decompensated heart failure. Her care team is discussing the optimal transition of care to prevent avoidable readmissions, as she is at highest risk for decompensation in the coming weeks. Based on systematic reviews of randomized controlled trials, which of the following post-discharge strategies is associated with a decrease in all-cause mortality and rehospitalization?

• ✓ Interventions that utilize case management or a multidisciplinary disease management approach
• ○ Routine scheduling of biweekly echocardiograms for the first 3 months
• ○ Strict fluid restriction to 500 mL per day regardless of symptom status
• ○ Transitioning all oral heart failure medications to continuous intravenous infusions

Explanation. Interventions that use case management (where a case manager or nurse coordinates care for high-risk patients) or a multidisciplinary disease management approach have been shown to decrease all-cause mortality and rehospitalization following hospital discharge for heart failure.

Question 196

A 72-year-old woman with heart failure with reduced ejection fraction (HFrEF) is preparing for discharge after an admission for acute decompensated heart failure. During her stay, her diuretic dose was adjusted, and she was started on a new evidence-based medication. The care team is compiling written discharge instructions for the patient and her caregiver. To ensure proper transitional care, which of the following comprehensive sets of topics should be addressed in her written discharge materials?

• ✓ Activity level, diet, discharge medications, follow-up appointment, weight monitoring, cardiac rehabilitation, and action steps for worsening symptoms.
• ○ Fluid restriction limits, low-sodium diet, discharge medications, follow-up appointment, daily blood pressure monitoring, and deep vein thrombosis prophylaxis.
• ○ Activity level, diet, discharge medications, follow-up appointment, weight monitoring, daily electrocardiogram (ECG) transmission, and caregiver resuscitation training.
• ○ Strict bed rest, diet, discharge medications, a complete list of all previously discontinued medications, weight monitoring, and action steps for worsening symptoms.

Explanation. Written discharge instructions or educational material given to the patient, family members, or caregiver during the hospital stay or at discharge to home should explicitly address the patient's activity level, diet, discharge medications, follow-up appointment, weight monitoring, cardiac rehabilitation, and what to do if symptoms worsen. Thorough discharge planning that incorporates these educational elements helps ensure adherence to an evidence-based medication regimen and is associated with improved patient outcomes in the post-discharge period.

Question 197

A 68-year-old man is hospitalized for an exacerbation of heart failure with reduced ejection fraction (HFrEF). The hospital recently implemented a new electronic health record system. As the attending physician prepares the discharge orders, an electronic point-of-care reminder alerts them that the patient is not currently prescribed a mineralocorticoid receptor antagonist, a component of guideline-directed medical therapy (GDMT). What is the primary benefit of utilizing such electronic point-of-care reminders and associated quality improvement programs in this setting?

• ✓ They increase GDMT prescription at discharge and decrease readmissions and mortality.
• ○ They reduce the need for early post-discharge outpatient follow-up.
• ○ They allow for the isolation of unique intervention effects in transitional care.
• ○ They decrease the length of hospital stay by expediting discharge planning.

Explanation. Quality improvement programs designed to increase the prescription of appropriate discharge medications can increase GDMT prescription at discharge and decrease readmissions and mortality, and electronic point-of-care reminders to prescribe GDMT in patients with HFrEF improve its use.

Question 198

A 68-year-old man with a history of heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction 28%) presents to the cardiology clinic reporting progressive fatigue and decreased exercise capacity over the last 3 months. He is currently stable on optimal guideline-directed medical therapy. Laboratory evaluation reveals a hemoglobin of 14.1 g/dL, a serum ferritin of 75 ng/mL, and a transferrin saturation of 16%, consistent with iron deficiency. Which of the following interventions is most appropriate to improve this patient's functional status and quality of life?

• ○ Initiate oral iron supplementation
• ✓ Prescribe intravenous iron replacement
• ○ Arrange for a packed red blood cell transfusion
• ○ Add an erythropoiesis-stimulating agent

Explanation. In patients with heart failure with reduced ejection fraction and iron deficiency, with or without the presence of concurrent anemia, intravenous iron replacement is reasonable to improve functional status and quality of life.

Question 199

A 72-year-old female with heart failure with reduced ejection fraction (HFrEF) presents to the clinic complaining of persistent fatigue and reduced exercise tolerance. She is currently stable on maximally tolerated doses of guideline-directed medical therapy (GDMT). Recent laboratory studies reveal a hemoglobin level of 9.5 g/dL and normal iron indices. The clinician considers initiating an erythropoietin-stimulating agent to address her anemia. Which of the following represents the most appropriate approach regarding the use of this therapy?

• ○ Initiate the erythropoietin-stimulating agent to reduce the risk of heart failure hospitalizations.
• ○ Initiate the erythropoietin-stimulating agent to improve overall mortality.
• ✓ Withhold the erythropoietin-stimulating agent as it should not be used to improve morbidity and mortality.
• ○ Withhold the erythropoietin-stimulating agent until the hemoglobin level falls below 8.0 g/dL.

Explanation. In patients with heart failure and concurrent anemia, erythropoietin-stimulating agents should not be used to improve morbidity and mortality.

Question 200

A 68-year-old woman with a history of heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction 28%) and permanent atrial fibrillation (AF) complains of persistent fatigue and shortness of breath with minimal exertion (NYHA class III). Her symptoms are significantly exacerbated by rapid heart rates. Despite maximally tolerated guideline-directed medical therapy, her resting heart rate remains 115 bpm, and further up-titration of beta-blockers is limited by hypotension. She has previously failed multiple attempts at pharmacological rhythm control and is not deemed a candidate for pulmonary vein isolation. Which of the following is a reasonable next step to improve her symptoms?

• ✓ Atrioventricular (AV) nodal ablation and cardiac resynchronization therapy (CRT) implantation
• ○ Initiation of dronedarone for rhythm control
• ○ Implantation of a permanent single-chamber ventricular pacemaker (VVI) followed by AV nodal ablation
• ○ Addition of non-dihydropyridine calcium channel blockers (e.g., diltiazem) for strict rate control

Explanation. In patients with heart failure who have symptoms attributable to atrial fibrillation (such as poorly controlled heart rates causing worsening heart failure symptoms), atrioventricular (AV) nodal ablation combined with cardiac resynchronization therapy (CRT) implantation is a reasonable intervention to ensure strict rate control while preserving ventricular synchrony.

Question 201

A 72-year-old man with a history of heart failure with reduced ejection fraction and stage 4 chronic kidney disease presents to the cardiology clinic with increasing shortness of breath, orthopnea, and severe lower extremity edema. He reports strict adherence to his prescribed loop diuretic and guideline-directed medical therapy (GDMT). Based on the pathophysiological relationship between heart failure and chronic kidney disease, which of the following statements best describes the impact of his renal dysfunction on his heart failure management?

• ✓ It impairs the response to diuretics and increases the risk of toxicities from heart failure therapies.
• ○ It enhances the efficacy of his guideline-directed medical therapy by decreasing drug clearance.
• ○ It indicates a unidirectional pathophysiological process where heart failure solely drives renal dysfunction.
• ○ It provides a highly predictable response to guideline-directed medical therapy due to extensive trial data in this population.

Explanation. Renal dysfunction in patients with heart failure is known to impair the patient's response to diuretics and increases the risk of toxicities associated with heart failure therapies.

Question 202

A 68-year-old male with a history of chronic heart failure presents to the clinic reporting progressive fatigue and a noticeable reduction in his exercise capacity over the past three months. He is currently on optimal medical therapy. Physical examination reveals no evidence of acute volume overload. Laboratory assessment reveals a hemoglobin level of 11.8 g/dL, a serum ferritin level of 145 µg/L, and a transferrin saturation of 16%. Which of the following is the most appropriate intervention to improve this patient's exercise capacity and quality of life?

• ✓ Intravenous iron repletion
• ○ Oral ferrous sulfate supplementation
• ○ Subcutaneous erythropoiesis-stimulating agents
• ○ Packed red blood cell transfusion

Explanation. Intravenous repletion of iron improves exercise capacity and quality of life in patients with heart failure who have iron deficiency, which is clinically defined as a ferritin level less than 100 µg/L or between 100 to 300 µg/L if the transferrin saturation is less than 20%.

Question 203

A 65-year-old man with a history of heart failure with an ejection fraction of 35% is hospitalized for acute decompensation. Laboratory studies reveal a hemoglobin of 14.1 g/dL, a serum ferritin of 75 ng/mL, and a transferrin saturation of 15%. His physician considers iron replacement therapy. Which of the following statements regarding the management of his iron status is most accurate?

• ✓ Intravenous ferric carboxymaltose has been shown to decrease hospitalizations for heart failure in this patient population.
• ○ Oral iron supplementation is recommended as it effectively replenishes iron stores in patients with heart failure.
• ○ Iron supplementation is not indicated because the patient's hemoglobin level is within normal limits.
• ○ Intravenous ferric carboxymaltose has been shown to significantly reduce cardiovascular death in recently hospitalized patients.

Explanation. In patients with an ejection fraction <50% hospitalized for heart failure, the administration of intravenous ferric carboxymaltose has been demonstrated to decrease subsequent hospitalizations for heart failure. This clinical benefit occurs independently of whether the patient has concurrent anemia, making intravenous iron an appropriate therapeutic choice to improve outcomes in this population.

Question 204

A 68-year-old male with a history of heart failure with reduced ejection fraction (HFrEF) presents for a routine follow-up. He reports increasing fatigue over the past few months. Laboratory results reveal a hemoglobin level of 9.4 g/dL. His iron studies, vitamin B12, and folate levels are within normal limits. He recently read about erythropoietin-stimulating agents and asks if starting an agent like darbepoetin alpha would improve his symptoms and keep him out of the hospital. What is the most appropriate response regarding the use of this medication for his anemia?

• ○ It should be initiated because it significantly improves functional capacity and reduces heart failure hospitalizations.
• ✓ It is not recommended because it provides no clinical benefit and is associated with an increased risk of thrombotic events, including stroke.
• ○ It is the preferred treatment since his anemia is likely driven by primary impaired erythropoietin production independent of heart failure.
• ○ It should be used to target a hemoglobin level above 12 g/dL to optimally decrease his risk of incident cardiovascular events.

Explanation. Erythropoietin-stimulating agents, such as darbepoetin alpha, are not recommended for the treatment of anemia in patients with heart failure. High-quality randomized trial data and meta-analyses have demonstrated that these agents provide no clinical benefit in this population and are associated with a significant increase in adverse thrombotic events, including stroke.

Question 205

A 68-year-old male with heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction of 25%) and New York Heart Association (NYHA) class III symptoms is evaluated in the clinic. His wife reports that he frequently stops breathing at night, though the patient denies any excessive daytime sleepiness. A polysomnography confirms the diagnosis of severe central sleep apnea. The patient asks about treatment options for his sleep apnea. What is the most appropriate advice regarding positive airway pressure therapy for this patient?

• ○ Adaptive servo-ventilation should be initiated as it decreases mortality in patients with HFrEF and central sleep apnea.
• ✓ Continuous positive airway pressure (CPAP) can be initiated to improve sleep quality and nocturnal oxygenation, although it has not been shown to improve survival.
• ○ Treatment for sleep apnea is not indicated because the absence of daytime sleepiness rules out clinically significant sleep-disordered breathing.
• ○ Adaptive servo-ventilation is the preferred therapy as it provides the most substantial reduction in brain natriuretic peptide (BNP) levels.

Explanation. In patients with heart failure and central sleep apnea, continuous positive airway pressure (CPAP) is associated with better sleep quality and nocturnal oxygenation, though it has not been shown to affect overall survival. Additionally, positive airway pressure therapy in adults with HFrEF and sleep-disordered breathing can result in a moderate reduction in brain natriuretic peptide and improvements in blood pressure and left ventricular ejection fraction.

Question 206

A 68-year-old woman with a history of type 2 diabetes mellitus and heart failure (left ventricular ejection fraction of 32%, New York Heart Association class III) presents to the cardiology clinic for a routine follow-up. She is currently treated with a beta-blocker, a mineralocorticoid receptor antagonist, and an angiotensin receptor-neprilysin inhibitor. Her physician decides to add empagliflozin to her regimen. Which of the following is an accurate statement regarding the expected benefits and characteristics of this medication in this clinical context?

• ○ The improvement in cardiovascular outcomes is entirely attributed to the medication's glucosuric effect.
• ✓ It has been shown in large randomized controlled trials to significantly reduce the relative risk of all-cause death.
• ○ It represents the second class of glucose-lowering agents to receive Food and Drug Administration (FDA) approval specifically for the treatment of heart failure with reduced ejection fraction.
• ○ It reduces hospitalizations for heart failure but does not have an impact on cardiovascular mortality.

Explanation. Empagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown in large randomized controlled trials (such as EMPEROR-Reduced and DAPA-HF) involving patients with NYHA class II-IV heart failure and an ejection fraction of 40% or less to significantly reduce the relative risk of all-cause death.

Question 207

A 65-year-old female with a history of type 2 diabetes mellitus presents to the hospital with worsening shortness of breath, lower extremity edema, and orthopnea. She is diagnosed with acutely decompensated heart failure (HF) and successfully diuresed. Prior to discharge, her care team discusses adding a sodium-glucose cotransporter-2 inhibitor (SGLT2i) to her regimen based on data from the SOLOIST-WHF trial, which extends the benefits of this therapy to her specific clinical presentation. When counseling the patient on the potential risks associated with this new medication, for which of the following adverse events should she be closely monitored?

• ✓ Severe genitourinary infections
• ○ Life-threatening hyperkalemia
• ○ Symptomatic severe bradycardia
• ○ Thyroid dysfunction

Explanation. Patients initiated on sodium-glucose cotransporter-2 inhibitors require close monitoring for potential risks that include severe genitourinary infections and, less commonly, diabetic ketoacidosis.

Question 208

A 72-year-old female presents with highly symptomatic, persistent atrial fibrillation (AF) and heart failure. Her ventricular rate remains difficult to control, frequently ranging from 120 to 140 beats per minute despite maximally tolerated doses of beta-blockers, nondihydropyridine calcium channel blockers, and previous failed trials of amiodarone for rhythm control. Her most recent echocardiogram reveals a left ventricular ejection fraction (LVEF) of 55%. The decision is made to proceed with atrioventricular (AV) node ablation and implantation of a permanent pacemaker. Which of the following pacing strategies is most appropriate for this patient?

• ✓ Permanent pacemaker with right ventricular (RV) pacing
• ○ Permanent pacemaker with cardiac resynchronization therapy (CRT)
• ○ Dual-chamber pacemaker with right atrial and right ventricular pacing
• ○ Implantable cardioverter-defibrillator (ICD) with biventricular pacing

Explanation. In patients with heart failure and difficult-to-control ventricular rates who require atrioventricular node ablation and implantation of a permanent pacemaker, right ventricular pacing is the indicated pacing strategy when the left ventricular ejection fraction is greater than 50%. There is no evidence that cardiac resynchronization therapy provides additional benefit compared with standard right ventricular pacing in this specific population with preserved ejection fraction.

Question 209

A 55-year-old man with a history of heart failure and hypertension presents with newly diagnosed atrial fibrillation. He has no history of diabetes mellitus, previous stroke, transient ischemic attack, or vascular disease. He and his physician are currently debating between a rate control versus a rhythm control strategy for his atrial fibrillation. Which of the following is the most appropriate recommendation regarding stroke prevention for this patient?

• ✓ Initiate anticoagulation therapy regardless of whether rhythm or rate control is chosen.
• ○ Initiate anticoagulation therapy only if a rate control strategy is chosen.
• ○ Withhold anticoagulation therapy as his CHA2DS2-VASc score is less than 2.
• ○ Initiate dual antiplatelet therapy for stroke prevention instead of anticoagulation.

Explanation. For male patients with heart failure and atrial fibrillation who have a CHA2DS2-VASc score of ≥2 (this patient has a score of 2 due to heart failure and hypertension), anticoagulation is recommended for stroke prevention regardless of whether they receive a rhythm or rate control strategy.

Question 210

A 68-year-old man presents for management of newly diagnosed non-valvular atrial fibrillation. His medical history is significant for symptomatic heart failure with a left ventricular ejection fraction of 35%, hypertension, and type 2 diabetes mellitus. He is currently taking eight different medications for his chronic conditions. The physician discusses starting a direct oral anticoagulant (DOAC) rather than warfarin. Based on trial data evaluating the use of DOACs versus warfarin, what is the expected comparative efficacy and safety profile for this patient?

• ✓ DOACs more effectively reduce the rates of stroke, systemic embolism, and major bleeding compared to warfarin, with these benefits remaining consistent regardless of the patient's heart failure status.
• ○ DOACs provide equivalent reduction in systemic embolism compared to warfarin, but significantly increase the risk of major bleeding in the setting of concurrent heart failure.
• ○ While DOACs reduce the rate of intracranial bleeding, their efficacy in preventing stroke is notably attenuated in patients with heart failure compared to those without heart failure.
• ○ Warfarin remains superior to DOACs for the prevention of systemic embolism in heart failure patients, though DOACs offer the advantage of not requiring routine anticoagulation monitoring.

Explanation. Direct oral anticoagulants (DOACs) offer an improved benefit-risk profile compared with warfarin therapy. They more effectively reduce the rates of stroke, systemic embolism, major bleeding, and intracranial bleeding compared to warfarin, and these superior efficacy and safety outcomes exhibit no treatment heterogeneity based on heart failure status.

Question 211

A 64-year-old male with a history of non-ischemic cardiomyopathy (Left Ventricular Ejection Fraction 28%), New York Heart Association (NYHA) class III heart failure, and an implantable cardioverter-defibrillator (ICD) presents with worsening fatigue. Electrocardiogram confirms persistent atrial fibrillation (AF). He is currently on optimal medical therapy for heart failure. If catheter ablation is pursued for rhythm control instead of standard medical care, what is the expected impact on his long-term clinical outcomes?

• ✓ Catheter ablation reduces the composite endpoint of death or rehospitalization and lowers overall mortality.
• ○ Catheter ablation improves the maintenance of sinus rhythm but does not alter overall mortality compared to amiodarone.
• ○ Catheter ablation reduces heart failure hospitalizations but has no demonstrated effect on survival in patients with an ICD.
• ○ Catheter ablation is less effective than amiodarone at maintaining normal sinus rhythm at 24 months.

Explanation. In patients with heart failure with reduced ejection fraction (LVEF < 35%), NYHA class II to IV symptoms, and an implantable cardioverter-defibrillator who experience paroxysmal or persistent atrial fibrillation, catheter ablation lowers the composite endpoint of death or rehospitalization compared with standard medical care. Additionally, catheter ablation is associated with a lower overall mortality and a substantial decrease in hospitalizations.

Question 212

A 72-year-old female with persistent atrial fibrillation (AF) complains of ongoing dyspnea and fatigue. Rhythm control strategies have previously failed and are no longer desired. Her ventricular rate is consistently 115-125 bpm despite maximal therapy with beta-blockers, calcium channel blockers, and digoxin. Echocardiography shows a left ventricular ejection fraction (LVEF) of 44%. Because all medical options are exhausted, she is scheduled for atrioventricular (AV) nodal ablation. Which of the following pacing strategies is most appropriate for this patient?

• ○ Standard right ventricular (RV) pacing
• ✓ Cardiac resynchronization therapy (CRT)
• ○ Dual-chamber pacing with right atrial and right ventricular leads
• ○ Observation without pacing to allow a junctional escape rhythm

Explanation. When atrioventricular nodal ablation is performed for refractory atrial fibrillation, implantation of a cardiac resynchronization therapy (CRT) device provides improved clinical outcomes compared to right ventricular pacing, including in patients who have a left ventricular ejection fraction greater than 35%.

Question 213

A 58-year-old man is evaluated in the clinic following a recent hospitalization for new-onset heart failure (HF) with reduced ejection fraction (LVEF 30%). During his hospital stay, telemetry recorded several episodes of paroxysmal atrial fibrillation (AF). He has no other past medical history; specifically, he has no hypertension, diabetes, vascular disease, or prior stroke. His CHA2DS2-VASc score is 1. Which of the following is the most appropriate approach regarding stroke prevention for this patient?

• ✓ Initiate oral anticoagulation, as heart failure alone in the setting of atrial fibrillation may support its use after weighing risks and benefits.
• ○ Delay anticoagulation until the patient develops at least one additional stroke risk factor to reach a CHA2DS2-VASc score of 2.
• ○ Prescribe aspirin 81 mg daily, as oral anticoagulation is not indicated for a CHA2DS2-VASc score of 1.
• ○ Withhold anticoagulation, as paroxysmal atrial fibrillation does not significantly increase the risk of stroke compared to persistent atrial fibrillation.

Explanation. Heart failure is a hypercoagulable state and an independent risk factor for stroke, systemic embolism, and mortality in the setting of atrial fibrillation. Because heart failure itself is a significant risk factor, additional risk factors may not be required to support the use of anticoagulation, and the decision to anticoagulate can be individualized based on a risk-versus-benefit assessment.

Question 214

A 74-year-old woman with a history of hypertension, type 2 diabetes mellitus, and severe osteoarthritis is evaluated in the cardiology clinic for a new diagnosis of heart failure (HF). During the evaluation, the clinical team discusses population-specific differences in HF incidence, risk factors, and outcomes to guide patient expectations and care delivery. Compared to male patients with HF, which of the following best describes the typical clinical profile and prognostic outlook for female patients like her?

• ✓ She presents later in life with more comorbidities, and her overall survival outlook is generally more favorable.
• ○ She presents later in life with more comorbidities, and her overall survival outlook is generally less favorable.
• ○ She presents earlier in life with lower patient-reported health status, and her overall survival outlook is generally more favorable.
• ○ She presents earlier in life with fewer comorbidities, but her overall survival outlook is generally less favorable.

Explanation. Female patients typically present with heart failure at an older age, carry a higher burden of comorbidities, and report a lower health status compared to male patients, yet they generally exhibit a more favorable survival trajectory.

Question 215

A 48-year-old man who immigrated to the United States from Central America 15 years ago presents with progressive dyspnea on exertion, fatigue, and bilateral lower extremity edema. Echocardiography demonstrates a dilated left ventricle with a reduced ejection fraction of 35% and a distinct apical aneurysm. He has no history of hypertension, diabetes, or coronary artery disease. Which of the following is the most likely infectious etiology of this patient's cardiomyopathy?

• ✓ Trypanosoma cruzi
• ○ Borrelia burgdorferi
• ○ Toxoplasma gondii
• ○ Mycobacterium tuberculosis

Explanation. Immigrants to the United States from Mexico and Central America may have asymptomatic Trypanosoma cruzi infection, which can progress to Chagas cardiomyopathy in approximately 20% of cases.

Question 216

A 78-year-old male with a history of heart failure (HF) is evaluated in the clinic after his third hospital admission this year for acute decompensation. He lives alone, struggles with food insecurity due to low income, and missed his last two appointments because he lacks reliable transportation. He is currently not on optimal doses of guideline-directed medical therapy (GDMT). Which of the following represents an essential strategy to address the barriers hindering this patient's optimal disease management?

• ✓ Integration of case management and social work services into his multidisciplinary care team.
• ○ Automatic transfer to a nursing facility to guarantee adequate prescription of guideline-directed medical therapy.
• ○ Reduction of his medical regimen to a single diuretic to accommodate his lack of caregiver support.
• ○ Immediate referral for psychiatric evaluation to medically manage his social isolation.

Explanation. Case management and social work services are essential components of a comprehensive multidisciplinary heart failure team approach to coordinate complex medical, psychiatric, and social needs across multiple sectors, specifically addressing barriers to optimal disease management such as food insecurity, lack of transportation, low income, and social isolation.

Question 217

A multidisciplinary task force at a hospital is developing a new discharge pathway for patients with heart failure (HF) in an effort to reduce disparities in care and improve health literacy. They are drafting new written educational materials regarding sodium restriction, daily weight monitoring, and medication adherence to provide to patients and their caregivers upon discharge. To optimize comprehension, at what maximum reading level should these written educational materials be targeted?

• ○ Fourth-grade reading level
• ✓ Sixth-grade reading level
• ○ Eighth-grade reading level
• ○ Tenth-grade reading level

Explanation. Heart failure written educational materials for patients and caregivers should be delivered at or below the sixth-grade reading level to ensure adequate comprehension and promote effective engagement in medical care.

Question 218

A 62-year-old woman with a history of breast cancer is currently undergoing treatment with doxorubicin and trastuzumab. Prior to initiating her cancer therapeutics, her baseline left ventricular ejection fraction (LVEF) was 62%. She presents for a routine follow-up echocardiogram halfway through her treatment course. She reports feeling well, is completely asymptomatic, and continues her routine of jogging 3 miles daily. Her current echocardiogram demonstrates an LVEF of 48% with normal right ventricular function. Based on these findings, which of the following is the most accurate assessment of her cardiac status?

• ✓ She has developed cancer therapy-related cardiomyopathy.
• ○ She does not meet the criteria for cancer therapy-related cardiomyopathy because she is asymptomatic.
• ○ She does not meet the criteria for cancer therapy-related cardiomyopathy because her LVEF remains above 45%.
• ○ She does not meet the criteria for cancer therapy-related cardiomyopathy because the absolute decrease in LVEF is less than 15%.

Explanation. Cancer therapy-related cardiomyopathy is defined as a decrease in left ventricular ejection fraction (LVEF) of at least 10% to an absolute value of less than 50%, and the disease can present as entirely asymptomatic left ventricular dysfunction. This patient experienced a 14% absolute decline in LVEF (from 62% to 48%), resulting in a value under 50%, which definitively meets the diagnostic criteria.

Question 219

A 62-year-old woman with a history of breast cancer previously treated with anthracyclines presents to the cardiology clinic with new-onset fatigue, orthopnea, and lower extremity swelling. Echocardiography demonstrates a left ventricular ejection fraction of 30% with global hypokinesis. She is diagnosed with heart failure (HF) secondary to cancer therapy-related cardiomyopathy. When considering the long-term trajectory for this patient, which of the following describes the general prognosis of this specific HF etiology?

• ✓ It is associated with significantly worse outcomes.
• ○ It is associated with significantly better outcomes.
• ○ It has an equivalent prognosis to ischemic cardiomyopathy.
• ○ It is characterized by near-universal spontaneous recovery.

Explanation. Heart failure secondary to cancer therapy-related cardiomyopathy is associated with significantly worse outcomes compared to other standard etiologies.

Question 220

A 48-year-old woman with HER2-positive breast cancer is undergoing treatment with trastuzumab. During routine surveillance echocardiography, her left ventricular ejection fraction (LVEF) is noted to have decreased from 62% at baseline to 46%. She reports no shortness of breath, orthopnea, or lower extremity edema, and she continues her normal daily activities, including exercising, without limitation. Her overall cardiovascular risk is deemed low. Which of the following is the most appropriate management strategy?

• ✓ Continue trastuzumab and initiate neurohormonal blockade.
• ○ Discontinue trastuzumab indefinitely due to the high mortality associated with its continued use.
• ○ Suspend trastuzumab temporarily until her LVEF normalizes, without initiating cardiovascular medications.
• ○ Continue trastuzumab without initiating any new cardiovascular medications.

Explanation. In low-risk patients receiving trastuzumab who develop an asymptomatic decrease in left ventricular ejection fraction, the offending agent is often continued while neurohormonal blockade is concurrently initiated, as asymptomatic decreases have a high recovery rate and a low rate of actual therapy discontinuation.

Question 221

A 56-year-old woman is evaluated for new-onset exertional dyspnea six months after completing a chemotherapy regimen containing doxorubicin (an anthracycline) for breast cancer. An echocardiogram reveals a newly reduced left ventricular ejection fraction (LVEF) of 42%. What is the most appropriate pharmacological management for this patient's cardiac findings?

• ✓ Initiate and uptitrate a beta-blocker and an angiotensin-converting enzyme inhibitor (ACEi).
• ○ Avoid neurohormonal therapies due to the heterogeneity of offending agents and poorly understood pathophysiology.
• ○ Prescribe a non-dihydropyridine calcium channel blocker to improve left ventricular relaxation.
• ○ Observe the patient clinically and repeat the echocardiogram in 6 months before considering medical therapy.

Explanation. Beta-blockers and angiotensin-converting enzyme inhibitors (ACEi) are effective in improving left ventricular dysfunction in patients with anthracycline-induced cardiomyopathy. The initiation and uptitration of standard heart failure therapies is the mainstay of treatment for patients with cancer therapy-related cardiomyopathy presenting with a left ventricular ejection fraction (LVEF) of less than 50%.

Question 222

A 62-year-old woman with newly diagnosed breast cancer is scheduled to receive a potentially cardiotoxic chemotherapy regimen. Her past medical history is significant for hypertension, type 2 diabetes mellitus, and obesity. Her oncologist refers her for a pretherapy cardiovascular evaluation. Which of the following describes the most appropriate initial imaging modality for assessing her left ventricular ejection fraction (LVEF) and a primary rationale for its use?

• ○ Cardiac magnetic resonance imaging; it is the first-line modality to definitively diagnose preexisting cardiomyopathy before therapy.
• ○ Radionuclide ventriculography (MUGA scan); it is recommended as the first-line modality because of its high reproducibility in establishing a baseline.
• ✓ Echocardiography; it is the first-line modality to establish a reference baseline LVEF, stratify risk, and guide the choice of cancer therapy.
• ○ Echocardiography; it is recommended primarily because systematic screening of all cancer patients has been proven highly cost-effective.

Explanation. Echocardiography is the recommended first-line imaging modality for assessing left ventricular ejection fraction (LVEF) due to its availability, safety, relatively low cost, and ability to provide structural and functional information beyond LVEF. Pretherapy quantification of LVEF serves critical purposes, including establishing a reference baseline for future comparisons, pretherapy risk stratification, diagnosing preexisting cardiomyopathy, and guiding the choice of cancer therapy.

Question 223

A 45-year-old woman is undergoing treatment with an anthracycline-based regimen for breast cancer. She is identified as high-risk for cancer therapy-related cardiomyopathy and is undergoing serial left ventricular ejection fraction (LVEF) monitoring. An echocardiogram reveals a new decrease in LVEF, diagnostic of cancer therapy-related cardiomyopathy, though she reports only mild fatigue on exertion (New York Heart Association class II). Based on available data regarding patients who develop anthracycline-induced cardiomyopathy, what is the expected outcome following the initiation of beta-blockers and angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)?

• ○ The majority of patients will experience irreversible decline in LVEF despite medical therapy.
• ✓ Most patients will have at least a partial recovery of LVEF, which correlates with a lower incidence of future cardiac events.
• ○ LVEF recovery will occur only if the anti-cancer agent is permanently discontinued prior to the development of symptoms.
• ○ The incidence of cardiac events remains unchanged regardless of whether LVEF recovery is achieved.

Explanation. Following the development of cancer therapy-related cardiomyopathy from agents such as anthracyclines, the initiation of beta-blockers and angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) leads to at least partial recovery of LVEF in the vast majority of patients (approximately 86%), and those who achieve recovered LVEF experience a significantly lower incidence of future cardiac events.

Question 224

A 52-year-old female with newly diagnosed breast cancer is scheduled to receive a high-dose anthracycline-based chemotherapy regimen. Her baseline echocardiogram shows a Left Ventricular Ejection Fraction (LVEF) of 58%. Following her first cycle of chemotherapy, she is noted to have an asymptomatic troponin rise to 0.09 ng/mL. Her oncologist considers initiating preemptive enalapril, referencing a study in which ACE inhibitors prevented a greater than 10% decrease in LVEF in patients with post-treatment troponin elevations. As the consulting cardiologist evaluating the potential benefit of this intervention, what is the most accurate assessment regarding the preemptive use of heart failure therapies in this setting?

• ○ Preemptive enalapril has been definitively shown to reduce both the incidence of LVEF decline and subsequent heart failure hospitalizations.
• ✓ While preemptive enalapril may prevent a significant decrease in LVEF in this specific population, no studies have demonstrated an improvement in clinical outcomes such as mortality or heart failure hospitalization.
• ○ Trials consistently demonstrate a large, clinically significant preservation of LVEF of greater than 15% across all chemotherapy patients treated preemptively with ACE inhibitors.
• ○ Preemptive use of heart failure therapies is universally recommended for primary prevention in all patients receiving high-dose chemotherapy regardless of biomarker status.

Explanation. Small clinical trials have shown that preemptive administration of heart failure therapies, such as enalapril for patients with a post-chemotherapy troponin elevation, can prevent a substantial drop in Left Ventricular Ejection Fraction (LVEF) to below 50%. However, current evidence is limited entirely to surrogate imaging endpoints, as there is an absence of studies assessing whether this preemptive strategy translates to improvements in hard clinical outcomes, specifically mortality and hospitalizations for heart failure.

Question 225

A 48-year-old woman with breast cancer is evaluated in the cardio-oncology clinic one month after completing an anthracycline-based chemotherapy regimen. She is currently asymptomatic. Her echocardiogram shows a left ventricular ejection fraction (LVEF) of 53%, which is considered equivocal compared to her pretreatment baseline of 55%. Laboratory testing reveals a serum troponin level of 0.09 ng/mL, representing a significant posttreatment increase. Based on clinical trial data evaluating patients with a posttreatment troponin elevation, initiation of which of the following medications is most strongly supported to prevent a subsequent decline in LVEF?

• ✓ Enalapril
• ○ Carvedilol
• ○ Spironolactone
• ○ Atorvastatin

Explanation. In patients receiving cardiotoxic chemotherapy, a posttreatment increase in troponin is associated with a greater risk of cancer therapy-related cardiomyopathy. Clinical trial data evaluating the use of biomarkers for risk stratification demonstrated that when patients with a posttreatment increase in troponin (>0.07 ng/mL) were treated with enalapril, none experienced a decrease in left ventricular ejection fraction (LVEF), compared to a 43% decline observed in the standard of care group.

Question 226

A 34-year-old woman of African descent presents to the emergency department with severe dyspnea, orthopnea, and lower extremity edema three weeks after the delivery of twins. She had a history of preeclampsia during her pregnancy. An echocardiogram demonstrates a left ventricular ejection fraction (LVEF) of 35% with left ventricular dilation. She has no prior history of cardiovascular disease. In addition to standard heart failure medical therapy adjusted for her breastfeeding status, which of the following therapeutic strategies has been trialed for this specific condition based on its unique pathophysiology?

• ○ Intravenous immunoglobulin therapy to suppress autoantibodies against the beta-1 adrenergic receptor.
• ○ Administration of recombinant human relaxin-2 to mediate systemic and renal vasodilation.
• ✓ Inhibition of a pathogenic 16-kDa prolactin fragment using the dopamine-agonist bromocriptine.
• ○ Direct antagonism of dopamine receptors to reduce hyperactive sympathetic nervous system tone.

Explanation. Peripartum cardiomyopathy is characterized by systolic dysfunction and left ventricular dilation occurring in late pregnancy or the early postpartum period. The identification of a pathogenic 16-kDa prolactin fragment as a contributing factor in the disease process has led to targeted therapeutic trials utilizing bromocriptine, a dopamine-agonist, to suppress prolactin secretion.

Question 227

A 32-year-old woman presents to the cardiology clinic for preconception counseling. Three years ago, she was diagnosed with peripartum cardiomyopathy following the birth of her first child, with an initial left ventricular ejection fraction (LVEF) of 30%. She has been on medical therapy and is currently asymptomatic. A recent echocardiogram demonstrates an LVEF of 54%. She is inquiring about the maternal risks associated with a subsequent pregnancy. What is the most accurate information to provide regarding her risk profile?

• ✓ She remains at substantial risk for LVEF deterioration and heart failure symptoms, although her mortality risk is near zero.
• ○ She has approximately a 16% risk of maternal mortality due to her history of peripartum cardiomyopathy, despite her current recovery.
• ○ Her LVEF at the time of her initial diagnosis is the strongest prognostic determinant for adverse maternal outcomes in a subsequent pregnancy.
• ○ She has less than a 5% risk of further LVEF deterioration since her LV function has fully recovered.

Explanation. For women with a history of peripartum cardiomyopathy, the strongest prognostic determinant for a subsequent pregnancy is the LVEF before the subsequent pregnancy. Among women who have recovered their left ventricular function prior to a subsequent pregnancy, there remains a notable risk of morbidity, with approximately 27% experiencing further LVEF deterioration and 32% developing heart failure symptoms, but the mortality rate is 0%.

Question 228

A 30-year-old female presents to the emergency department with severe dyspnea and orthopnea 3 weeks after an uncomplicated vaginal delivery. An echocardiogram reveals a left ventricular ejection fraction (LVEF) of 28% with no evidence of an intracardiac thrombus. She is diagnosed with acute heart failure secondary to peripartum cardiomyopathy. As part of her management, the clinical team elects to initiate treatment with bromocriptine. Which of the following is most appropriate to include in her pharmacological regimen?

• ✓ At least prophylactic-dosed anticoagulation
• ○ Dual antiplatelet therapy for 6 to 8 weeks
• ○ High-dose intravenous corticosteroids
• ○ Routine administration of a thrombolytic agent

Explanation. When bromocriptine is used in postpartum women with severe acute heart failure caused by peripartum cardiomyopathy and a left ventricular ejection fraction of less than 35%, it should be accompanied by at least prophylactic-dosed anticoagulation because of the potential association with thromboembolic events.

Question 229

A 32-year-old woman, G1P1, presents to the emergency department with severe orthopnea and bilateral lower extremity edema one month after an uncomplicated vaginal delivery. Echocardiography demonstrates a left ventricular ejection fraction (LVEF) of 35% with global hypokinesis. The cardiologist notes that the patient's presentation is classic for PPCM and initiates guideline-directed medical therapy (GDMT). Based on standard cardiovascular terminology, what does the abbreviation PPCM stand for?

• ✓ Peripartum cardiomyopathy
• ○ Postpartum cardiomyopathy
• ○ Primary peripartum cardiomegaly
• ○ Pregnancy-provoked cardiomyopathy

Explanation. The abbreviation PPCM stands for peripartum cardiomyopathy.

Question 230

A 31-year-old female presents with severe dyspnea and orthopnea 3 weeks postpartum. An echocardiogram demonstrates a markedly dilated left ventricle with a left ventricular ejection fraction of 22%. She is diagnosed with acute peripartum cardiomyopathy. Along with standard guideline-directed medical therapy for heart failure, the clinical team decides to initiate bromocriptine. Which of the following is an essential co-intervention when administering this medication?

• ✓ Initiation of at least prophylactic-dosed anticoagulation
• ○ Continuation of breastfeeding to promote maternal-infant bonding
• ○ Administration of high-dose intravenous corticosteroids
• ○ Placement of a temporary transvenous pacemaker

Explanation. The use of bromocriptine in the management of peripartum cardiomyopathy must be accompanied by at least prophylactic-dosed anticoagulation due to the potential risk of medication-induced hypercoagulability.